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ABSTRACT
Purpose: This study compares overall survival (OS) and biochemical failure-free
survival (bFFS) in low- and intermediate-risk prostate cancer patients that received
brachytherapy [low-dose-rate brachytherapy (LDR-BT) or high-dose-rate brachytherapy
with external beam radiation therapy (HDR-BT+EBRT)] versus external beam radiation
therapy (EBRT) alone.
Materials/Methods: Patient data was obtained from the ProCaRS database, which
contains 7974 prostate cancer patients treated at four Canadian institutions. Propensity
score (PS) matching was used to generate matched cohorts with balanced baseline
prognostic factors.
Results/Conclusions: Final PS matches included two 1:1 intermediate-risk patient
matches, LDR-BT vs. EBRT (total n = 254) and HDR-BT+EBRT vs. EBRT (total
n=388), and a 4:1 (LDR-BT:EBRT) low-risk match (total n=400). Hazard ratios for OS
were 0.79 (p=0.69), 0.64 (p=0.47), and 1.41 (p=0.50), respectively. Hazard ratios for
bFFS were 0.22 (p=0.001), 0.48 (p=0.007), and 0.35 (p=0.004), respectively.
Conclusions: PS matching showed BT significantly improved bFFS but not OS in
matched prostate cancer patients.
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1.0

Introduction
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy and

is the third leading cause of cancer-related death in Canadian men (Canadian Cancer
Society 2012). Primary radiation therapy (RT) treatment of prostate cancer has been
shown to provide similar local control and survival benefits compared to surgical
management for patients with localized disease (Thompson 2007). Treatment options for
patients with low-risk prostatic disease include either conservative management through
active surveillance, or definitive therapy via radical prostatectomy (RP), external beam
radiation therapy (EBRT), or brachytherapy (BT). Increased risk of local recurrence and
distant metastasis following single modality therapy for patients with intermediate- or
high-risk prostate cancer has led to increased use of adjuvant hormone therapy
accompanied by dose escalated RT regimens (Thompson 2007). Intensity modulated
radiation therapy (IMRT) prescription doses of >80 Gy have been explored for patients
at higher risk of disease recurrence. However, standard prescription doses from primary
EBRT treatments tend to range from 70-80 Gy given in 1.8 to 2.0 Gy fractions
(Washington 2004).
BT options available to men with prostate cancer include low dose rate
brachytherapy (LDR-BT) and high dose rate brachytherapy (HDR-BT). Permanent seed
LDR-BT is generally given as a monotherapy, while HDR-BT boost has been explored as
concurrent therapy with EBRT (HDR-BT+EBRT) (Thompson 2007). Higher doses are
achievable using highly conformal BT treatments compared to EBRT treatments, with
total doses of ≥115Gy delivered using permanent seed LDR-BT implants (Nag 1999).
Biologically equivalent dose (EQD2Gy), which is a standardized equivalent EBRT dose
given in 2 Gy fractions, has been used to describe the total combined dose given with
HDR-BT+EBRT treatments (Morton 2011). Modern HDR-BT+EBRT treatments giving
two fractions of 10 Gy HDR-BT with 45 Gy EBRT have an estimated total EQD2Gy of 95
Gy (Morton 2011).
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Currently, a lack of high quality randomized controlled trial (RCT) data on
prostate cancer RT survival outcomes are available in the literature. No definitive RCT
data exists directly comparing two or more RT treatments. As a result, comparative
evidence has been predominately generated from observational data. However, RT
survival comparisons in several of these non-experimental studies do not control for the
effects of adjuvant hormone therapy and they tend to assess heterogeneous patient
populations composed of low-, intermediate- and high-risk patients. Novel comparisons
of the effectiveness of the different RT modalities available within each prostate cancer
risk-stratum are warranted, specifically aimed at isolating the effects of RT in the absence
of hormone therapy.
The goal of this study was to assess primary RT survival outcomes of overall
survival (OS) and biochemical failure-free survival (bFFS) in individual prostate cancer
risk categories. This study used propensity score (PS) matching analysis to control for
the effects of baseline prognostic factors on survival as well as to create separate, unique
cohorts of entirely low-risk and intermediate-risk patients for analyses. There were three
matched comparisons made. LDR-BT was compared with EBRT in separate low-risk
and intermediate-risk cohorts, while combination HDR-BT+EBRT was compared with
EBRT in an intermediate-risk cohort only.
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2.0

Prostate Cancer
2.1

Introduction

In Canada, prostate cancer is the most commonly diagnosed non-cutaneous cancer
in men, with an estimated 26,500 new cases reported in 2012 (Canadian Cancer Society
2012). The incidence of prostate cancer has risen steadily since 1980, with the exception
of two rapid rises in incidence, the first peaking in 1993 and the second in 2001.
Increased early detection of prostate cancer due to intensified prostate specific antigen
(PSA) screening has been linked to both peaks in prostate cancer incidence. The first
peak in prostate cancer incidence, in 1993, coincided with the introduction of the PSA
blood test, while the second peak, in 2001, occurred during a time of increased public
awareness and promotion of PSA screening following the prostate cancer diagnosis of
then Canadian Minister of Health, Allan Rock (Fradet 2009). Both sharp rises in prostate
cancer incidence were followed by equally significant declines. Currently, the incidence
of prostate cancer has remained relatively constant in Canada, with an estimated
incidence of 121 per 100,000 men in 2012 (Canadian Cancer Society 2012).
In contrast to incidence, death from prostate cancer is less common. Prostate
cancer has the third highest mortality rate among all cancers in Canadian men. In 2012,
prostate cancer was estimated to account for roughly 10% of all cancer-related deaths in
Canadian men (Canadian Cancer Society 2012). The lower yearly mortality rate relative
to incidence rate is attributable to the generally slow growing nature of prostate cancer,
with diagnoses predominantly occurring in men with early stage disease. Overall,
prostate cancer has a good prognosis, with 5-year survival rates of >90% for low-risk
patients (Rubin 2001). The trend in prostate cancer mortality has been relatively stable
over time. More recently, there has been a slight decline in prostate cancer mortality at a
rate of 4.3% per year, from 2001 to 2007 (Canadian Cancer Society 2012). Early
detection and improvements in the quality of care are popular explanations for this recent
decrease in prostate cancer mortality (Fradet 2009).
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Prostate cancer incidence varies by geographical region, with the highest rates
reported in North America and the lowest rates in Asia (Curado 2007). Reduced dietary
fat intake commonly found in oriental cuisine is thought to be responsible for these lower
prostate cancer incidence rates seen in Asian countries (Fleshner 2004). Aside from the
obvious requirement of being male, there are numerous additional factors that can
increase an individual’s risk for developing prostate cancer. Increased age has been
associated with prostate cancer risk, with the majority of patients presenting over the age
of 60 (Rubin 2001). African American and Hispanic men are at higher risk than
Caucasians for prostate cancer (Hoffman 2001), as are men with at least one familial
relative diagnosed with the disease (Bratt 2002). Chemical exposure to tobacco as well
as certain pesticides increases risk for prostate cancer, while exposure to antioxidants,
such as genistein (soy beans), lycopene (tomatoes), and vitamin E, could potentially be
protective (Damber 2008). Conventionally studied etiological factors, such as alcohol
consumption, obesity and reduced physical activity, do not appear to increase risk for
prostate cancer. Although benign prostatic hypertrophy (BPH) presents with similar
symptoms as prostate cancer, no study has been able to show a causal association
between BPH and the development of prostate cancer (Rubin 2001).
The natural history of disease progression for prostate cancer originates as a
mutation occurring in normal human cells. Prostate cancer can develop locally from cells
originating in prostatic tissues, or distantly, as a result of metastasis from cancers of the
lung, skin, colon or lymphatic tissues. Prostate cancer spreads locally by invading
surroundings tissues, specifically the seminal vesicles, bladder, rectum, and pelvic soft
tissues. Distant spread of prostate cancer tends to follow a sequential pattern, beginning
with regional dissemination predominantly to the pelvic lymph nodes. Regional spread is
followed by distant metastasis, usually to the bone. Although prostate cancer is a slow
growing malignancy, metastasis to the bone and other organs including the liver, lung
and occasionally, the brain, can eventually result in death (Rubin 2001).
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2.2

Clinical Detection and Diagnosis

Most men with prostate cancer are asymptomatic and are diagnosed by an
elevated PSA blood test. PSA is a serine protease enzyme that is secreted by prostatic
epithelial cells. The primary function of PSA is to keep semen in a fluidic state prior to
ejaculation (Balk 2003). Trace levels of PSA are normally detectable in peripheral blood
serum, with higher concentrations found in the prostatic lumen. Localized disease, such
as prostate cancer or BPH, can cause an increased amount of PSA to leak out of the
prostatic lumen into the peripheral blood stream. Standard PSA screening tests use a
serum total PSA threshold of 4.0 ng/mL to indicate the need for further biopsy evaluation
(Balk 2003). However, controversy exists over the specificity of this PSA threshold, as
aggressive, organ confined, prostate cancer is diagnosed in roughly 50% of individuals
with low levels of serum PSA, ranging from 0 to 4ng/mL (Schröder 2000).
Additional methods have been proposed to help improve the accuracy of PSA
screening. One such method uses age-specific reference ranges (ASRRs) to account for
rising PSA levels as men age. The recommended PSA serum concentration using ASRRs
starts from 0 to 2.5 ng/mL, for younger men aged 40 to 49 years and increases up to a
maximum range of 0 to 6.5 ng/mL, for older men aged 70 and above (Oesterling 1993).
There are two main theoretical advantages of using ASRRs. The first advantage is that
ASRRs innately diagnose an increased number of prostate cancers in younger men. This
means that a higher number of men, who are likely to require some form of interventional
therapy, are properly identified. The second advantage of ASRRs is that fewer diagnoses
are made in older men who are unlikely to die of their disease. This reduces the number
of unnecessary biopsies and additional investigations in older individuals (Crawford
1999).
There are additional approaches to improving PSA measurement accuracy. One
approach is to standardize PSA blood concentration relative to the prostate volume, also
known as the PSA density. This technique attempts to differentiate benign elevated PSA
levels from those caused by prostate cancer (Benson 1994). Measuring the change in
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PSA over time, or PSA velocity, has also been identified as a means of screening for
prostate cancer. A PSA velocity showing a yearly increase of 0.75 ng/mL is the most
common criteria indicating a positive test result (Kadmon 1996). Limitations of PSA
velocity are that it requires previous knowledge of PSA measurements and is unable to
account for natural fluctuations in PSA serum concentration over time (Kadmon 1996).
The PSA found in prostate cancer cells tends to avoid inactivation via proteolytic
cleavage. This results in a lower fraction of free-PSA, or inactivated PSA, relative to
total PSA in the peripheral blood. The fraction of free-PSA to total PSA can be measured
and is known as the PSA index. A PSA index ≤25% in patients with total PSA
measurements ranging from 4-10 ng/mL has been shown to increase risk for prostate
cancer (Catalona 1998).
Controversy exists regarding the overall benefit of PSA screening for prostate
cancer in otherwise healthy men. Although, PSA screening has increased the number of
men diagnosed with early stage, low-risk prostate cancer, it has not been found to
significantly reduce prostate cancer-specific mortality or all-cause mortality in men
(Andriole 2009). In fact, over diagnosis from PSA screening can increase the morbidity
for men, including increased stress and anxiety over the need for more invasive tests and
treatments. One recent European randomized trial containing 162,243 men estimated that
1410 men would need to be PSA screened to prevent one death from prostate cancer
(Schröder 2009).
In addition to screening, PSA testing can be used on follow-up examination to
monitor efficacy of primary therapy. Elevated PSA has long been established as an
indicator for clinical relapse following RP or RT (Kuriyama 1981). As low levels of PSA
are normally detectable following RT, there have been multiple definitions for a rising
PSA used to indicate treatment failure. The most current Radiation Therapy Oncology
Group (RTOG) and American Society for Therapeutic Radiology and Oncology
(ASTRO) definition for biochemical failure following primary RT is a PSA rise of 2
ng/mL, or more, above the nadir, or the lowest recorded PSA value (Roach 2006). This
definition replaced the previous RTOG-ASTRO recommendation of three consecutive
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rises in PSA after the nadir as indicative of biochemical failure (Roach 2006). Neither of
these definitions accounts for the benign rises in PSA (also known as ‘PSA bounce’) that
has been documented following BT radiation in prostate cancer patients (Mehta 2013).
Current studies on PSA bounce have been unable to identify the etiology of this
phenomenon (Chira 2013, Mehta 2013).
Besides PSA screening, clinical detection of prostate cancer can occur as a result
of other investigations. One common presentation of prostate cancer is an abnormal
nodular growth found on digital rectal examination (DRE). Although the specificity and
sensitivity of using DRE alone to accurately diagnose prostate cancer has been
questioned (Byar 1972), the combination of patient history, serum PSA measurement,
and DRE are commonly used to assess prostate cancer risk and help shape biopsy
decision making (Rubin 2001). In rare instances, a prostate cancer diagnosis can occur
following transurethral resection of the prostate (TURP) for urinary obstructive
symptoms. However, pre-existing urinary obstructive symptoms have not been found to
be associated with decreased survival among men with prostate cancer (Brawn 1994).
Trans-rectal ultrasound (TRUS) guided biopsy is performed for definitive diagnosis of
prostate cancer in the instance of elevated PSA or abnormal DRE. Other routine tests
such as chest x-ray, bone scans and computerized tomography (CT) scans or magnetic
resonance imaging (MRI), are not involved in the diagnosis of prostate cancer, but are
instead used for staging disease (Rubin 2001).
2.3

Classification and Histopathology

The prostate is made of both glandular and non-glandular tissues that are
contained within the prostatic capsule. The glandular tissues are classified into three
major zones, the peripheral zone, central zone and transitional zone. Each classified zone
has unique histological architecture and function. The peripheral zone accounts for 70%
of the glandular tissue and is the most common site for development of multifocal
prostate carcinomas. The central zone is a conical shaped structure that makes up
roughly 25% of the glandular tissue and is relatively resistant to prostate cancers and
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other prostatic diseases. Finally, the transitional zone, which makes up the remaining
5%-10% of the glandular tissue, is the site most associated with the development of BPH
(McNeal 1988).
Histologically, adenocarcinoma accounts for roughly 95% of all clinically
diagnosed prostate cancers, most commonly originating in the peripheral zone.
Additional histological subtypes that can occur within the prostate include: small cell
(anaplastic) carcinoma, lymphoma, sarcoma, basal cell carcinoma, and transitional cell
carcinoma (Rubin 2001). The most widely used histologic grading system for prostate
cancer was first introduced by Gleason and Mellinger (Gleason 1974), and is called the
Gleason score. A discrete value ranging from 1 to 5 is used in the creation of the Gleason
score, with higher values indicating increasing degree of malignancy of histologic
pattern. The total Gleason score is the sum of the two most common histologic patterns,
resulting in a discrete numerical value ranging from 2 to 10. Prostate cancer patients with
higher Gleason scores tend to have a poorer prognosis, as Gleason score is correlated
with both pathological staging and survival (Rubin 2001).
2.4

Prostate Cancer Staging

The most commonly used prostate cancer staging system is the American Joint
Committee on Cancer (AJCC), TNM classification system. TNM is an acronym that
describes the size and extent of the primary tumor (T), spread to regional lymph nodes
(N) and distant metastasis (M). Once histological finding of prostate cancer is confirmed,
TNM classification can be used to both clinically and pathologically stage the disease.
Clinical staging for prostate cancer occurs prior to the delivery of any definitive therapy,
using information from several preliminary diagnostic tests, such as serum PSA level,
DRE, and imaging. Alternatively, pathological staging is performed following surgical
resection of the prostate, seminal vessels and pelvic lymph nodes with histological
examination of the resected specimens for involvement with prostate cancer. Clinical
and pathological staging is used to assess the extent of the disease and aid in treatment
decision-making (Fleming 1997).
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Several revisions to the AJCC TNM staging definitions for prostate cancer have
occurred since their creation in 1977. The most dramatic change occurred in 1997, where
the T-stage category T2 from the “T” portion of the TNM staging, went from three
subcategories to two subcategories (Fleming 1997). Implementation of the 1997 TNM
system ended in 2002, when the AJCC guidelines were changed back to their original
definitions (Greene 2002). This major change in T-staging for patients treated from the
years 1997 to 2002 is problematic in prostate cancer research, as comparisons between
studies using different TNM definitions can be challenging. The current TNM staging
system implemented in 2010 by the AJCC (Edge 2009) is shown in Tables 1 and 2.
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Table 1: AJCC TNM clinical and pathological staging definitions.
Primary Tumor (T)
Clinical
TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
T1: Clinically inapparent tumor neither palpable nor visible by imaging
T1a: Tumor incidental histologic finding in 5% or less of tissue resected
T1b: Tumor incidental histologic finding in more than 5% of tissue resected
T1c: Tumor identified by needle biopsy (for example, because of elevated PSA)
T2: Tumor confined within prostate
T2a: Tumor involves one-half of one lobe or less
T2b: Tumor involves more than one-half of one lobe but not both lobes
T2c: Tumor involves both lobes
T3: Tumor extends through the prostate capsule
T3a: Extracapsular extension (unilateral or bilateral)
T3b: Tumor invades seminal vesicles(s)
T4: Tumor is fixed or invades adjacent structures other than seminal vesicles, such as
external sphincter, rectum, bladder, levator muscles, and/or pelvic wall
Pathologic (pT)
pT2: Organ confined
pT2a: Unilateral, one-half of one side or less
pT2b: Unilateral, involving more than one-half of side but not both sides
pT2c: Bilateral disease
pT3: Extraprostatic extension
pT3a: Extraprostatic extension or microscopic invasion of bladder neck
pT3b: Seminal vesicle invasion
pT4: Invasion of rectum, levator muscles, and/or pelvic wall
Regional Lymph Nodes (N)
Clinical
NX: Regional lymph nodes were not assessed
N0: No regional lymph node metastasis
N1: Metastasis in regional lymph node(s)
Pathologic
pNX: Regional nodes not sampled
pN0: No positive regional nodes
pN1: Metastases in regional node(s)
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Distant Metastasis (M)
M0: No distant metastasis
M1: Distant metastasis
M1a: Nonregional lymph node(s)
M1b: Bone(s)
M1c: Other site(s) with or without bone disease
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Table 2: AJCC prostate cancer anatomical stage/prognostic groupings.
Stage I
T1a-T1c, N0, M0, PSA < 10, Gleason ≤ 6
T2a, N0, M0, PSA < 10, Gleason ≤ 6
T1-2a, N0, M0, *PSA X, βGleason X
Stage IIA
T1a-T1c, N0, M0, PSA < 20, Gleason = 7
T1a-T1c, N0, M0, 10 ≤ PSA < 20, Gleason ≤ 6
T2a, N0, M0, 10 ≤ PSA < 20, Gleason ≤ 6
T2a, N0, M0, PSA < 20, Gleason = 7
T2b, N0, M0, PSA < 20, Gleason ≤ 7
T2b, N0, M0, *PSA X, βGleason X
Stage IIB
T2c, N0, M0, any PSA, any Gleason
T1-T2, N0, M0, PSA ≥ 20, any Gleason
T1-T2, N0, M0, any PSA, Gleason ≥ 8
Stage III
T3a-T3b, N0, M0, any PSA, any Gleason
Stage IV
T4, N0, M0, any PSA, any Gleason
Any T, N1, M0, any PSA, any Gleason
Any T, any N, M1, any PSA, any Gleason
*PSA X = PSA not assessed
β
Gleason X = Gleason not assessed
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2.5

Risk Stratification and Treatment Options

Historically, prostate cancer patients have been grouped into three prognostic risk
categories, low-, intermediate- and high-risk. The three risk categories are used to predict
risk of disease recurrence and metastasis as well as tailor therapy (Rubin 2001). The
combination of serum PSA, Gleason score and T-stage are the most universally accepted
prognostic factors used to stratify patient risk, with all three prognostic factors being
independently associated with increased risk of disease progression (Partin 1997).
Although there is currently a debate whether updating the Genitourinary Radiation
Oncologists of Canada (GUROC) three-category, risk-stratification system for prostate
cancer is warranted, the current consensus requirements remain unchanged (Lukka 2001,
Rodrigues 2012). Table 3 shows the current GUROC consensus requirements for
prostate cancer, three-category risk stratification (Lukka 2001) and the most commonly
used treatment options for patients in each risk category (Keyes 2013, Rubin 2001,
Thompson 2007).
As highlighted in Table 3, there is a wide range of treatment options available to
prostate cancer patients in each risk category. Currently, there are three primary
treatment modalities that are used with curative intent for men with prostate cancer, RP,
EBRT and BT (Thompson 2007). All three treatments can be used alone, for patients
with clinically localized disease, or they can be used in combination with other therapies
for locally advanced, high-risk patients. Due to the slow growing nature of prostate
cancer, active surveillance, or the process of observing a patient until their disease
reaches a critical stage before providing therapy, is a unique option available to low-risk
patients. Although observation is an attractive option for older men with low-risk cancer,
it is not suitable for those in the intermediate- or high-risk categories, as these individuals
have disease generally requiring intervention (Keyes 2013). In the case of metastatic
disease, patients usually are no longer given primary therapies with curative intent.
Androgen deprivation therapy (ADT) is a hormone therapy predominantly used alone or
in combination with small doses of radiation to palliate patients with metastatic prostate
cancer. ADT can also be used in the adjuvant setting for patients with locally confined
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disease (Rubin 2001). Although the decision on treatment modality primarily depends on
patient risk category, other factors such as the patient age, comorbid conditions, and
personal preference can determine treatment choice (Keyes 2013, Rubin 2001,
Thompson 2007).
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Table 3: GUROC consensus requirements and treatment options by prostate cancer risk.
Risk
GUROC Consensus
Standard Treatment Options
Category
Low
Must have all of the
Observation (active surveillance or watchful
following:
waiting);
Radical prostatectomy +/- nerve sparing;
• PSA ≤ 10 ng/mL
• Gleason Score ≤ 6 External beam radiation only;
Brachytherapy only
• Stage T2a or less
Intermediate Must have all of the
following if not low-risk:
• PSA ≤ 20ng/mL
• Gleason Score < 8
• Stage T1/T2
High

Radical prostatectomy +/- lymphadenectomy;
External beam radiation +/- ADT;
Brachytherapy +/- ADT;
External beam radiation + brachytherapy +/ADT

Must have at least one of
the following:
• PSA > 20ng/mL
• Gleason Score ≥ 8
• Stage ≥ T3a

Prostatectomy +/- lymphadenectomy +
External beam radiation + ADT;
External beam radiation only + ADT;
External beam radiation + brachytherapy +
ADT;
ADT only
Abbreviations: ADT = androgen deprivation therapy; PSA= prostate specific
antigen; GUROC= Genitourinary Radiation Oncologists of Canada
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2.6

Surgical Management of Prostate Cancer

RP has been established as an appropriate monotherapy for treatment of clinically
localized prostate cancer (Thompson 2007). RP involves complete removal of the
prostate gland, seminal vesicles and part of the vas deferens. Commonly, RP is
performed using an open retropubic or perineal incision, with both techniques yielding
similar recurrence rates and survival (Lance 2001). Due to high rates of impotency and
incontinence associated with RP, a nerve-sparing surgical technique can be performed on
men with favorable tumor and patient characteristics. This technique has been found to
yield desirable results in men, with up to 70% reporting returned potency following
surgery (Catalona, 1999). The overall improvement of symptoms from nerve-sparing
surgery depends on patient selection. The lowest rates of impotency following RP
reported in the literature tend to include younger, healthier men, with less advanced
disease (Talcott 1997). Pelvic lymphadenectomy is generally performed concurrently
with RP in patients at high risk for nodal spread (Rubin 2001). An advantage of RP over
other treatment options is that complete removal of the prostate gland will result in cure
when disease is truly localized. However, when disease has spread outside of the prostate
gland, additional therapies must be considered to reduce risk of recurrence (Thompson
2007).
There are a number of acute and chronic side effects from RP that can impact
patient quality of life. Erectile dysfunction (ED) is common in men following RP, with
varying degrees of severity. Factors that can influence the severity of ED include:
whether nerve-sparing surgery was used, patient age, the patient’s ability to achieve and
maintain erections prior to surgery, and the use of ED medications such as Sildenafil
(Viagra) following surgery (Kundu 2004, Stanford 2000, Walsh 2000). Urinary
incontinence, urethral stricture, rectal pain and rectal incontinence are additional
complications that can occur following RP (Benoit 2000). Short-term morbidities from
the surgical procedure are rare, but include myocardial infarction, thrombosis, wound
infection and death (Shabbir 2005).
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2.7

Radiation Therapy Management of Prostate Cancer
2.7.1

Introduction

RT is the therapeutic delivery of ionizing radiation with the aim of reducing or
eliminating disease. The biological mechanism of how the radiation dose is deposited in
the tissue is quite complex. On the cellular level, charged particles (protons and
electrons) and uncharged particles (photons and neutrons) excite water molecules, which
create secondary reactive molecules called free radicals. These free radicals damage the
deoxyribonucleic acid (DNA) within the cell, leading to apoptosis, or cell death. Because
radiation damages both cancer cells and normal cells, there is a constant trade-off
between delivering adequate dose to the tumor target and attempting to spare the
surrounding tissues. Cells that are actively dividing are known to be more sensitive to
radiation than slower growing cells. This feature of radiation allows it to be very
effective in treating cancers with high rates of growth. Additionally, dose fractionation
(partitioning of dose) and ensuring adequate tissue oxygenation take advantage of the
radiobiology of tumor cells and have been shown to improve the therapeutic effect of RT
treatments (Washington 2004).
With respect to RT management of prostate cancer, EBRT and BT are standard
treatment options (Rubin 2001). No definitive randomized controlled trial data exists
directly comparing either RT treatment modality to RP with respect to patient important
outcomes. Observational data have demonstrated that both EBRT and BT provide local
control and survival benefits similar to RP in men with regionally localized prostate
cancer (Thompson 2007). Two large observational studies suggest both BT and EBRT
are superior to RP with respect to ED and urinary incontinence, but inferior in preventing
bowel toxicities (Martin 2008, Resnick 2013).
Higher doses of radiation have been shown to improve probability of cure
following RT treatment for prostate cancer (Washington 2004). However, the incidence
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of gastrointestinal (GI) and genitourinary (GU) side effects increases when higher
volumes of the pelvis are irradiated. Possible acute GI side effects from RT treatments
include proctitis, diarrhea, abdominal cramps, rectal bleeding and fecal incontinence. GU
side effects include cystitis, frequency, dysuria, hematuria, urethral stricture and loss of
potency or ED. EBRT can cause irritation to the skin in the treatment field, ranging from
mild erythema and pruritus, to dry or moist desquamation. Rectal injury is uncommon
from TRUS-guided BT, although it can occur. Fatigue is also a common side effect for
men receiving RT treatments for prostate cancer (Rubin 2001).
2.7.2

External Beam Radiation Therapy (EBRT)

EBRT has been established as a form of radiation therapy delivery that provides
excellent local control and relatively low risk of long-term morbidity for prostate cancer
patients. EBRT uses high-energy photons that penetrate tissue and deliver radiation dose
to the tumor target. EBRT machines deliver focused beams of radiation at different
angles so that the highest dose reaches the tumor, while shielding is used to spare
surrounding tissues. Currently, there is no consensus on what standard EBRT dose
prescription, treatment technique or fractionation schedule should be used to treat
prostate cancer. A typical EBRT treatment course for a prostate cancer patient involves
daily treatments given over approximately 6 to 8 weeks. In cases where there is a high
probability of local or regional spread, whole pelvis EBRT is generally given, with doses
of 46-50 Gy prescribed to the pelvic lymph nodes and 54-56 Gy to the seminal vesicles
(Washington 2004).
The development of 3D conformal and IMRT treatment planning and delivery
techniques has allowed higher doses to be delivered to patients with improved accuracy.
One randomized controlled trial containing 393 patients with low- to intermediate-risk
prostate cancer found conformal EBRT doses of 79 Gy reduced PSA biochemical
recurrence by >15% compared to doses of ≤70 Gy (p < 0.001). However, there was no
statistically significant difference in overall survival or long-term side effects between the
groups at 5-years (Zeitman 2005). Long-term follow-up of another randomized trial with
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low- to high-risk patients found similar results, with a high dose of 78 Gy leading to nonfailure rates of 70% compared to 64% in the 70 Gy group at 6-years (p <0.03) (Pollack
2002). Currently, there is a lack of quality evidence to indicate whether dose escalation
is beneficial for low-risk prostate cancer patients. Observational data and subgroup
analysis from a randomized controlled trial have found doses >70 Gy to significantly
reduce biochemical recurrence in men with PSA > 10ng/mL, but not in those with PSA <
10ng/mL (Hanks 1998, Pollack 2002).
As a single modality therapy, EBRT can be used to treat patients with low-,
intermediate- and high-risk of recurrence. An advantage of EBRT over RP is that it can
be prescribed for patients who are unfit for surgery (Rubin 2001). Post-operative RT to
the pelvic lymph nodes and prostate bed following RP has become a frequently
prescribed treatment of high-risk prostate cancer. One large, European randomized
controlled trial, found immediate post-operative RT improves biochemical progressionfree survival (hazard ratio = 0.49; 95% CI, 0.41-0.59) at > 10-years in patients with highrisk prognostic features (capsular perforation, positive surgical margins, or seminal
vesicle invasion) compared to delayed management (Bolla 2012). A separate American
randomized trial with 425 men, with a median follow-up of 10.5 years, reported
significantly reduced PSA relapse (hazard ratio = 0.43; 95% CI, 0.31-0.58) and disease
recurrence (hazard ratio = 0.62; 95% CI, 0.46-0.82) with postoperative EBRT compared
to observation, but found no statistically significant difference in overall survival
(Thompson 2006). Additionally, EBRT can be used to treat bone metastases originating
from prostate cancer. Single fraction EBRT doses of 8 Gy have been shown to be
equally effective at relieving pain symptoms from metastatic bone lesions compared to
multiple fraction doses (20 Gy in 5 fractions or 30 Gy in 10 fractions), with roughly 60%
of patients experiencing relief of their pain (Sze 2004).
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2.7.3

Brachytherapy (BT)

The second radiation therapy option available to prostate cancer patients is BT.
The term brachytherapy originates from the Greek word “brachys” meaning “short
distance” therapy (Devlin 2007). For prostate cancer patients, BT involves the surgical
implantation of small radioactive sources (seeds) in and around the prostate. These
radioactive sources decay creating alpha, beta and gamma particles, which ionize cellular
molecules (including DNA), depositing dose similar to EBRT (Beltas 2007). BT is a
highly conformal therapy; meaning the radiation dose delivered is tightly confined to the
cancer target, with surrounding tissues only receiving relatively low doses. The
conformal dose achievable with BT can be attributed to the short-range radiation
produced by the implanted sources, which have a steep dose fall-off with distance (Khan
2003). As a result, BT can achieve higher doses to the tumor target compared to EBRT
and still adequately spare the surrounding tissues (Washington 2004).
For prostate cancer, TRUS guided LDR-BT can be used alone as a single
modality treatment or to boost radiation dose to the primary tumor following EBRT.
LDR-BT treatments usually involve a one-day, outpatient surgical procedure, where
radioactive sources are permanently implanted within the prostate bed (Keyes 2013).
This is one advantage of LDR-BT, as the time commitment for patients is much less than
EBRT. Postoperative recovery following LDR-BT is quick in comparison to RP, with
the potential for patients to undergo spinal, instead of general anesthetic (Keyes 2013).
The effective treatment time for LDR-BT, or the time it takes for the permanent LDR-BT
sources to fully decay and deposit the total dose, can last up to 9 months depending on
the radioactive isotope used (Ling 1992).
Commercially available iodine-125 (I-125) and palladium-103 (Pd-103) are the
most common radioisotopes used for LDR-BT. Standard minimum prescription doses of
144 Gy for I-125 and 115-120 Gy for Pd-103 are recommended by the American
Brachytherapy Society for permanent seed LDR-BT (Nag 1999). An additional isotope,
cesium-131, has also been explored for LDR-BT monotherapy use in the United States,
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with a prescribed dose of 115 Gy (Kehwar 2009). For radiation boost following 40 to 50
Gy EBRT, LDR-BT doses of 100-110 Gy I-125 and 80-90 Gy Pd-103 are recommended
(Nag 1999). Studies have shown that patients with favorable risk factors treated with
either I-125 or Pd-103 LDR-BT have biochemical free recurrence rates >90% at 5-years
(Blasko, 2000; Grimm 2001). No association has been found between radioisotope type
and BT treatment efficacy (Merrick 2001, Rodrigues 2013).
HDR-BT is an additional radiation therapy technique available to men with
prostate cancer. HDR-BT differs from LDR-BT with respect to the treatment delivery
process and overall treatment time. HDR-BT sources have a higher dose per unit time
than LDR-BT sources. As a result, HDR-BT treatments are usually delivered in multiple
fractions to allow for optimal normal tissue repair (Nag 1994). Handling of HDR-BT
sources can be dangerous due to the potential of rapid overexposure. The invention of
automated devices that insert and remove the HDR-BT sources remotely (referred to as
afterloading units), have allowed physicians to safely perform HDR-BT treatments from
outside the treatment room (Henschke 1963). Prior to prostate HDR-BT treatment
delivery, the patient is placed under epidural or spinal anesthesia, while temporary
catheter tubes are surgically implanted throughout the target volume. Following patient
recovery, CT imaging is used to create an optimized treatment plan, accounting for the
location of the implanted catheters, while maximizing dose to the target volume and
limiting dose to the surrounding tissues. During HDR-BT treatment delivery, radiation
dose is delivered as the HDR-BT source “dwells” inside the patient at computer
calculated points along the implanted catheters. These pre-calculated dwell points are
planned so that they optimize radiation dose uniformity throughout the target volume
(Slessinger 2010). Although the treatment time required for HDR-BT delivery via
remote afterloading units can vary depending on the total dose prescribed and source
strength, it generally lasts approximately 10 to 20 minutes (Keyes 2013). For an average
size prostate, the use of 15 to 20 implanted catheters has been found to provide adequate
tumor dose coverage for HDR-BT treatments (Charra-Brunaud 2003).
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Iridium-192 (Ir-192) is the most common radioisotope used in HDR-BT. Prostate
HDR-BT is predominantly used concurrently with EBRT to boost dose to the primary
tumor in men with intermediate- to high-risk disease. Original HDR-BT boost treatment
regimens developed in the 1980’s gave two Ir-192 HDR-BT treatments of 15 Gy each,
following 40-50 Gy pelvic RT (Nag 1994). More modern HDR-BT treatments tend to
have lower doses of either 10 Gy fractions delivered over two treatments with concurrent
45 Gy EBRT, or a single 15 Gy HDR-BT treatment given with 37.5 Gy EBRT (Morton
2011). In general, HDR-BT+EBRT dose regimens reported in the literature have
estimated EQD2Gy doses 25% to 50% higher than standard fraction, 74 Gy EBRT (Fowler
2005, Morton 2011). Monotherapy HDR-BT has been shown to have similar
biochemical control as LDR-BT with potentially reduced urinary and rectal toxicities in
low-risk patients (Grills 2004). However, more studies are required to determine the full
utility of monotherapy HDR-BT in the treatment of prostate cancer.
2.8

Additional Treatment Options
2.8.1

Observation (Active Surveillance/Watchful Waiting)

Evidence from autopsy series estimates roughly 20-30% of men over the age of
70 years old will have asymptomatic, undiagnosed prostate cancer (Sanchez-Chapado
2003; Stamatiou 2006). The use of PSA screening likely has increased the over diagnosis
and over treatment of prostate cancers, especially in men with low-risk disease (Klotz
2013). In general, conservative management for patients with low-volume, low-risk
prostate cancer is provided using active surveillance protocols. Recommendations for
patients under active surveillance are to perform serial PSA tests, DRE exams and annual
biopsy while they are followed (Klotz 2013). A positive test result from a rising PSA or
evidence of histological progression initiates decision on definitive, curative therapy.
This differs from watchful waiting protocols, where patients are passively followed until
clinical symptoms present, usually indicative of disseminated disease. Therefore,
patients who receive watchful waiting tend to not undergo curative therapy because, by
the time they are symptomatic, they have metastatic disease and so, instead, they are
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palliated at the appropriate time. This is why active surveillance is preferred for
individuals with low-risk prostate cancer, so that patients have the potential of being
spared unnecessary morbidity from radical therapies, yet still preserving the chance for
cure (Klotz 2012).
No randomized data exists comparing active surveillance to RP or RT in entirely
low-risk patients. However, two recent RCTs have attempted to compare watchful
waiting to RP in men with prostate cancer, yielding conflicting results (Bill-Axelson
2011, Wilt 2012). The first of these trials, named the Prostate Cancer Intervention
Versus Observation (PIVOT) trial, contained 731 men diagnosed with prostate cancer
from 1994 to 2002. Results from the PIVOT trial indicated that there was no OS
difference between watchful waiting compared to RP with a reported hazard ratio of 0.88
(95% CI 0.71 to 1.08) (Wilt 2012). The results of the PIVOT trial were contradictory to
the second trial, that found RP to be superior to watchful waiting, reporting a relative risk
of death of 0.75 (95% CI 0.61 to 0.92) after 15-year follow-up of 695 prostate cancer
patients (Bill-Axelson 2011). Both of these trials included patients with low-,
intermediate- and high-risk prostate cancers, making it difficult to compare efficacy of
observation versus RP in entirely low-risk patients. Lower level evidence from cohort
studies suggest active surveillance provides acceptable treatment outcomes for low-risk
patients. One Canadian, single arm cohort study found that out of 450 low-risk patients
treated with active surveillance, 30% were upgraded to higher risk disease and given
either RT or RP, with only 1% dying from prostate cancer during a 10-year follow-up
(Klotz 2012). Due to the lack of evidence, common practice guidelines consider RP,
EBRT, BT and active surveillance as equal options for patients with low-risk cancer, but
not those in the higher risk categories (Keyes 2013, Rubin 2001).
2.8.2

Hormone Therapy

Hormone manipulation using ADT is the standard single modality therapy
reserved for patients with metastatic prostate cancer (Loblaw 2007). The primary goal of
ADT is to block the stimulating effects of testosterone (androgen) on the prostate gland
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and cause the prostate cancer to regress. The testes produce over 90% of the total
circulating testosterone, with the additional 5-10% produced by the adrenal glands (Rubin
2001). Reduction of testosterone produced by the testes can be achieved surgically, with
bilateral orchiectomy, or medically, through the use of luteinizing hormone-releasing
hormone (LHRH) agonists or antagonists that block the production of sex hormones.
LHRH agonists have been found to lower testosterone levels below 50ng/mL, which is
generally achievable through surgical castration. Therefore, both therapies are
considered equally effective (Rubin 2001). The use of antiandrogens to reduce the
remaining testosterone produced by the adrenal glands can be used in combination with
the above-mentioned ADTs and is termed combined androgen blockade (CAB).
However, single ADTs such as LHRH agonists and orchiectomy tend to be preferred over
CAB due to the higher costs associated with CAB and the lack of evidence suggesting
any survival benefits. Additionally, CAB can cause increased severity in patient side
effects, such as decreased libido, fatigue, diarrhea and anemia (Eisenberger 1998).
In addition to the treatment of metastatic disease, ADT is used to treat men with
non-metastatic prostate cancer. ADT given with definitive primary therapy, such as RP
or RT, is recommended for men with locally advanced disease (Rubin 2001). Long-term
follow-up of one randomized trial from the RTOG found that ADT with EBRT led to
improved local-control and disease free-survival compared to EBRT alone in patients
with T3-4 or N1 stage prostate cancer (Lawton 2001). In a separate RCT carried out
jointly by the United States National Cancer Institute and the United Kingdom Medical
Research Council, called the PR3 trial, demonstrated that the addition of ADT to RT
provided improved OS compared with ADT alone after six-year follow-up of 1205 men,
with a reported hazard ratio of 0.77 (95% CI 0.61 to 0.98, p=0.03) (Warde 2011).
Another trial from the European Organization for Research and Treatment of Cancer
found that the 5-year OS was 78% in patients receiving EBRT plus ADT for 3 years
compared to 62% in the EBRT only arm (p<0.001). This study contained a cohort of 412
men with advanced stage, non-metastatic prostate cancer (Bolla 2002). Six-month
androgen suppression following EBRT has been shown to provide similar improvements
in survival in a randomized study of intermediate- to high-risk patients (D’Amico 2004).
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Although the benefits of ADT use in the treatment of men with unfavorable prognostic
features are well documented, there is no definitive evidence to indicate its effectiveness
in clinically localized, low-risk prostate cancer. Observational data indicates that
hormone therapy given with RT significantly reduces PSA biochemical recurrence in
intermediate- and high-risk patients, but not in men with low-risk disease, when
compared to RT alone (D’Amico 2000). Neoadjuvant ADT can be used to reduce tumor
bulk prior to RT or surgery leading to improved local control, as well as identify patients
with hormone sensitive prostate cancer (Lee 1999).
Roughly 10-20% of men do not respond to initial ADT management and are
identified as having castration resistant disease (Rubin 2001, Tannock 2004). Given
enough time, of the remaining men that do initially respond to ADT, the majority will
eventually develop hormone refractory prostate cancer, manifesting symptoms of
treatment failure. Many chemotherapy agents have been studied to help treat patients
with castration resistant prostate cancer, of which taxane derivatives are the most
effective (Tannock 2004). The addition of up-front chemotherapy to ADT management
of hormone sensitive prostate cancer has shown no clinical benefit (Gravis 2013).
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3.0

Comparative Effectiveness Research (CER)
3.1

Introduction

Comparative Effectiveness Research (CER) contrasts the advantages and/or
disadvantages that are afforded to patients receiving different therapies. CER generates
new evidence in the form of experimental or observational studies, or synthesizes
evidence from previous studies through systematic review. The primary goal of CER is
to improve the quality of care provided to patients by creating or compiling evidence,
which can later be used to help guide clinical decision-making (Luce 2010).
Historically, the term CER gained popularity in the United States, through a
government initiative to improve the quality and transparency of their comparative
studies (Wilensky 2006, VanLare 2010). In Canada, the term CER is now becoming
more frequently used and familiar with Canadian researchers when describing their
comparative studies in multiple health care fields (Whicher 2009, Sun 2014).
Commonly, the term Evidence-Based Medicine (EBM) has been used synonymously
with CER, due to the similarities between terms. However, there are some differences
between the definitions of EBM versus CER. For example, both EBM and CER are
focused on evidence synthesis through systematic review, however, EBM is more
focused on using this evidence to drive decision-making and create practice guidelines,
while CER is more focused on improving the evidence created in the primary studies.
Therefore, CER is more concerned with answering both the effectiveness and value
questions of “does it work in a clinical setting?” and “is it worth it?” while EBM takes it
once step further by answering the efficacy and clinical practice driven questions of “will
it work?” and “should we our change practice?” (Luce 2010). As a result, CER shifts the
focus towards the creation of quality primary evidence generation in experimental and
observational studies, which is later used in the EBM decision-making process.
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3.2

CER in Experimental Studies

RCTs are generally considered to be the gold standard in CER. A properly
designed RCT allows researchers to compare different therapies, while also minimizing
the effects of all known and unknown confounding variables, which are, on average,
made equal following randomization. In oncology, RCTs have advanced the care for
patients by enabling investigators to answer important questions regarding the efficacy of
a particular therapy aimed at driving EBM decision-making. RCTs also provide insight
into which subgroups of patients might benefit the most from treatment as well as allow
for prospective follow-up of patient reported side effects aimed at improving quality of
life. Pragmatic RCTs, or experimental studies that are implemented under routine
clinical conditions, fall under the category of CER, as they typically compare the
effectiveness of a drug or therapy compared to the alternative standard of care given to
patients. Additionally, pragmatic RCTs tend to be focused on important outcomes
instead of surrogate end points (Hahn 2012).
Although pragmatic RCTs are the foundation of CER, there are some limitations
that can make RCTs in general less appealing to researchers. RCTs can be costly to
conduct, may require a large number of patients to detect small differences in treatment
effect, may take a long time to finish depending on patient accrual time and the outcomes
investigated, and tend to have highly selected patient enrollment that may not be
representative of actual clinical populations (Friedman 2010). Due to these limitations,
obtaining evidence through other means, such as systematic reviews or observational
studies, can become exceedingly valuable for policy makers (Hahn 2012).
3.3

CER in Observational Studies
3.3.1

Introduction

Although RCTs have long been considered the first choice for evidence
generation in medicine, due to their high level of internal validity and ability to provide
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the least biased estimates of risk, there are many instances where results from
experimental studies are not indicative of real-life application. Observational studies are
a source of evidence generation that can answer research questions that are less suited for
an RCT. For example, observational studies can be more appropriate in instances of rare
diseases, when it is unethical to randomly assign the intervention of interest, when it is
impossible to randomize the factor of interest (eg. a genetic factor), or when it is
impractical to assign the intervention (Friedman 2010). Additionally, observational
studies have the advantage of being less costly and labor intensive to carry out than an
experimental study and can provide initial evidence to support the implementation of a
future RCT (Dreyer 2010).
In CER, observational studies play an important role in the generation of primary
evidence for practice guideline construction and policy driven decision-making. The use
of administrative data in observational studies has the advantage of being inexpensive to
use, contains information on very large populations and provides information on
outcomes requiring a longer follow-up time (Hershman 2012). However, limitations in
observational studies exist, which if not properly accounted for can lead to erroneous
results. The inability to randomly allocate patients to different therapies can lead to
confounding, which occurs when there are imbalances between confounding variables
among patient groups (Hershman 2012). A confounding variable is defined as a variable
that is associated with the primary variable of interest (independent variable) and
associated with the outcome of interest (dependent variable), but is not an intermediate
variable in the causal pathway between the independent variable and dependent variable
(Szklo 2014). Adjustment for confounding is very important, as an imbalance in
confounders has the potential to change the magnitude or even direction of estimated
treatment effect. However, a properly designed study using appropriate analytical
methods can help reduce the confounding bias, or inaccurate estimates of the association
between treatment and outcome that is caused by confounding variables (Hershman
2012).
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3.3.2

Instrumental Variable Analysis

Instrumental variable analysis is an analytical approach that can be used in
observational studies to overcome imbalances between confounding variables among
treatment groups. An instrumental variable “C” estimates the effect of a separate
independent variable “A” on the outcome variable “B” without requiring the
measurement of any confounders that bias the effects of A on B. For C to be a true
instrumental variable, it must satisfy the following assumptions: each patient’s outcome
is not affected by treatment status of other individuals, C is correlated with A, C is not
directly or indirectly associated with B, and all effects of C on B are manifested through
the effects of C on A (Angrist 1996). In theory, the use of an instrumental variable
attempts to balance all known and unknown confounding variables by using a
characteristic that influences the treatment a patient receives, but does not have any sway
on outcome, therefore providing an unbiased means of measuring treatment effect. Thus,
a well-chosen instrumental variable can balance unmeasured confounding in a nonexperimental study in a way similar to that of an RCT (Rassen 2009). However,
validating whether an instrumental variable is appropriate can be challenging, especially
when there are unforeseen associations between the instrumental variable and outcome,
or when the correlation between the instrumental variable and treatment assignment is
weak (Armstrong 2012). Some common instrumental variables found in the literature
include: rates of treatment use by region, physician prescription preferences, distance
from hospital or treatment facility, density of health care providers by geographical area,
health care provider costs, and changes in health care infrastructure (Hershman 2012).
3.3.3

Regression-Based Modeling

Multivariable regression modeling is a traditional analytical approach used in
observational studies to account for confounding bias. Regression-based modeling
allows investigators to estimate the association between a treatment and outcome, while
keeping other covariates in the model constant (Szklo 2014). As long as the number of
outcomes of interest in the study sample is large, regression modeling using either, linear
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regression for continuous outcomes, or logistic regression for binary outcomes, has the
advantage of adjusting for a substantial number of confounding variables. Additionally,
advanced, multi-level modeling techniques are able to adjust for correlated observations,
when clustering of patient outcomes occurs within single institutions in multi-institutional
studies (Armstrong 2012). However, there are some limitations to regression-based
models, some of which include: they do not account for confounders which are not
included in the model, they are unable to provide accurate estimates of association when
there is insufficient overlap among covariates between treatment groups, and they are
bound by the assumptions of the regression model chosen (Vittinghoff 2012).
3.3.4

Matching

Matching is another analytical tool used to control for the influences of
confounding variables. Although matching is predominately used in case-control studies,
it has also been used in cohort studies in oncology to control for multiple prognostic
factors pertaining to survival (Coen 2012, Khor 2013, Pickle 2010, Szklo 2014). There
are many different types of matching techniques that have been developed. Matching
directly on an individual-by-individual basis is the most common, where subjects are
matched so that both individuals have the same baseline-measured covariates. Direct
individual matches are generally made based on both categorical variables (eg. male vs.
female) and continuous variables using cutoff ranges (eg. age ≤ 65 years, or > 65 years)
(Szklo 2014). Frequency matching is another common technique found in comparative
studies, where matched patients are selected based on the distribution of covariates in
each group (Szklo 2014). Minimum Euclidean distance measure matching is a more
complex technique that has been developed to match patients. Matching using minimum
Euclidean distance measures is based on the distance two subjects are apart in their
combination of covariates represented in a standardized score (Smith 1977). An example
of a simple match using minimum Euclidean distance measures is shown in Figure 1,
where patient matches (group #1 and groups #2) are considered based on the covariates
of age and PSA concentration in a two-dimensional diagram. Minimum distance
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matching can be expanded to include multiple variables in ‘n’ dimensional space (Szklo
2014).
There are many advantages and disadvantages in using matching compared to
other analytical techniques. For example, results from matched designs are easily
interpretable and are able to provide balance in confounding baseline prognostic factors
within the treatment groups. Additionally, matching allows for an increase in statistical
power when strong confounders are used to create the matches (Szklo 2014). However,
matching does have several disadvantages, some of which include: reduced sample size
when matches are made based on a large number of variables, association and interaction
assessment between variables used in the matching process is no longer possible, highly
selected matched cohorts can lead to a reduction in the external validity, and possible loss
of statistical efficiency when variables used to match subjects are not strongly correlated
with exposure or outcome (Thompson 1982, Szklo 2014).
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Fig. 1. Diagram demonstrating matching according to minimum distance method.
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3.3.5

Propensity Score (PS) Matched Analysis

Propensity score (PS) matching is an analytical tool that has been used in
observational studies to account for the effects of confounding. Similar to minimum
distance matching, subjects are matched based on having a similar score (known as their
propensity score), which is the estimated probability that an individual would receive a
particular treatment given their specific combination of baseline covariates (Rosenbaum
1983). Multivariable logistic regression modeling is used to generate the PS for each
patient, with treatment assignment as the dependent variable regressed on baseline
prognostic factors found to impact the outcome of interest (Austin 2007). Matching
based on correctly specified propensity score models has been demonstrated to provide
balance in baseline prognostic factors in groups of patients receiving different therapies
in a wide range of settings (Rubin 1996). Once PS matching is completed and adequate
balance in baseline prognostic factors is achieved, investigators can then compare
differences in the occurrence of outcomes between treatment groups. Popular in
oncology, PS matching has been used in a variety of oncology research, including studies
on cancers of the lung, breast, colon, brain, and prostate (Chen 2011, Ganz 2011, Khor
2013, O’Conner 2011, Rodrigues 2013, Verstegen 2013, Wong 2006). Similar to other
matching techniques, PS matching has the advantage of being an active attempt at
balancing baseline prognostic factors in groups of patients that can yield a high-level of
internal validity in an observational study. However, PS matching has the disadvantage
of only being able to provide balance in known confounders that are included in the PS
model. Thus, balance in confounders, that are either unknown to the investigator or are
unavailable to be included in the PS model, cannot be achieved in a PS matched study
like it could be in a RCT (Armstrong 2012).
3.4

CER in Prostate Cancer Radiation Therapy Literature

As was previously discussed, experimental studies are regarded as the highest
form of evidence generation in the CER literature. To date, a relatively small number of
RCTs exist that have aimed to generate evidence comparing treatment outcomes in
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prostate cancer. There are a number of relatively small RCTs comparing surgery to other
treatment options, including two RCTs comparing RP vs. watchful waiting (Bill-Axelson
2005, Wilt 2012), an RCT comparing RP vs. BT (Gilberti 2009) and an RCT comparing
RP vs. EBRT (Paulson 1982). Additionally, there are several RCTs that compare
differences within a single radiation therapy modality, including studies comparing
different EBRT dose fractionation sizes (Lukka 2005, Pollack 2006, Yeoh 2006), EBRT
escalated doses (Kuban 2008, Peeters 2006, Zietman 2005), I-125 vs. Pd-103 BT implant
sources (Merrick 2007), and BT+EBRT dose regimens (Wallner 2005). However, there
is no definitive RCT data available that compares differences in effectiveness between
two or more primary prostate cancer RT treatment modalities. No RCT exists that
compares survival outcomes or side effects in EBRT vs. permanent implant BT
treatments, or BT alone vs. combination BT+EBRT treatments. There is a single
institutional RCT that compares outcomes of combination HDR-BT+EBRT vs. EBRT
alone (Sathya 2005), however, due to some limitations, the evidence generated in this
study can only be considered of lower quality.
In their study, Sathya et al compared 35 Gy Ir-192 permanent seed BT implants
with adjuvant 40 Gy in 20 fractions EBRT to EBRT alone delivered to a total dose of 66
Gy in 33 fractions. A total of 138 patients treated at the Hamilton Regional Cancer
Centre, Hamilton, ON, Canada, from 1992 to 1997 were adequately randomized to
receive HDR-BT+EBRT (n=70) or EBRT only (n=68). OS and bFFS differences
between groups were assessed with a median follow-up of 8 years. Results from this
study indicated that HDR-BT+EBRT led to statistically significantly improved bFFS
compared to EBRT alone (hazard ratio=0.42; p=0.024), but there was a non-statistically
significant difference in OS (hazard ratio=1.36; p=0.54).
There were several study limitations in the RCT by Sathya et al. Intention-to-treat
was violated, as 19 patients in the HDR-BT+EBRT group and 15 patients in the EBRT
group were not included in the final analysis. Therefore, the balance of known and
unknown confounders following randomization was no longer present in their final
analysis. Additionally, the study had the limitation of being a relatively small, single
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institutional study that included a combination of intermediate- and high-risk patients in
their comparison. Subgroup analysis did show that HDR-BT+EBRT significantly
improved bFFS in both intermediate- and high-risk subgroups, however this analysis was
exploratory, making it difficult to assess whether this result is universal across all prostate
cancer risk categories, including low-risk. Finally, EBRT dose was relatively low in this
RCT at only 66 Gy. EBRT doses ≥ 72 Gy have been shown to improve survival
outcomes for localized prostate cancer compared to lower doses (Kupelian 2000).
There are two active RCTs that potentially could improve the quality of evidence
directly comparing RT treatment options. One of these trials, named the Effectiveness of
Prostate Cancer Treatments, or the E-PROSTCaT trial (http://www.clinicaltrials.gov #NCT01492751), compares quality of life measures and survival outcomes in prostate
cancer patients treated with RP, EBRT or LDR-BT. However, results of the EPROSTCaT trial are not expected until at least 2015. The other trial (#NCT00063882),
sponsored by the RTOG (RTOG trial #0232) and the National Cancer Institute, compares
EBRT+BT vs. BT alone in intermediate-risk patients, with results expected in 2017.
Both of these trials are in the data analysis stage and are no longer recruiting patients. An
additional trial was proposed by the British Columbia Cancer Agency to compare EBRT
vs. LDR-BT (#NCT00407875), however, this trial was terminated due to low patient
accrual.
Low patient accrual is one plausible explanation as to why RCTs comparing
prostate cancer therapies are nonexistent in the literature. Differences between the
various prostate cancer treatment modalities are known to impact final treatment choice
(Rubin 2001). Radiation treatments are less invasive than surgery. Several studies have
demonstrated that the risk of GU or GI side effects are not universal across surgical or RT
treatment options (Martin 2008, Resnick 2013, Rubin 2001). The risk of impotency has
been identified as a strong indicator for treatment choice in young, sexually active men,
with the majority finding it difficult to consent to receiving a therapy that might increase
their risk of losing potency (Rubin 2001). Additionally, the time commitment for
patients receiving primary radiation can be quite different depending on treatment
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chosen. For example, dose escalated IMRT treatment delivery can last over 8-weeks in
duration, while permanent BT implantation is delivered on a single day, outpatient basis
(Washington 2004, Keyes 2013). Thus, the advantages and disadvantages of each
therapy could theoretically reduce the number of patients who are willing to enter a trial
that randomizes them into receiving one RT treatment over another, as patients usually
have strong preferences in their treatment selection (Rubin 2001).
Although the available RCT generated CER comparing outcomes from two or
more RT modalities is quite sparse, a large number of observational comparative studies
exist in the literature. Thirty-seven observational CER studies directly comparing
prostate cancer primary RT outcomes were identified upon literature review, 29 of which
were retrospective studies (Abel-Waheb 2008, Aoki 2009, Beyer 2000, Burdick 2009,
Coen 2012, D’Amico 1998, da Silva Franca 2010, Deutsch 2010, Eade 2008, Elliot 2007,
Gelbium 2000, Goldner 2012, Gondi 2007, Huang 2010, Klein 2009, Khor 2013, Krestin
2000, Kupelian 2004, Nieder 2008, Ojha 2010, Pe 2009, Pickles 2010, Pinkawa 2010,
Vassil 2010, Wong 2009, Zelefsky 1999, Zelefsky 2008, Zelefsky 2011, Zhou 2009) and
eight were prospective studies (Davis 2001, Ferrer 2008, Joseph 2008, Kalakota 2010,
Lee 2001, Lev 2009, Smith 2009, Talcott 2003). Methods used to adjust for confounding
included various forms of regression modeling in 30 studies (Abel-Wahab 2008, Aoki
2009, Beyer 2000, Burdick 2009, D’Amico 1998, d Silva Franca 2010, Deutsch 2010,
Eade 2008, Elliot 2007, Ferrer 2008, Gelbium 2000, Goldner 2012, Gondi 2007, Huang
2010, Kalakota 2010, Klein 2009, Kupelian 2004, Nieder 2008, Ojha 2010, Pe 2009,
Pinkawa 2010, Smith 2009, Talcott 2003, Vassil 2010, Wong 2009, Zelefsky 1999,
Zelefsky 2008, Zelefsky 2011, Zhou 2009) and matching in four studies (Coen 2012,
Khor 2013, Krestin 2000, Pickles 2010). No study on primary radiation outcomes
involved the use of instrumental variable analysis, and three studies reported unadjusted
results, making no effort to account for confounding variables (Davis 2001, Joseph 2008,
Lee 2001). A summary of these observational studies on primary RT outcomes as well as
the RCT by Santhya et al are shown in Appendix I. A description of the literature search
strategy for CER articles directly comparing primary RT outcomes is described in
Appendix II.
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With respect to survival outcomes, biochemical failure was assessed in the highest
number of observational studies, totaling 20 (Beyer 2000, Burdick 2009, Coen 2012,
D’Amico 1998, da Silva Franca 2010, Deutsch 2010, Eade 2008, Goldner 2012, Gondi
2007, Klein 2009, Khor 2013, Krestin 2000, Kupelian 2004, Pe 2009, Pickles 2010,
Pinkawa 2010, Vassil 2010, Wong 2009, Zelefsky 1999, Zelefsky 2011). However, a
number of limitations in the bFFS comparisons existed in these studies. For example,
different biochemical failure definitions were used, including the original RTOG-ASTRO
definition of three consecutive PSA rises following nadir (Roach 2006) in four studies
(Gondi 2007, Krestin 2000, Kupelian 2004, Zelefsky 1999), and the more currently
accepted ASTRO-Phoenix definition of a PSA rise of 2ng/mL, or more, following nadir
(Roach 2006) in 16 studies (Burdick 2009, Coen 2012, da Silva 2010, Deutsch 2010,
Eade 2008, Goldner 2012, Gondi 2007, Klein 2009, Khor 2013, Pe 2009, Pickles 2010,
Pinkawa 2010, Vassil 2010, Wong 2009, Zelefsky 2011). This made it difficult to
compare results of biochemical failure in older studies compared to more modern ones.
Biochemical failure was also included as part of a composite outcome, failure-freesurvival (FFS), in one additional study, defined as the initiation of secondary therapy,
positive biopsy post-treatment, PSA rise of 10 ng/dL or more even without three
consecutive elevations, or development of metastasis (Beyer 2000). Additionally,
follow-up was short in the majority of these studies, with only eight studies having a
follow-up time ≥ 8-years (Beyer 2000, Burdick 2009, Coen 2012, Deutsch 2010, Goldner
2012, Klein 2009, Khor 2013, Zelefsky 2011). Only four of these studies with longer
follow-up included patients from multiple cancer centres (Coen 2012, Deutsch 2010,
Goldner 2012, Klein 2009) and only three studies accounted for differences in ADT use
between treatment groups (Coen 2012, Klein 2009, Khor 2013).
One additional issue with the majority of observational studies using bFFS as
their primary outcome (Burdick 2009, Coen 2012, da Silva Franca 2010, Deutsch 2010,
Eade 2008, Goldner 2012, Gondi 2007, Klein 2009, Khor 2013, Krestin 2000, Kupelian
2004, Pe 2009, Pickles 2010, Pinkawa 2010, Vassil 2010, Wong 2009, Zelefsky 1999,
Zelefsky 2011), was that comparisons were made in populations composed of mixed low,
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intermediate and high-risk patients. This made it difficult to distinguish how PSA failure
from the compared RTs would be affected within each prostate cancer risk category.
There were only eight studies that assessed comparative cohorts made up of a singular
prostate cancer risk category; five assessed entirely low-risk patients (Eade 2008,
Goldner 2012, Pe 2009, Zelefsky 1999, Zelefsky 2011) and three assessed intermediaterisk patients (Gondi 2007, Klein 2009, Vassil 2010). Three of the five low-risk studies
compared ASTRO-Phoenix bFFS differences in patients receiving LDR-BT vs. EBRT
with ≥ 5-years of follow-up time (Goldner 2012, Pe 2009, Zelefsky 2011). In the lowrisk studies by Goldner et al and Pe et al, both compared 74 Gy EBRT to 144 Gy I-125
permanent implant LDR-BT. Goldner et al reported no clinically significant difference in
bFFS between groups, reporting 5-year survival percentages of 94% (LDR-BT, n=667)
and 91% (EBRT, n=170), while Pe et al reported similar 5-year survival percentages of
96% (LDR-BT, n=171) vs. 95% (EBRT, n=189), p=0.70. The low-risk study by
Zelefsky et al (2011) reported results of a comparison between high dose 81 Gy IMRT
(n=448) vs. the same LDR-BT dose regimen of 144 Gy (n=281). Their results
demonstrated a statistically significant difference in 5-year bFFS of 95% (LDR-BT) vs.
89% (EBRT), p=0.04. Although efforts were made to account for confounding, through
Cox proportional hazard regression adjustment, in all of the low-risk prostate cancer
studies comparing ASTRO-Phoenix defined bFFS, two of the studies did not account for
differences in ADT use (Goldner 2012, Zelefsky 2011), and another study by Pe et al,
reported results from their single institution with a relatively short median follow-up of
37 months in their BT cohort.
In the intermediate-risk studies that compared ASTRO-Phoenix bFFS, 144 Gy
LDR-BT was compared to EBRT doses ranging from 70-80 Gy (Vassil 2010), or a
singular dose prescription of 81 Gy (Klein 2009). Vassil et al reported a non-statistically
significant difference in bFFS comparing LDR-BT (n=256) vs. EBRT (n=305) with a
hazard ratio of 0.99 (95% CI 0.62-1.58, p=0.97). Similarly, Klein et al reported nonstatistically significant bFFS 8-year actuarial percentages of 82% (LDR-BT, n=204) vs.
75% (EBRT, n=321), p>0.05. Again, attempts to account for confounding though Cox
regression adjustment was performed in both studies, however, one of the studies made
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the mistake of classifying the prostate cancer etiological factor ‘race’ as a prognostic
factor in their adjustment (Vassil 2010). Race is known to be a risk factor for the
development of prostate cancer, but is not known to impact treatment prognosis (Rubin
2001). Since race is thus not a classical confounding variable, as it is not associated with
the outcome of interest, some authors feel that it should not be included in the regression
model (Szklo 2014). Klein et al, accounted for the confounder ADT use in their study by
eliminating all ADT patients, this was not done by Vassil et al. However, Klein et al did
not report age differences between groups, and made no reference to adjusting for this
strong confounder in their analysis.
Attempts to ascertain results comparing bFFS in separate risk categories were
attempted in five studies through subgroup analyses (Coen 2012, Deutsch 2010, Khor
2013, Pickles 2010, Wong 2009). Beyond that cautious interpretation of subgroup
analysis is universally recommended, due to the increased likelihood of chance findings
(Friedman 2010), there were some additional limitations found in these exploratory
analyses. For example, one study did not account for ADT (Deutsch 2010), while
another study did not account for either ADT or age (Wong 2009). There were also some
limitations in two additional matched studies, one using conventional 1:1 case-by-case
matching (Pickles 2005) and the other using propensity score matching (Khor 2013). In
their single institutional, Canadian study, Pickles et al compared bFFS in a cohort of lowand intermediate-risk patients, receiving either 145 Gy I-125 LDR-BT (n=139) or 52-72
Gy EBRT (n=139). Although matching did bring balance to comparison groups with
respect to most of the important prognostic factors, including ADT, the confounding
variable age was curiously not used in the matching process. This led to a >7 year
median age gap between treatment groups. In their subgroup analysis, Pickles et al
reported 5-year bFFS actuarial percentages of 94% (LDR-BT) vs. 88% (EBRT), p<0.001,
for low-risk patients, and 100% (LDR-BT) vs. 78% (EBRT), p=0.02, for intermediaterisk patients, respectively. In another single institutional study from Australia, Khor et al
compared 19.5 Gy Ir-192 with 46 Gy adjuvant EBRT (HDR-BT+EBRT) to 74 Gy EBRT
alone using propensity score matched analysis (total n=688, matched ratio 1:1). Their
cohort was comprised of intermediate- and high-risk patients, and PS matching was
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performed based on the variables of age, ADT use and prostate cancer risk category.
Results from subgroup analysis showed a statistically significant improvement in bFFS in
the HDR-BT+EBRT compared to the EBRT patients with intermediate-risk disease
(hazard ratio=0.44, 95% CI 0.28-0.70, p<0.001), but a non-statistically significant
difference in the high-risk patients (hazard ratio=0.82, 95% CI 0.52-1.28).
The outcome of OS was assessed in a relatively low number of studies found in
the literature (Coen 2012, Klein 2009, Zhou 2009, Wong 2009). Coen et al reported a
non-statistically significant difference in OS (secondary outcome) between high dose
protons with adjuvant EBRT vs. EBRT alone, with 8-year actuarial percentages of 93%
vs. 96% (p=0.45). Zhou et al reported a significant difference between BT (n=664) and
EBRT (n=876), with 5-year OS percentages of 82% and 72% (p<0.001), respectively.
However, the type of BT (HDR or LDR) and source type (I-125, Pd-103, Ir-192) was not
reported by Zhou et al, as well as total dose, fractionation schedule or ADT use. This
made it difficult to decipher the exact comparison being made. Klein et al reported a
borderline statistically significant difference in their LDR-BT vs. EBRT comparison of
OS in entirely intermediate-risk patients, with 8-year actuarial percentages of 94% (LDRBT) vs. 81% (EBRT).
There were a number of additional primary outcomes that were investigated in the
prostate cancer CER RT literature, including late GI or GU side effects (Aoki 2009, Elliot
2007, Gelbium 2000, Kalakota 2010, Zelefsky 2008), patient reported quality of life
(Davis 2001, Ferrer 2008, Huang 2010, Joseph 2008, Lee 2001, Lev 2009, Smith 2009,
Talcott 2003) and secondary cancers (Abel-Waheb 2008, Nieder 2008, Ojha 2010).
However, our CER study only focuses on overall survival and biological failure
outcomes. For reference, the results from these studies are available in Appendix I.
Upon literature review, it was clear that the CER comparing primary RT survival
outcomes is lacking. Most studies that were found compared primary RT survival
outcomes in a mixture of low-, intermediate- and high-risk patients, with very few studies
comparing treatment differences within one prostate cancer risk group. A short follow-
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up time and poor adjustment for ADT use between comparative groups were also
important limitations that were seen. The goal of this study is to help improve the quality
of CER evidence by retrospectively comparing primary RT survival outcomes in
separately matched prostate cancer risk groupings, in the absence of ADT use.
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4.0

Research Study
4.1

1a)

Primary Study Objectives

To compare overall survival rates between prostate cancer patients who received
either external beam radiation alone or brachytherapy with or without adjuvant
external beam radiation as their primary mode of treatment.

1b)

To compare overall survival rates for propensity score matched low-risk prostate
cancer patients that received external beam radiation alone or low dose rate
brachytherapy.

1c)

To compare overall survival rates for propensity score matched intermediate-risk
prostate cancer patients that received external beam radiation alone or
brachytherapy (low dose rate brachytherapy alone or high dose rate brachytherapy
with adjuvant external beam radiation).

1d)

To compare overall survival rates for propensity score matched high-risk prostate
cancer patients that received external beam radiation alone or brachytherapy (low
dose rate brachytherapy alone or high dose rate brachytherapy with adjuvant
external beam radiation).
4.2

2a)

Secondary Study Objectives

To compare biochemical failure-free survival rates between prostate cancer
patients who received either external beam radiation alone or brachytherapy with
or without adjuvant external beam radiation as their primary mode of treatment.

2b)

To compare biochemical failure-free survival rates for propensity score matched
low-risk prostate cancer patients that received external beam radiation alone or
low dose rate brachytherapy.
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2c)

To compare biochemical failure-free survival rates for propensity score matched
intermediate-risk prostate cancer patients that received external beam radiation
alone or brachytherapy (low dose rate brachytherapy alone or high dose rate
brachytherapy with adjuvant external beam radiation).

2d)

To compare biochemical failure-free survival rates for propensity score matched
high-risk prostate cancer patients that received external beam radiation alone or
brachytherapy (low dose rate brachytherapy alone or high dose rate brachytherapy
with adjuvant external beam radiation).
4.3

Study Hypothesis

The overall hypothesis of this study is that brachytherapy with or without
adjuvant external beam radiation provides superior overall survival and biochemicalfailure-free survival compared with external beam radiation alone as a primary treatment
option for prostate cancer patients.
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5.0

Methods
5.1
1.

Summary of Methods
Conducted a literature review to obtain expert knowledge on prostate cancer
radiation and propensity score matching methodology.

2.

Established a theoretical casual framework for the mechanism of action of
radiation treatment on survival by modeling a directed acyclic graph (DAG)

3.

Performed ProCaRS database quality assurance to ensure patients were
correctly risk-stratified.

4.

Obtained low-, intermediate-, and high-risk study populations from the
ProCaRS database using appropriate inclusion and exclusion criteria.

5.

Selected preliminary comparison populations in each risk strata based on
sample size.

6.

Selected the covariates used to create the propensity score models for each
comparison group based on literature review and availability in the ProCaRS
database.

7.

Performed propensity score matching on all final comparison populations.

8.

Chose the best match for each comparison group based on an assessment of
confounding covariate balance following propensity score matching.

9.

Assessed overall survival and biochemical failure-free survival for each
comparison using the Kaplan Meier method.
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5.2

Case Definitions

The primary goal of this study was to determine whether BT treatment options
were superior to EBRT in providing a survival benefit for prostate cancer patients. The
exposure and outcome definitions used for this study are shown in Table 4.
Table 4: Exposure and outcome definitions.
Exposures (E):
E1) EBRT exposure definition:
•

Any EBRT treatment given (3D conformal or IMRT) that met the minimum
radiation dose requirements.
•

The minimum EBRT dose requirements are further described in
section 5.5.

•

Possible radiation therapy treatments that fell under this category:
•

EBRT only.

E2) Brachytherapy exposure definition:
•

Any primary RT treatment option that involved either LDR-BT or HDR-BT
with or without EBRT.

•

LDR-BT exposure was defined as any patient who underwent iodine-125 or
palladium-103 permanent seed LDR-BT.

•

HDR-BT was defined as any patient who received iridium-192 HDR-BT.
•

Minimum dose requirements for both LDR-BT and HDR-BT with or
without EBRT are further described in section 5.5.

•

Possible radiation therapy treatments that fell under this category:
•

LDR-BT only.

•

HDR-BT + EBRT.

•

LDR-BT + EBRT.
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Outcomes (O):
O1) Overall survival:
•

The time from which a patient ends radiation treatment until death. Death
could be from any cause.

O2) Biochemical failure-free survival:
•

The time from which a patient ends radiation treatment until biochemical
failure. Biochemical failure was defined using ASTRO-RTOG Phoenix II
definition of a PSA rise by 2 ng/mL or more above the nadir PSA (Roach
2006). To eliminate the possibility of false positive biochemical failure in the
BT group because of PSA bounce (Mehta 2013), a PSA of ≥ 0.5 ng/mL on
last known follow-up was an additional requirement for biochemical failure in
BT patients (Rodrigues 2013).

5.3

Theoretical Causal Framework/Directed Acyclic Graph (DAG)

A Directed Acyclic Graph (DAG), which is a visual representation of the possible
causal mechanisms (including confounding) that can lead to the primary outcome of
interest (Szklo 2014), was used to establish a causal framework for this study. The DAG
model was used to visualize all probable associations that were thought to exist between
the known confounding variables and both the primary independent and dependent
variables. The visual representation of the causal mechanisms in the DAG model was
used to establish which confounders were most appropriate to control for (Szklo 2014).
Following literature review, five variables were identified as the strongest patient
confounders of the association of prostate cancer radiation treatment and survival, age, Tstage, PSA concentration, Gleason total, and adjuvant hormone therapy use (see Section
2.0, “Prostate Cancer”). Age and hormone therapy were included in the DAG model
individually, while T-stage, PSA concentration, and Gleason total were combined as
‘tumor factors’ for simplicity.
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An additional variable identified as a confounder of surgical management of
prostate cancer and survival, with the potential to be a confounder of prostate cancer RT
outcomes, was the percentages of prostate cancer found in core biopsies (Hinkelammert
2013). The percentage of positive cores was added to the variable ‘tumor factors’ in the
DAG model. Finally, the effect of treatment variation across centres (‘treatment centre
factors’) and the effects of any changes in radiation therapy practice (‘time trends’),
which have both previously been shown to influence RT outcomes (Cooperberg 2010),
were accounted for in the DAG model.
All backdoor paths in the DAG model, which are the possible causal pathways
created between the primary independent variable and the dependent variable via their
associations with known confounders, regardless of the direction of association (Szklo,
2014), were used to help determine which confounders were to be adjusted for in our
analyses. The DAG representing the theoretical causal framework for the mechanism of
action of radiation treatment on overall survival (OS) including all backdoor paths is
shown in Figure 2.
The variables age, tumor factors, hormone therapy, treatment centre and time
trends were all identified as confounders to be accounted for in this study. Controlling
for these factors blocked all backdoor paths, including the ensured blocking of backdoor
paths 1, 2, 5, 8 and 11 (Fig. 2). No colliders, or variables where two pathways meet (ie.
‘variable a’ à ‘collider variable b’ ß ‘variable c’), were identified in the DAG model,
meaning that all of the above variables could be adjusted for without introducing further
bias, assuming there was no unknown confounding (Cole 2002).
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Fig. 2. Directed acyclic graph (DAG) for examining effects of radiation type on OS.
Possible Backdoor Paths:
1)
2)
3)
4)
5)
6)
7)
8)

Radiation Treatment Type ß Age à OS
Radiation Treatment Type ß Tumor Factors à OS
Radiation Treatment Type ß Tumor Factors ß Hormone Therapy à OS
Radiation Treatment Type ß Tumor Factors ß Hormone Therapy ß Time
Trends à Treatment Centre Factors à OS
Radiation Treatment Type ß Hormone Therapy à OS
Radiation Treatment Type ß Hormone Therapy ß Time Trends à Treatment
Centre Factors à OS
Radiation Treatment Type ß Hormone Therapy à Tumor Factors à OS
Radiation Treatment Type ß Treatment Centre à OS
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9) Radiation Treatment Type ß Treatment Centre ß Time Trends à Hormone
Therapy à OS
10) Radiation Treatment Type ß Treatment Centre ß Time Trends à Hormone
Therapy à Tumor Factors à OS
11) Radiation Treatment Type ß Time Trends à OS
12) Radiation Treatment Type ß Time Trends à Hormone Therapy à OS
13) Radiation Treatment Type ß Time Trends à Hormone Therapy à Tumor
Factors à OS
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5.4

The Prostate Cancer Risk Stratification (ProCaRS) Database
(Data Source)

Patient information from the Prostate Cancer Risk Stratification (ProCaRS)
database was used as the data source for this study. The ProCaRS database contains
primary RT outcome data on 7974 prostate cancer patients treated at four major cancer
institutions (Princess Margaret Hospital, Toronto, Ontario, Canada; l’Université Laval,
Quebec, Canada; McGill University, Montréal, Canada; and the British Columbia Cancer
Agency, British Columbia, Canada) (Rodrigues 2013). Following a review of the most
current guidelines for prostate cancer risk stratification (Rodrigues 2012), the creation of
the ProCaRS database was sanctioned by the GUROC in an attempt to advance research
in prostate cancer RT outcomes and methodology. Results from recursive partitioning
risk stratification modeling using the ProCaRS data suggested that a six category prostate
cancer risk stratification system, including categories of extreme-low-, low-,
intermediate-low-, intermediate-high-, high- and extreme-high-risk, should replace the
current GUROC three-category system of low-, intermediate- and high-risk (Rodrigues
2013). Multivariable Cox proportional hazard regression using ProCaRS data indicated
that BT was a significant predictor in the outcome of bFFS (Rodrigues 2012). The results
from this initial analysis led to the current study, using PS matched analysis to compare
EBRT versus BT outcomes of OS and bFFS in homogenous cohorts of entirely low-risk,
intermediate-risk and high-risk patients. For the purpose of this investigation, the
previously described original GUROC three-category risk stratification system (Lukka
2001) was used to stratify patients into low-, intermediate- and high-risk categories prior
to PS matching and analysis (see Section 2.5, Table 3 for the GUROC low-, intermediateand high-risk category requirements).
All available variables in the ProCaRS database as well as brief descriptions are
displayed in Appendix III.
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5.5

Selection of Study Populations for Propensity Score Matches
5.5.1

Initial Patient Selection Process and Sample Size Assessment

The initial process used to select all RT treatment comparison groups prior to
propensity score matching is outlined in Figure 3.
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7974 Men registered in ProCaRS database
7913 Men registered in ProCaRS database with complete GUROC
staging information
Separated men by GUROC risk classification

3928 Low-risk prostate
cancer patients

2883 Intermediate-risk
prostate cancer patients

1102 High-risk prostate
cancer patients

Excluded men treated with hormones
3017 Low-risk patients
received primary
radiotherapy alone

1635 Intermeidate-risk
patients received primary
radiotherapy alone

323 High-risk patients
received primary
radiotherapy alone

Excluded men with missing data on baseline characteristics (age,
PSA, Gleason, T-stage) and outcome measures (OS and BFFS)

Low-Risk (n=2887):
- 30 Received HDR+EBRT
- 2446 Received LDR-BT
- 411 Received EBRT

Excluded
HDR+EBRT due
to small sample
size

Intermediate-risk (n=1412):
- 450 Recived HDR+EBRT
- 47 Received LDR+EBRT
- 252 Received LDR-BT
- 663 Received EBRT

Excluded
LDR+EBRT due
to small sample
size

Low-Risk (n=2857):
- 2446 Received LDR-BT
- 411 Received EBRT

Intermediate-risk (n=1365):
- 450 Recived HDR+EBRT
- 252 Received LDR-BT
- 663 Received EBRT

Further selection
considerations specific to
low-risk comparison is
shown in Fig. 4

Further selection
considerations specific to
intermediate-risk comparison
is shown in Fig. 5

Fig. 3. Initial patient selection process.
	
  

High-risk (n=289):
- 16 Received HDR+EBRT
- 1 Received LDR+EBRT
- 4 Received LDR-BT
- 268 Received EBRT

Discontinued work
on high-risk
patients due to low
numbers receiving
brachytherapy

X
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Patients were separated by GUROC prostate cancer risk category into three
homogenous groups of low-risk, intermediate-risk, or high-risk. Patients receiving
hormone therapy were removed from the comparison groups, as ADT has been
previously established as a strong confounder of prostate cancer RT survival outcomes
(Bolla 2002, D’Amico 2004, Lawton 2001). Patients with missing data on important
baseline characteristics including age, PSA concentration, Gleason total pattern and Tstage, as well as outcome data on OS and bFFS were excluded. This was done to ensure
that all patients had data on the most important baseline variables and outcomes used in
all propensity score models and matched analyses. Following these exclusions the total
numbers of individuals receiving each RT treatment option was assessed. Adequate
sample size was found in low-risk patients that received either LDR-BT (n=2446) or
EBRT alone (n=411) and intermediate-risk patients who had HDR-BT+EBRT (n=450),
LDR-BT (n=252), or EBRT alone (n=663). There were insufficient numbers of low-risk
patients that received HDR-BT+EBRT (n=30) and intermediate-risk patients that
received LDR-BT+EBRT (n=47); these patients were excluded prior to propensity score
matching. Due to the lack of high-risk patients treated with any of the BT modalities (ie.
HDR-BT or LDR-BT with or without EBRT), work on the high-risk patient population
was abandoned. Before PS matching, some additional selection considerations for the
low-risk and intermediate-risk patient populations were considered separately and are
discussed in section 5.5.2 and 5.5.3, respectively. The SAS code used to create the initial
patient populations shown in Figure 3 can be seen in Appendix V and Appendix VI.
5.5.2

Patient Selection for Low-Risk Propensity Score Match

The patient selection process for PS matching specific to the low-risk prostate
cancer comparison is shown in Figure 4. The SAS coding for this selection process is
shown in Appendix VI.
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Low-risk frequencies (n= 2857):
- 2446 Men received LDR-BT
- 411 Men received EBRT

Minimum required
radiation dose:
EBRT ≥ 70 Gy
LDR-BT ≥ 144 Gy

- 0 Men excluded due to missing data on radiation dose
- 45 Men excluded for receiving EBRT total dose 5250 cGy
- 29 Men excluded for receiving EBRT total dose 6000 cGy
- 23 Men excluded for receiving EBRT total dose 6400 cGy
- 153 Men excluded for receiving EBRT total dose 6600 cGy
- 1 Man excluded for receiving EBRT total dose 6728 cGy
- 56 Men excluded for receiving EBRT total dose 6800 cGy
- 138 Men excluded for receiving LDR-BT dose <14400 cGy
-

Low-risk frequencies (n = 2412):
- 2308 Men received LDR-BT
- 104 Men received EBRT

Excluded men with
missing data on T2b
TNM staging year

- 58 Men excluded from LDR-BT group due to missing data on
T2b TNM staging year
-

Low-risk frequencies (n=2354):
- 2250 Men received LDR-BT
- 104 Men received EBRT

- Variables centre and percent positive
cores were not included in PS model
- RT start year was added to PS model
-

Assessed additional covariates for
Propensity Score (PS) model: centre,
RT start year, percent positive cores

RT start restricted to
years 1999-2006

- 30 Men excluded from LDR-BT group treated
prior to 1999
- 504 Men excluded from LDR-BT group treated
after 2006
-

FINAL Low-risk comparison group used in PS match (n=1820):
- 1716 Men received LDR-BT
- 104 Men received EBRT

Fig. 4. Low-risk comparison group selection process (cont. from fig. 3).
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Radiation Dose Considerations for Low-Risk Comparison:
To ensure a fair comparison was made between low-risk radiation treatment
modalities, a minimum radiation dose requirement of 70 Gy for the EBRT group and 144
Gy for the LDR-BT group was required to be included in the PS match. These doses
were chosen based on literature review. Currently, a debate exists as to whether the
benefits of dose escalation in low-risk patients is as beneficial compared to intermediate
or high-risk patients. Two randomized trials found in subgroup analysis that dose
escalation up to 78 Gy provides a benefit in low-risk patients (Kuban 2008, Zietman
2005), while a separate trial found no significant difference between 68 Gy and 78 Gy in
their subgroup analysis (Peeters 2006). Due to the lack of quality evidence to support
EBRT doses exceeding 70 Gy for low-risk prostate cancer, a required EBRT dose of ≥ 70
Gy for all low-risk patients was chosen for this study. Additionally, the minimum dose
of 144 Gy given with I-125 LDR-BT was chosen based on standard treatment
recommendations (Nag 1999). Although a large number of patients that received EBRT
doses < 70 Gy were excluded (n=307), the benefits of EBRT dose escalation on survival
are well documented (Hanks 1999, Zelefsky 1998, Kupelian 2000). Therefore, a
minimum EBRT dose of at least 70 Gy was required in this comparison group to ensure
that an adequate EBRT dose was being compared to the higher doses given with LDRBT. There were no patients eliminated from the low-risk population due to missing data
on RT dose.
TNM Staging Considerations for Low-Risk Comparison:
Low-risk patients with T2b T-stage with missing data on TNM staging year were
removed prior to PS matching. This ensured that there were no patients with bilateral
disease in the patient cohort, which would have categorized them as being intermediaterisk. Palpable bilateral disease is defined as T2b using the 1997 AJCC TNM staging
definitions and T2c using the more current definitions adopted after 2002 (Fleming 1997,
Greene 2002, Edge 2009). This excluded 58 men from the LDR-BT group.
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Additional Variable Assessment for Low-Risk Propensity Score Model:
All variables used in the PS models were required for a patient to receive a PS and
be used in the PS matches. An assessment was made whether including additional
variables in the low-risk PS model would impact patient numbers available for PS
matching. Some of the additional covariates considered for inclusion in the low-risk PS
model prior to matching included: percent positive cores, treatment centre, and RT start
year. The variable ‘percent positive cores’ was not included in the PS model, as this
would have prevented 17 EBRT patients and 1078 LDR-BT patients from receiving a PS
(roughly 16% and 48% of the remaining EBRT and LDR-BT populations, respectively).
Additionally, the variable ‘treatment centre’ was also not included due to the distribution
of RT treatment modalities provided by the various cancer centres. For example, cancer
centres 1, 2 and 3 provided data on low-risk patients treated with LDR-BT, while only
centres 1 and 2 gave data on EBRT. Therefore, if the variable ‘treatment centre’ was
included in the PS model, all LDR-BT patients from cancer centre 3 (n=942) would
receive no PS and could not be matched. Finally, RT start year was included in the PS
model. Restricting RT start dates was viable because all low-risk EBRT treatments
occurred during the years 1999-2006, with ample numbers of low-risk LDR-BT patients
receiving treatment over that same timeframe. In total, 104 EBRT and 1716 LDR-BT
patients made up the eventual population used for the low-risk PS match.
5.5.3

Patient Selection for Intermediate-Risk Propensity Score
Matches

The patient selection process for PS matches specific to the intermediate-risk
prostate cancer comparisons are shown in Figure 5. The SAS coding for this selection
process is shown in Appendix V.
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Intermediate-risk frequencies (n= 1365):
- 450 Men received HDR+EBRT
- 252 Men received LDR-BT
- 663 Men received EBRT

- 6 Men excluded in HDR+EBRT group due to
missing data on RT dose
- 17 Total men excluded in HDR+EBRT group
with unusual radiation dose:
- 1 excluded for receiving 1000 cGy + 4400 cGy
- 1 excluded for receiving 1800 cGy + 4400 cGy
- 3 excluded for receiving 1900 cGy + 4400 cGy
- 1 excluded for receiving 2000 cGy + 4200 cGy
- 2 excluded for receiving 2000 cGy + 4600 cGy
- 8 excluded for receiving 2000 cGy + 4500 cGy
- 1 excluded for receiving 2000 cGy + 4700 cGy
- 398 Total men excluded due to low EBRT dose:
- 38 excluded for receiving 5250 cGy
- 51 excluded for receiving 6000 cGy
- 3 excluded for receiving 6200 cGy
- 15 excluded for receiving 6400 cGy
- 225 excluded for receiving 6600 cGy
- 1 excluded for receiving 6660 cGy
- 37 excluded for receiving 6800 cGy
- 25 excluded for receiving 7000 cGy
- 1 excluded for receiving 7200 cGy
- 1 excluded for receiving 7250 cGy
- 1 Man excluded with unusual EBRT dose of
7524 cGy
- 12 Men excluded for low LDR dose <144 cGy

Minimum required radiation dose:
HDR+EBRT (5 most common):
- 10 Gy + 50 Gy
- 15 Gy + 40 Gy
- 15 Gy + 44 Gy
- 19 Gy + 45 Gy
- 20 Gy + 44 Gy
LDR ≥ 144 cGy
EBRT ≥ 74 cGy

Intermediate-risk frequencies (n= 932):
- 427 Men received HDR+EBRT
- 240 Men received LDR-BT
- 265 Men received EBRT

Excluded men with
missing data on
T2b TNM staging
year

- 35 Men excluded from HDR+EBRT group due to missing data
on T2b TNM staging year
- 1 Man excluded from LDR-BT group due to missing data on
T2b TNM staging year
-

Intermediate-risk frequencies (n= 896):
- 392 Men received HDR+EBRT
- 239 Men received LDR-BT
- 265 Men received EBRT
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Assessed additional covariates for
Propensity Score (PS) model: centre,
RT start year, percent positive cores
and Gleason total 4+3 vs 3+4

Excluded patients with
Gleason total pattern 2 to 5

- Variables centre, RT start year, percent
positive cores and Gleason total 4+3 vs
3+4 were not included in PS model
-

- 10 Total men excluded for having Gleason total 2
to 5
- 2 Men excluded from HDR+EBRT group
- 8 Men excluded from LDR-BT group
-

FINAL Intermediate-risk comparison
group #1 used in PS match (n=655):
- 390 Men received HDR+EBRT
- 265 Men received EBRT

FINAL Intermediate-risk comparison
group #2 used in PS match (n=496):
- 231 Men received LDR-BT
- 265 Men received EBRT

Fig. 5. Intermediate-risk comparison group selection process (cont. from fig. 3).
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Radiation Dose Considerations for Intermediate-Risk Comparisons:
Similar to low-risk, a minimum radiation dose was required to be included in the
intermediate-risk PS matches. LDR-BT minimum dose remained the same as in the lowrisk cohort, at ≥ 144 Gy. Current literature suggests EBRT doses of at least 72 Gy
provide improved survival outcomes for localized prostate cancer compared to lower
doses (Kupelian 2000). The minimum EBRT dose chosen for this study was slightly
higher than this recommendation, at ≥ 74 Gy because only two intermediate-risk patients
received doses of at least 72 Gy but less than 74 Gy. This allowed for an increase in
minimum dose and ensured that dose escalation was used for all EBRT patients in the
intermediate-risk PS matches. HDR-BT+EBRT doses were limited to the five most
common dose regimens found in the ProCaRS database (Fig 5). There were an additional
six men removed from the HDR-BT+EBRT population due to missing data on RT dose.
TNM Staging Considerations for Intermediate-Risk Comparisons:
Intermediate-risk patients with T2b T-stage with missing data on TNM staging
year were excluded prior to PS matching. This was done for similar reasons as in the
low-risk category, to ensure that patients with T-stage T2b were correctly identified as
having either unilateral or bilateral disease (Fleming 1997, Greene 2002, Edge 2009).
There were 35 T2b staged men from the HDR-BT+EBRT group and a single T2b staged
man from the LDR-BT group that were excluded because of missing data on TNM
staging year.
Variable Assessment for Intermediate-Risk Propensity Score Models:
Again, similar to the low-risk cohort, the additional variables of treatment centre,
RT start year, and percent positive cores were assessed for inclusion in the PS models.
The variable ‘treatment centre’ was not included in the PS models for the same reason as
in the low-risk cohort. For intermediate-risk patients, cancer centres 1 and 2 provided
treatment data on LDR-BT and EBRT, cancer centre 3 on LDR-BT and HDR-BT+EBRT,
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and centre 4 gave data exclusively on HDR-BT+EBRT. RT start year was not included
in the PS models due to a wide range of years that each treatment modality was given,
LDR-BT was given from the year 1994 to 2010, EBRT from 1999-2006, and HDRBT+EBRT from 2001 to 2010. This precluded the possibility of restricting treatment
year for the PS modeling. The percentage of positive cores was not included in the PS
models due to a large proportion of men (310 in the HDR-BT+EBRT group, 70 in the
LDR-BT group, and 26 in EBRT group) who had missing data on this variable.
Additionally, an assessment was made whether Gleason total 7 in the
intermediate-risk cohort could be further subdivided into sub-patterns 3+4 vs. 4+3.
Current evidence suggests that Gleason pattern 4+3 compared to Gleason pattern 3+4 can
lead to a worse survival prognosis for men with prostate cancer (Wright 2009).
Unfortunately, splitting Gleason 7 into two sub categories was not possible for the
intermediate-risk PS modeling, as there were a large number of patients receiving BT
with missing sub-pattern data (306 men in the HDR-BT+EBRT group and 59 in the
LDR-BT group). Therefore, Gleason pattern 7 was kept as a single category in the
intermediate-risk PS models.
Finally, following an assessment of the distribution of Gleason total pattern in the
intermediate-risk patient population, it was discovered that all patients with Gleason
totals of 2, 3, 4 or 5 received BT and not EBRT. These patients were removed prior to
matching as including them would lead to difficulties in PS model convergence. This
was due to the category of Gleason total 2 to 5 predicting 100% probability of receiving
BT in the PS model. Thus, only patients with Gleason total 6 or 7 were included in the
intermediate-risk matches.
5.6

Overview of Propensity Score Matching Methodology

Propensity score matching methodology described by Peter Austin (2007) in his
systematic review entitled “Propensity-score matching in cardiovascular surgery
literature from 2004 to 2006: A systematic review and suggestions for improvement”
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was used as a general guideline for the PS methods used in this study. There were four
steps involved in the PS matching and analysis in this study: i) creating PS model(s); ii)
performing PS matching; iii) statistical assessment of covariates balance following
matching; iv) estimating treatment effects.
5.6.1

Creation of Final Propensity Score Models

As was previously discussed, the PS for each patient was estimated indicating
their probability of receiving a particular treatment based on a number of baseline
variables in a PS model (Heinze 2011). Multivariable logistic regression modeling was
used to create the PS models for this study. RT treatment designation was the dependent
variable in the logistic models, while the confounders for RT treatment outcomes were
the independent variables. The independent variables chosen for all PS models were
chosen a priori and were all known to confound prostate cancer survival outcomes. This
followed current theory that variables used in PS models should predict outcome and not
necessarily treatment given (Brookhart 2006). Four out of the five main prognostic
factors of prostate cancer radiation therapy were included in all PS models: age, T-stage,
baseline PSA concentration and Gleason Total. Due to the requirement that patients must
have data on all variables in the PS model to receive a PS, baseline data on all four of
these variables were required throughout the patient inclusion process. The fifth main
confounding factor of RT treatment and survival, hormone therapy, was accounted for by
excluding all patients who received ADT from the cohorts prior to matching.
The prognostic factors of ‘percent positive cores’ and ‘treatment centre’ were not
included in any of the PS models following initial sample size assessments. RT start year
was included in the low-risk PS model, but not in the intermediate-risk models due to
reasons previously mentioned in sections 5.5.2 and 5.5.3. All variables were included in
the models as main effects with no interactions. Although interactions have been used in
PS modeling, there is no current method of assessing the balance created in the
combinations of variables following matching (Heinze 2011). The covariates age and
baseline PSA were included as continuous variables in the PS models, while the
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covariates T-stage, Gleason total and RT start year were included as categorical variables.
In the low-risk comparison PS model, T-stage had two categories (any T1; T2), Gleason
total had two categories (Gleason total 2 to 5 inclusive; Gleason total 6), and RT start
year had eight categories (one for each year from 1999 to 2006). In the intermediate-risk
PS models, T-stage had three categories (any T1; unilateral T2; bilateral T2) and Gleason
total had two categories (Gleason total 6; Gleason total 7). The final PS model formulas
with variable definitions for low-risk and intermediate-risk comparisons are shown in
Table 5. The SAS code for low-risk PS model is shown in Appendix IX. The SAS codes
for the intermediate-risk PS models are shown in Appendices VII and VIII.
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Table 5: Propensity score models and variable definitions.
Low-risk model:
LDR-BT vs. EBRT:
Logit{π} = β0 + β1age + β2PSA + β3Tstage + β4GleasonTotal + β5RTStartYr2000 + β6
RTStartYr2001 + β7RTStartYr2002 + β8 RTStartYr2003 + β9RTStartYr2004 + β10
RTStartYr2005 + β11RTStartYr2006
Where Logit{π} = P(Y=1|age, PSA, Tstage, GleasonTotal, RTStartYr), Y={1 if LDRBT, 0 if EBRT only}
Age = {age in years}
PSA = {baseline PSA measured in ng/mL}
Tstage = {1 if baseline T-stage = T2, 0 if baseline T-staging = any T1}
GleasonTotal = {1 if Gleason total = 6, 0 if Gleason total = 2, 3, 4, or 5}
RTStartYr 2000 = {1 if RT Start occurred in 2000, 0 otherwise}
RTStartYr 2001 = {1 if RT Start occurred in 2001, 0 otherwise}
RTStartYr 2002 = {1 if RT Start occurred in 2002, 0 otherwise}
RTStartYr 2003 = {1 if RT Start occurred in 2003, 0 otherwise}
RTStartYr 2004 = {1 if RT Start occurred in 2004, 0 otherwise}
RTStartYr 2005 = {1 if RT Start occurred in 2005, 0 otherwise}
RTStartYr 2006 = {1 if RT Start occurred in 2006, 0 otherwise}
Intermediate-risk models:
LDR-BT vs. EBRT:
Logit{π} = β0 + β1age + β2PSA + β3TstageT2unilateral + β4 TstageT2bilateral +
β5GleasonTotal7
Where Logit{π} = P(Y=1|age, PSA, Tstage, GleasonTotal), Y={1 if LDR-BT, 0 if EBRT
only}
Age = {age in years}
PSA = {baseline PSA measured in ng/mL}
TstageT2unilateral = {1 if unilateral T2 disease, 0 if any T1 or T2 bilateral disease}
TstageT2bilateral = {1 if bilateral T2 disease, 0 if any T1 or T2 unilateral disease}
GleasonTotal = {1 if Gleason total = 7, 0 if Gleason total = 6}
HDR-BT+EBRT vs. EBRT:
Logit{π} = β0 + β1age + β2PSA + β3TstageT2unilateral + β4 TstageT2bilateral +
β5GleasonTotal7
Where Logit{π} = P(Y=1|age, PSA, Tstage, GleasonTotal, RTStartYr), Y={1 if HDRBT+EBRT, 0 if EBRT only}
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Age = {age in years}
PSA = {baseline PSA measured in ng/mL}
TstageT2unilateral = {1 if unilateral T2 disease, 0 if any T1 or T2 bilateral disease}
TstageT2bilateral = {1 if bilateral T2 disease, 0 if any T1 or T2 unilateral disease}
GleasonTotal = {1 if Gleason total = 7, 0 if Gleason total = 6}

	
  

65	
  
5.6.2

Propensity Score Matching

To ensure that optimal matches were achieved, several matches were attempted in
each comparison group. Nearest-neighbor matching methodology also known as ‘greedy
matching’ was used for all matches. This meant that each randomly selected EBRT
patient was matched to the nearest BT patient based on patient ‘score’ regardless of
whether that patient would be a better overall candidate for a different match (Austin
2007). Sampling was done without replacement, meaning once a patient was matched
they were no longer available for future matches (Szklo 2014). An assessment of the
total number of patients was performed prior to matching to determine what matching
ratios would be attempted. One-to-one matches were explored prior to one-to-many
matches. One-to-many matches were used only when there was sufficient sample size
disparity between treatment groups (ie. if roughly a 1:2 ratio existed, a 1:2 match was
explored). In the intermediate-risk comparisons, 1:2 matches were attempted with the
slightly larger treatment group acting as the control or ‘many’ group. Due to the large
number of BT patients available in the low-risk comparison group (n=1716), 1:2, 1:3, and
1:4 matches were explored with EBRT patients matched to multiple LDR-BT patients. A
maximum ratio of 1:4 was chosen based on previous literature indicating matches with
higher ratios beyond 1:4 are not usually attempted, as the gain in statistical power
becomes insignificant (Silva 1999). Although one-to-one-to-one PS matching has been
documented (Rassen 2013), the statistical methodology used to assess covariate balance
in three-way PS matches is not fully developed, therefore 1:1:1 (EBRT:LDR-BT:HDRBT+EBRT) matching in the intermediate-risk comparison grouping was not attempted.
A variety of caliper widths, or the range of PS values within which an acceptable
match was allowed, were explored in this study. Caliper widths ranging from as low as
0.005 (Christakis 2003) to as high as 0.1 (Moss 2003) of a propensity score have been
reported. In a Monte Carlo simulation study, a caliper of 0.2 of a standard deviation of
the logit of the propensity score was shown to lead to improved covariate balance
compared to other common caliper widths (Austin 2009). However, other
recommendations have not yielded a consensus on which caliper size is most appropriate
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for PS matching (Calideno 2008, Lunt 2013, Stuart 2010). For the matches in this study,
the initial caliper used was 0.2 of a standard deviation of the logit of the propensity score.
These initial matches were compared concurrently with additional matches on the
propensity score scale, which included a tight, previously utilized, caliper width of 0.025
(Verstegen 2013), a moderate caliper width of 0.05, and a generous caliper width of 0.1.
An assessment of the covariate balance and sample size was made to determine which
matches were to be used in the final analyses. The SAS codes used to generate the final
matches were based on a previously described SAS code (Coca-Perralillon 2006) and are
shown in Appendices VII, VIII and IX.
5.6.3

Statistical Assessment of Covariate Balance After Matching

Following PS matching, the balance created in each match was assessed
statistically by comparing the standardized difference in the matched variables. The
advantage of using the standardized difference to assess balance over significance testing
is that the standardized difference is unaffected by sample size or power (Heinze 2011).
The formula used to calculate the standardized difference for continues variable was
(1)
Additionally, for dichotomous variables, the standardized difference formula used was
(2)
For formula (1), x̅ treatment and x̅ control indicate the mean of the continuous variable in
‘treated’ and ‘control’ subjects, while the s2treatment and s2control denote their variances. In
formula (2), for a dichotomous variable, the pT and pC are the proportion of treated and
control patients, respectively (Heinze 2011). For this study, the recommended
standardized difference cut-point of >0.10 (Austin 2007) was used to indicate significant
imbalance in the baseline covariates. The use of the standardized difference statistic was
chosen based on recommendations that a proper statistical test of balance should not be
effected by sample size and is related to the sample population not a theoretical one,
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which are not features of standard p-value testing (Imai 2008). Previously described SAS
code (Faries 2010) was used to generate the standardized differences assessing covariate
balance in each treatment comparison and is shown in Appendix X.
The choice of which matches were used in the final analyses were based on the
following criteria:
1. Following matching all variables used in the PS model must have a standardized
difference <0.10.
2. One-to-one matches were assessed prior to one-to-many matches.
3. A match must be identified in each comparison group having the ‘best’
distribution of balance among all variables.
4. Side-by-side box plots and five number summaries of continuous variables in
each matched cohort must be similar on visual inspection.
5. If two or more matches were found to have similar balance in a comparison
group, the match with the highest number of variables with the lowest
standardized difference was chosen (indicating a tighter match).
6. If two or more matches were found to have comparable balance in all variables,
then the match with the larger sample size was chosen.
7. If no suitable match was found (with standardized difference <0.10 in all matched
variables) using the original calipers of 0.2 of a standard deviation of the logit of
the propensity score, or 0.025, 0.05 or 0.1 of a propensity score, in either one-toone matches or one-to-many matches, then a tighter caliper match was performed
starting with a caliper of 0.01 of a propensity score.
Selection of the Final Match for Analysis in Low-risk LDR-BT vs. EBRT
Cohort:
A summary of the sample sizes created using different matching criteria for the
low-risk LDR-BT vs. EBRT cohort is shown in Table 6. For the low-risk cohort
comparing LDR-BT to EBRT, 1:1 matches did not achieve balance (standardized
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difference <0.10) in PSA, Gleason total or RT start year, regardless of the caliper size
used. The matches using ratios (EBRT:LDR-BT) of 1:2 and 1:3 did not bring balance to
RT start year. However, balance was achieved in 1:4 matches using a caliper width of
0.2 of a standard deviation of the logit of the propensity score and a caliper width of
0.025 of a propensity score. Due to the similar balance produced in both of these
matches, the 0.2 of a standard deviation of the logit of the propensity score match using a
1:4 ratio (EBRT:LDR-BT) was chosen for final analysis based on a slightly larger sample
size (n=400). Tables 7-10 give examples of the balance produced using different caliper
widths in the low-risk LDR-BT vs. EBRT matches.
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Table 6: Sample size based on propensity score matching in low-risk cohort (pre-match
n=1820).
Caliper
0.025
0.025
0.025
0.025
0.05
0.05
0.05
0.05
0.1
0.1
0.1
0.1
0.2*1SDevLogit
0.2*1SDevLogit
0.2*1SDevLogit
0.2*1SDevLogit

Ratio
(LDR:EBRT)
1:1
2:1
3:1
4:1
1:1
2:1
3:1
4:1
1:1
2:1
3:1
4:1
1:1
2:1
3:1
4:1

Total N
206
282
332
395
206
294
384
410
208
300
376
425
206
294
340
400

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; SDev = standard deviation

	
  

70	
  
Table 7: Baseline characteristics of variables used in low-risk propensity score match
(pre-match n=1820) [1:1 Matches].
Caliper: 0.2*1SDevLogit
Ratio: 1 LDR : 1 EBRT
Total N = 206
VARIABLE
*Age – mean
± SDev

LDR
n = 103
68.6 ±
6.5

EBRT
n = 103
68.8 ±
6.4

S.D.
0.031

Caliper: 0.025
Ratio: 1 LDR : 1 EBRT
Total N = 206
LDR
n = 103
68.6 ±
6.5

EBRT
n = 103
68.9 ±
6.6

S.D.
0.043

Caliper: 0.1
Ratio: 1 LDR : 1 EBRT
Total N = 208
LDR
n = 104
68.7 ±
6.5

EBRT
n = 104
69.0 ±
6.6

S.D.
0.038

*Baseline
PSA – mean
± SDev
*Gleason
Total – n(%)
2-5
6

6.42 ±
1.9

6.07 ±
2.4

0.165

6.42 ±
1.9

6.04 ±
2.4

0.180

6.43 ±
1.9

6.06 ±
2.4

0.177

4(3.9)
99(96.1)

7(6.8)
96(93.2)

0.130

4(3.9)
99(96.1)

7(6.8)
96(93.2)

0.130

4(3.9)
100(96.2)

7(6.7)
97(93.3)

0.129

*T Stage –
n(%)
T1
T2

63(61.2)
40(38.8)

61(59.2)
42(40.8)

0.040

63(61.2)
40(38.8)

60(58.3)
43(41.8)

0.059

64(61.5)
40(38.5)

61(58.7)
43(41.4)

0.059

*RT Start
Year – n(%)
1999
2000
2001
2002
2003
2004
2005
2006

5(4.9)
19(18.5)
4(3.9)
28(27.2)
28(27.2)
11(10.7)
4(3.9)
4(3.9)

8(7.8)
18(17.5)
5(4.9)
27(26.2)
28(27.2)
7(6.8)
6(5.8)
4(3.9)

0.120
0.025
0.048
0.022
0.000
0.138
0.090
0.000

5(4.9)
19(18.5)
4(3.9)
28(27.2)
28(27.2)
11(10.7)
4(3.9)
4(3.9)

7(6.8)
18(17.5)
5(4.9)
28(27.2)
28(27.2)
7(6.8)
6(5.8)
4(3.9)

0.083
0.025
0.047
0.000
0.000
0.137
0.090
0.000

5(4.8)
19(18.3)
4(3.9)
28(26.9)
29(27.9)
11(10.6)
4(3.9)
4(3.9)

8(7.7)
18(17.3)
5(4.8)
28(26.9)
28(26.9)
7(6.7)
6(5.8)
4(3.9)

0.119
0.025
0.047
0.000
0.022
0.137
0.090
0.000

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard
deviation
*Variable(s) used in propensity-score computation procedures.
Grey Box = Variable with S.D > 0.10.
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Table 8: Baseline characteristics of variables used in low-risk propensity score match
(pre-match n=1820) [1:2 Matches].
Caliper: 0.2*1SDevLogit
Ratio: 2 LDR : 1 EBRT
Total N = 294
VARIABLE
*Age – mean
± SDev

LDR
n = 196
68.5 ±
6.0

EBRT
n = 98
68.5 ±
6.4

S.D.
0.011

Caliper: 0.025
Ratio: 2 LDR : 1 EBRT
Total N = 282
LDR
n = 188
68.2 ±
5.8

EBRT
n = 94
68.2 ±
6.4

S.D.
0.004

Caliper: 0.1
Ratio: 2 LDR : 1 EBRT
Total N = 300
LDR
n = 200
68.6 ±
6.0

EBRT
n = 100
68.6 ±
6.0

S.D.
0.000

*Baseline
PSA – mean
± SDev
*Gleason
Total – n(%)
2-5
6

6.01 ±
2.0

5.95 ±
2.4

0.067

6.01 ±
2.0

5.87 ±
2.4

0.085

6.12 ±
2.0

6.00 ±
2.4

0.053

13(6.6)
183(93.4)

7(7.1)
91(92.9)

0.020

13(6.9)
175(93.1)

7(7.5)
87(92.6)

0.021

14(7.0)
186(93.0)

7(7.0)
93(93.0)

0.000

*T Stage –
n(%)
T1
T2

116(59.2)
80(40.8)

58(59.2)
40(40.8)

0.000

113(60.1)
75(39.9)

55(58.5)
39(41.5)

0.033

119(59.5)
81(40.5)

59(59.0)
41(41.0)

0.010

*RT Start
Year – n(%)
1999
2000
2001
2002
2003
2004
2005
2006

16(8.2)
30(15.3)
6(3.1)
50(25.5)
55(28.1)
19(9.7)
11(5.6)
9(4.6)

8(8.2)
18(18.4)
5(5.1)
26(26.5)
24(24.5)
7(7.1)
6(6.1)
4(4.1)

0.000
0.082
0.103
0.023
0.081
0.092
0.023
0.025

15(8.0)
26(13.8)
6(3.2)
47(25.0)
55(29.3)
19(10.1)
11(5.9)
9(4.8)

7(7.5)
17(18.1)
5(5.3)
24(25.5)
24(25.5)
7(7.5)
6(6.4)
4(4.3)

0.020
0.116
0.106
0.012
0.084
0.094
0.022
0026

17(8.5)
30(15.0)
6(3.0)
53(26.5)
55(27.5)
19(9.5)
11(5.5)
9(4.5)

8(8.0)
18(18.0)
5(5.0)
26(26.0)
26(26.0)
7(7.0)
6(6.0)
4(4.0)

0.018
0.081
0.102
0.011
0.033
0.091
0.021
0.025

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard
deviation
*Variable(s) used in propensity-score computation procedures.
Grey Box = Variable with S.D > 0.10.
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Table 9: Baseline characteristics of variables used in low-risk propensity score match
(pre-match n=1820) [1:3 Matches].
Caliper: 0.2*1SDevLogit
Ratio: 3 LDR : 1 EBRT
Total N = 340
VARIABLE
*Age – mean
± SDev

LDR
n = 255
67.3 ±
5.6

EBRT
n = 85
67.3 ±
6.0

S.D.
0.007

Caliper: 0.025
Ratio: 3 LDR : 1 EBRT
Total N = 332
LDR
n = 249
67.2 ±
5.7

EBRT
n = 83
67.1 ±
6.0

S.D.
0.007

Caliper: 0.1
Ratio: 3 LDR : 1 EBRT
Total N = 376
LDR
n = 282
67.8 ±
5.6

EBRT
n = 94
68.1 ±
6.2

S.D.
0.051

*Baseline
PSA – mean
± SDev
*Gleason
Total – n(%)
2-5
6

6.02 ±
2.0

5.86 ±
2.4

0.086

6.03 ±
2.1

5.86 ±
2.4

0.079

6.11 ±
2.0

5.95 ±
2.4

0.074

15(5.9)
240(94.1)

6(7.1)
79(92.9)

0.048

15(6.0)
234(94.0)

6(7.2)
77(92.8)

0.049

17(6.0)
265(94.0)

6(6.4)
88(93.6)

0.015

*T Stage –
n(%)
T1
T2

151(59.2)
104(40.8)

52(61.2)
33(38.8)

0.040

148(59.4)
101(40.6)

52(62.7)
31(37.4)

0.066

112(39.7)
170(60.3)

38(40.4)
56(59.6)

0.014

*RT Start
Year – n(%)
1999
2000
2001
2002
2003
2004
2005
2006

17(6.7)
30(11.8)
12(4.7)
66(25.9)
76(29.8)
26(10.2)
15(5.9)
13(5.1)

6(7.1)
14(16.5)
5(5.9)
21(24.7)
22(25.9)
7(8.2)
6(7.1)
4(4.7)

0.016
0.136
0.053
0.027
0.088
0.068
0.047
0.018

16(6.4)
30(12.1)
12(4.8)
60(24.1)
77(30.9)
26(10.4)
15(6.0)
13(5.2)

7(8.4)
13(15.7)
5(6.0)
19(22.9)
22(26.5)
7(8.4)
6(7.2)
4(4.8)

0.077
0.104
0.053
0.028
0.098
0.069
0.049
0.018

21(7.5)
38(13.5)
12(4.3)
76(27.0)
81(28.7)
26(9.2)
15(5.3)
13(4.6)

6(6.4)
16(17.0)
5(5.3)
24(25.5)
26(27.7)
7(7.5)
6(6.4)
4(4.3)

0.042
0.101
0.050
0.032
0.024
0.064
0.045
0.017

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard
deviation
*Variable(s) used in propensity-score computation procedures.
Grey Box = Variable with S.D > 0.10.
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Table 10: Baseline characteristics of variables used in low-risk propensity score match
(pre-match n=1820) [1:4 Matches].
Caliper: 0.2*1SDevLogit
Ratio: 4 LDR : 1 EBRT
Total N = 400
VARIABLE
*Age – mean
± SDev

LDR
n = 320
66.9 ±
5.4

EBRT
n = 80
66.9 ±
5.9

S.D.
0.012

Caliper: 0.025
Ratio: 4 LDR : 1 EBRT
Total N = 395
LDR
n = 316
66.9 ±
5.4

EBRT
n = 79
66.8 ±
5.9

S.D.
0.022

Caliper: 0.1
Ratio: 4 LDR : 1 EBRT
Total N = 425
LDR
n = 340
67.3 ±
5.4

EBRT
n = 85
67.3 ±
6.0

S.D.
0.009

*Baseline
PSA – mean
± SDev
*Gleason
Total – n(%)
2-5
6

5.89 ±
2.1

5.86 ±
2.4

0.013

5.87 ±
2.1

5.84 ±
2.5

0.011

5.89 ±
2.1

5.84 ±
2.4

0.021

19(5.9)
301(94.1)

6(7.5)
74(92.5)

0.062

19(6.0)
297(94.0)

6(7.6)
73(92.4)

0.063

20(5.9)
320(94.1)

6(7.1)
79(92.9)

0.048

*T Stage –
n(%)
T1
T2

185(57.8)
135(42.2)

49(61.3)
31(38.8)

0.070

181(57.3)
135(42.7)

48(60.8)
31(39.2)

0.071

196(57.7)
144(42.4)

51(60.0)
34(40.0)

0.048

*RT Start
Year – n(%)
1999
2000
2001
2002
2003
2004
2005
2006

19(5.9)
42(13.1)
20(6.3)
77(24.1)
94(29.4)
31(9.7)
19(5.9)
18(5.6)

6(7.5)
12(15.0)
5(6.3)
18(22.5)
22(27.5)
7(8.8)
6(7.5)
4(5.0)

0.062
0.054
0.000
0.037
0.042
0.032
0.062
0.029

18(5.7)
41(13.0)
20(6.3)
75(23.7)
94(29.8)
31(9.8)
19(6.0)
18(5.7)

6(7.6)
12(15.2)
5(6.3)
18(22.8)
21(26.5)
7(8.9)
6(7.6)
4(5.1)

0.076
0.064
0.000
0.023
0.070
0.033
0.062
0.028

22(6.5)
48(14.1)
20(5.9)
79(23.2)
103(30.3)
31(9.1)
19(5.6)
18(5.3)

6(7.1)
16(18.8)
5(5.9)
19(22.4)
22(25.9)
7(8.2)
6(7.1)
4(4.7)

0.023
0.127
0.000
0.021
0.098
0.031
0.060
0.027

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard
deviation
*Variable(s) used in propensity-score computation procedures.
Grey Box = Variable with S.D > 0.10.
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Selection of the Final Match for Analysis in Intermediate-risk LDR-BT
vs. EBRT Cohort:
A summary of the sample sizes created using various matching criteria for the
intermediate-risk LDR-BT vs. EBRT cohort is shown in Table 11. One-to-one matches
in the LDR-BT vs. EBRT cohort using all original caliper widths including our tightest
calipers of 0.2 of a standard deviation of the logit of the propensity score as well as a
width of 0.025 of a propensity score were unable to balance the variable T-stage to within
a standardized difference of 0.10. Two-to-one (EBRT:LDR-BT) matches were also
unable to bring balance to T-stage, or balance the variables of baseline PSA or Gleason
total. However, an appropriate match was found when a 1:1 match with a tighter caliper
of 0.01 of a propensity score was used (n=254). This match was chosen for final analysis
in the intermediate-risk LDR-BT vs. EBRT cohort. Tables 12 and 13 give examples of
the balance produced using different caliper widths in the intermediate-risk LDR-BT vs.
EBRT matches.

	
  

75	
  
Table 11: Sample size based on propensity score matching in intermediate-risk LDR-BT
vs. EBRT cohort (pre-match n=496).
Caliper

Ratio
(LDR:EBRT)
0.01
1:1
0.025
1:1
0.025
1:2
0.05
1:1
0.05
1:2
0.10
1:1
0.10
1:2
0.2*1SDevLogit 1:1
0.2*1SDevLogit 1:2

Total N
254
260
207
264
216
278
225
268
219

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; SDev = standard deviation
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Table 12: Baseline characteristics of variables used in intermediate-risk LDR-BT vs.
EBRT propensity score match (pre-match n=496) [1:1 Matches].

VARIABLE
*Age – mean
± SDev

Caliper: 0.2*1SDevLogit
Ratio: 1 LDR : 1 EBRT
Total N = 268
LDR
EBRT
S.D.
n = 134
n = 134
68.8 ±
68.5 ±
0.050
6.4
6.1

Caliper: 0.025
Ratio: 1 LDR : 1 EBRT
Total N = 260
LDR
EBRT
S.D.
n = 130
n = 130
68.9 ±
68.5 ±
0.060
6.4
6.1

Caliper: 0.1
Ratio: 1 LDR : 1 EBRT
Total N = 278
LDR
EBRT
S.D.
n = 139
n = 139
68.8 ±
68.6 ±
0.037
6.3
6.1

*Baseline
PSA –
mean ± SDev
*Gleason
Total – n(%)
6
7

7.77 ±
2.9

7.89 ±
3.9

0.035

7.79 ±
3.0

7.78 ±
3.8

0.004

7.66 ±
3.0

7.82 ±
3.8

0.047

34(25.4)
100(74.6)

32(23.9)
102(76.1)

0.035

32(24.6)
98(75.4)

29(22.3)
101(77.7)

0.055

37(26.6)
102(73.4)

33(23.7)
106(76.3)

0.066

*T Stage –
n(%)
Any T1
Low T2
High T2

58(43.3)
57(42.5)
19(14.2)

58(43.3)
64(47.8)
12(9.0)

0.000
0.105
0.164

56(43.1)
56(43.1)
18(13.9)

55(42.3)
63(48.5)
12(9.2)

0.016
0.108
0.149

60(43.2)
58(41.7)
21(15.1)

60(43.2)
67(48.2)
12(8.6)

0.000
0.130
0.201

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard
deviation
*Variable(s) used in propensity-score computation procedures.
Grey Box = Variable with S.D > 0.10.
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Table 13: Baseline characteristics of variables used in intermediate-risk LDR-BT vs.
EBRT propensity score match (pre-match n=496) [Exploratory Matches].

VARIABLE
*Age – mean
± SDev

Caliper: 0.01
Ratio: 1 LDR : 1 EBRT
Total N = 254
LDR
EBRT
S.D.
n = 127
n = 127
68.7 ±
68.5 ±
0.029
6.6
6.1

Caliper: 0.2*1SDevLogit
Ratio: 1 LDR : 2 EBRT
Total N = 219
LDR
EBRT
S.D.
n = 73
n = 146
71.4 ±
71.9 ±
0.093
5.7
4.1

Caliper: 0.025
Ratio: 1 LDR : 2 EBRT
Total N = 207
LDR
EBRT
S.D.
n = 69
n = 138
71.4 ±
71.9 ±
0.107
5.8
4.3

*Baseline
PSA –
mean ± SDev
*Gleason
Total – n(%)
6
7

7.87 ±
3.0

7.70 ±
3.8

0.050

7.92 ±
2.8

8.64 ±
3.9

0.210

7.87 ±
2.8

8.77 ±
3.8

0.270

30(23.6)
97(76.4)

27(21.3)
100(78.7)

0.057

4(5.5)
69(94.5)

25(17.1)
121(82.8)

0.374

44(63.8)
25(36.2)

95(68.8)
43(31.2)

0.495

*T Stage –
n(%)
Any T1
Low T2
High T2

56(44.1)
56(44.1)
15(11.8)

53(41.7)
62(48.8)
12(9.5)

0.048
0.095
0.077

27(37.0)
39(53.4)
7(9.6)

46(31.5)
83(56.9)
17(11.6)

0.116
0.070
0.067

25(36.2)
37(53.6)
7(10.1)

43(31.2)
81(58.7)
14(10.1)

0.108
0.102
0.000

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; PSA = prostate specific antigen; S.D. = standardized difference; SDev = standard
deviation
*Variable(s) used in propensity-score computation procedures.
Grey Box = Variable with S.D > 0.10.
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Selection of Final Match for Intermediate-risk HDR-BT+EBRT vs. EBRT
Cohort:
A summary of the sample sizes created by the various matching criteria for the
intermediate-risk HDR-BT+EBRT vs. EBRT cohort is displayed in Table 14. Matches in
the intermediate-risk HDR-BT+EBRT vs. EBRT cohort using a 1:1 ratio and caliper
widths of 0.2 of a standard deviation of the logit of the propensity score and widths of
0.025 and 0.1 on the propensity score scale were able to balance all variables used in the
match (standardized difference <0.10). Out of these three 1:1 matches, the match using
the 0.2 of a standard deviation of the logit of the propensity score was determined to be
the closest match as it had the lowest standardized difference values in all but one
variable (Gleason total). This match (n=388) was chosen for the HDR-BT+EBRT vs.
EBRT final analysis. Exploratory matches using 1:2 ratios did not produce acceptable
matches. Tables 15 and 16 give examples of the balance produced using different caliper
widths in the intermediate-risk HDR-BT+EBRT vs. EBRT matches.
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Table 14: Sample size based on propensity score matching in intermediate-risk HDRBT+EBRT vs. EBRT cohort (pre-match n=655).
Caliper

Ratio
(HDR:EBRT)
0.025
1:1
0.025
2:1
0.05
1:1
0.05
2:1
0.10
1:1
0.10
2:1
0.2*1SDevLogit 1:1
0.2*1SDevLogit 2:1

Total N
382
258
390
282
406
291
388
273

Abbreviations: EBRT = external beam radiation therapy; HDR = high dose rate
brachytherapy with adjuvant external beam radiation; SDev = standard deviation
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Table 15: Baseline characteristics of variables used in intermediate-risk HDR-BT+EBRT
vs. EBRT propensity score match (pre-match n=655) [1:1 Matches].

VARIABLE
*Age – mean
± SDev

Caliper: 0.2*1SDevLogit
Ratio: 1 HDR : 1 EBRT
Total N = 388
HDR
EBRT
S.D.
n = 194
n = 194
69.2 ±
69.2 ±
0.006
5.0
5.5

Caliper: 0.025
Ratio: 1 HDR : 1 EBRT
Total N = 382
HDR
EBRT
S.D.
n = 191
n = 191
69.0 ±
68.9 ±
0.026
5.3
5.6

Caliper: 0.1
Ratio: 1 HDR : 1 EBRT
Total N = 406
HDR
EBRT
S.D.
n = 203
n = 203
69.1 ±
69.2 ±
0.020
5.3
5.7

*Baseline
PSA – mean
± SDev
*Gleason
Total – n(%)
6
7

8.92 ±
4.0

8.62 ±
4.1

0.074

8.91 ±
4.0

8.60 ±
4.2

0.074

8.95 ±
4.0

8.61 ±
4.1

0.084

27(13.9)
167(86.1)

30(15.5)
164(84.5)

0.044

27(14.1)
164(85.9)

29(15.2)
162(84.8)

0.030

28(13.8)
175(86.2)

32(15.8)
171(84.2)

0.056

*T Stage –
n(%)
Any T1
Low T2
High T2

92(47.4)
90(46.4)
12(6.2)

92(47.4)
89(45.9)
13(6.7)

0.000
0.010
0.021

90(47.1)
89(46.6)
12(6.3)

88(46.1)
90(47.1)
13(6.8)

0.021
0.011
0.021

98(48.3)
92(45.3)
13(6.4)

95(46.8)
93(45.8)
15(7.4)

0.030
0.010
0.039

Abbreviations: EBRT = external beam radiation therapy; HDR= high dose rate
brachytherapy with adjuvant external beam radiation therapy; S.D. = standardized difference;
SDev = standard deviation
*Variable(s) used in propensity-score computation procedures.
Grey Box = Variable with S.D > 0.10.
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Table 16: Baseline characteristics of variables used in intermediate-risk HDR-BT+EBRT
vs. EBRT propensity score match (pre-match n=655) [Exploratory Matches].

VARIABLE
*Age – mean
± SDev

Caliper: 0.2*1SDevLogit
Ratio: 2 HDR: 1 EBRT
Total N = 273
HDR
EBRT
S.D.
n = 182
n = 91
65.6 ±
65.3 ±
0.067
4.9
4.8

Caliper: 0.025
Ratio: 2 HDR : 1 EBRT
Total N = 258
HDR
EBRT
S.D.
n = 172
n = 86
65.4 ±
64.8 ±
0.114
5.2
5.1

Caliper: 0.2*1SDevLogit
Ratio: 1 HDR: 2 EBRT
Total N = 141
HDR
EBRT
S.D.
n =47
n = 94
73.0 ±
73.5 ±
0.146
3.9
3.0

*Baseline
PSA – mean
± SDev
*Gleason
Total – n(%)
6
7

8.33 ±
3.8

8.82 ±
4.1

0.125

8.38 ±
3.8

8.83 ±
4.2

0.114

9.76 ±
4.3

8.73 ±
4.5

0.234

14(7.7)
168(92.3)

9(9.9)
82(90.1)

0.078

12(7.0)
160(93.0)

9(10.5)
77(89.5)

0.124

16(34.0)
31(66.0)

23(24.5)
71(75.5)

0.212

*T Stage –
n(%)
Any T1
Low T2
High T2

126(69.2)
52(28.6)
4(2.2)

59(64.8)
29(31.9)
3(3.3)

0.094
0.072
0.078

124(72.1)
46(26.7)
2(1.2)

57(66.3)
27(31.4)
2(2.3)

0.126
0.103
0.089

9(19.2)
28(59.6)
10(21.3)

16(17.0)
60(63.8)
18(19.2)

0.055
0.088
0.053

Abbreviations: EBRT = external beam radiation therapy; HDR = high dose rate
brachytherapy with adjuvant external beam radiation therapy; PSA = prostate specific antigen;
S.D. = standardized difference; SDev = standard deviation
*Variable(s) used in propensity-score computation procedures.
Grey Box = Variable with S.D > 0.10.
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5.6.4

Estimating Treatment Effects (Statistical Analysis)

Once final matches were obtained in each of the compared cohorts, Kaplan-Meier
survival curves stratified by treatment group (EBRT vs. BT option) were generated for
OS and bFFS. The Kaplan-Meier curves were created for both pre-matches and postmatches. The log-rank test was used to assess whether a significant difference in OS or
bFFS existed in the pre-match cohorts. Due to the lack of independence in the PS
matched cohorts, Cox proportional hazard regression adjusted for clustering (stratified by
matched pairs) was used to generate the reported p-value, instead of the log-rank test.
Both visual tests and global tests for violation of the proportionality assumption in the
Cox regression models were performed on each of the final PS matched cohorts. Visual
testing for violation of proportionality included Log-Minus-Log survival plots and
Schoenfeld residual plots, while global testing included the Suprmum-Kolmogorov test
(based on 1000 replications) and the Schoenfeld test. If there was indication of a
violation of the proportionality assumption in either the visual tests (ie. a lack of
parallelism on the Log-Minus-Log survival plot or bending of the Schoenfeld residual
plot), or global tests (ie. significance in either the Suprmum-Kolmogorov or Schoenfeld
test), then an extended Cox model was explored by adding a time dependent covariate
[Radiation type*Log(Survival)]. If the addition of the time dependent covariate was
significant (p<0.05) to the Cox model, then the extended Cox regression p-value using
the likelihood ratio test (with 2 degrees of freedom under the null) was reported. If the
addition of the time dependent variable was not significant, the p-value from the original
Cox regression adjusted for clustering was reported. In the event that results from model
testing were inconclusive, we compared results from both adjusted and extended Cox
models in sensitivity analysis. If results from sensitivity analysis using both models were
comparable, then the extended Cox regression p-value was reported. The survival
difference in all PS matches was tested against the null hypothesis of no difference
between groups at the 5% level of significance. The statistical methods used in this study
follow current consensus for appropriate propensity score matched survival analysis
(Austin, 2007, Kleinbaum 2012). The SAS code used to create the Kaplan-Meier curves,
the adjusted and extended Cox-models, the model assumption tests, and the significance
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tests are shown in Appendix XI. The visual plots and results from the global tests are
shown in Appendix XII. The extended Cox-modeling shown in Appendix XI was
achieved using a previously described SAS code (Kleinbaum 2012).
5.7

Power and Sample Size Considerations

The sample sizes for each comparison was determined through the PS match
selection process and was not considered prior to matching. The statistical power to
detect survival differences in each cohort was considered once the best matches with
adequate covariate balance were chosen. A range in the statistical power for each match
was calculated using SAS 9.3 statistical software. For all power calculations, sample size
was fixed and an alpha of 0.05 was used. In the low-risk comparison, the 4:1 (LDRBT:EBRT) match was accounted for in the power calculation. Based on the hypothesis
of this study, that in all comparisons the BT treatment options were expected to be
superior to EBRT, ranges in statistical power for each cohort assumed BT would have a
lower hazard than EBRT. Statistical power was calculated using 5-year and ≥7-year
bFFS actuarial percentages for prostate cancer patients treated with EBRT found in the
literature. Low-risk and intermediate-risk, 5-year bFFS percentages ranged from 84%
(Goldner 2012) to 95% (Pe 2009) and 74% (Wong 2009) to 86% (Vassil 2010),
respectively. The 7- to 10-year bFFS percentages following EBRT ranged from 75%
(Pickles 2010) to 89% (Zelefsky 2011) for low-risk and 75% (Klein 2009) to 81%
(Kupelian 2004) for intermediate-risk patients. The power calculations used in this study
were based on non-matched designs, thus the reported power may actually be under
estimating the true power. A minimum hazard ratio of at least 0.40 in favor of LDR-BT
was required for statistical power ≥ 0.8 in the low-risk LDR-BT vs. EBRT comparison
and a hazard ratio of 0.35 in favor of LDR-BT in the intermediate-risk comparison. A
hazard ratio of at least 0.45 in favor of HDR-BT+EBRT was required in the HDRBT+EBRT vs. EBRT comparison. Table 17 shows the estimated range in hazard ratios
required for statistical power of at least 0.8 in all comparisons. The SAS code used for
the power calculations is shown in Appendix XIII.
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Table 17: Hazard ratio required for statistical power of 0.8 using literature EBRT bFFS
percentages.
Comparison

Sample
size

5-year

7-to-10 year

HR range

EBRT

EBRT

for power

bFFS%

bFFS%

≥ 0.8

Low-risk: LDR-BT vs. EBRT

*400

95% - 84%

89% - 75%

0.25 - 0.40

Intermediate-risk: LDR-BT vs. EBRT

254

86% - 74%

81% - 75%

0.30 - 0.35

Intermediate-risk: HDR-BT+EBRT vs. EBRT

388

86% - 74%

81% - 75%

0.40 - 0.45

Abbreviations: EBRT = external beam radiation therapy; HDR-BT+EBRT = high dose
rate brachytherapy with adjuvant external beam radiation therapy; HR = hazard ratio; LDRBT = low dose rate brachytherapy
*4:1 (LDR-BT:EBRT) match
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6.0

Results
6.1

Descriptive Statistics of Propensity Score Matches

PS matching brought adequate balance to all variables used in each of the PS
models. The baseline characteristics of age, PSA, Gleason total and T-stage had
standardized differences <0.10 in all matches as well as RT start year in the low-risk
match. However, PS matching was unable to bring balance to many of the variables not
included in the PS models. In the low-risk, 4:1 (LDR-BT:EBRT) PS match (n=400), the
variables of ‘percent positive cores’ and ‘treatment centre’ were not balanced
(standardized difference > 0.1). Similarly, in the intermediate-risk matches, the variables
of percent positive cores, treatment year, and treatment centre were unbalanced. In
intermediate-risk matches, Gleason pattern 4+3 vs. 3+4 was balanced in the 1:1 HDR-BT
vs. EBRT match (n=388) but not in the 1:1 LDR-BT vs. EBRT match (n=254).
Median follow-up time was varied in the PS matched cohorts. For the low-risk
match, patients that received LDR-BT had a median follow-up of 82 months, while
EBRT patients had a median follow-up of 87 months. In the intermediate-risk, HDRBT+EBRT vs. EBRT cohort, HDR-BT+EBRT patients had a median follow-up of 32
months, and EBRT patients had a median follow-up of 81.5 months. Finally, in the
intermediate-risk LDR-BT vs. EBRT match, LDR-BT patients had a median follow-up of
49 months, while EBRT patients had a median follow-up of 83 months. The descriptive
statistics with standardized differences for all patients (low-risk and intermediate-risk)
prior to matching as well as following PS matching are shown in summary Tables 18-20.
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Table 18: Baseline characteristics for all low-risk patients (n=1820) and patients matched
on propensity scores (n=400), stratified by treatment type (LDR-BT vs. EBRT).
All Patients
N=1820
VARIABLE

Matched Patients
N= 400
Caliper: 0.2*1SDevLogit
Ratio: 4 LDR : 1 EBRT
LDR +
LDR
EBRT
EBRT
n = 320
n = 80
n = 400
66.93 ±
66.94 ±
66.87 ±
5.49
5.39
5.91
68.00
68.00
67.00
(51.00 –
(51.00 –
(51.00 –
80.00
79.00)
80.00)
5.88 ±
5.89 ±
5.86 ±
2.14
2.06
2.44
5.90
5.90
5.92
(0.26 –
(0.50 –
(0.26 –
10.00)
9.80)
10.00)

LDR +
EBRT
n = 1820
63.32 ±
7.07
63.00
(43.00 –
84.00)
5.44 ±
2.12
5.40
(0.26 –
10.00)

LDR
n = 1716

EBRT
n = 104

S.D.

62.97 ±
6.96
63.00
(43.00 –
83.00)
5.40 ±
2.10
5.34
(0.30 –
10.00)

68.98 ±
6.59
70.00
(51.00 –
84.00)
6.06 ±
2.36
6.23
(0.26 –
10.00)

0.886

*Gleason Total
– n(%)
2-5
6

136 (7.5)
1684(92.5)

129 (7.5)
1587(92.5)

7 (6.7)
97 (93.3)

0.031

25 (6.3)
375 (93.7)

19 (5.9)
301 (94.1)

6 (7.5)
74 (92.5)

0.062

*T Stage – n(%)
T1
T2

1112(61.1)
708 (38.9)

1051(61.3)
665 (38.8)

61 (58.7)
43 (41.4)

0.053

234 (58.5)
166 (41.5)

185 (57.8)
135 (42.2)

49 (61.3)
31 (38.8)

0.070

*RT Start Year
– n(%)
1999
2000
2001
2002
2003
2004
2005
2006

67 (3.7)
138 (7.6)
197 (10.8)
236 (13.0)
312 (17.1)
314 (17.3)
275 (15.1)
281 (15.4)

59 (3.4)
120 (7.0)
192 (11.2)
208 (12.1)
284 (16.6)
307 (17.9)
269 (15.7)
277 (16.1)

8 (7.7)
18 (17.3)
5 (4.8)
28 (26.9)
28 (26.9)
7 (6.7)
6 (5.8)
4 (3.9)

0.186
0.320
0.237
0.380
0.254
0.345
0.324
0.419

25 (6.3)
54 (13.5)
25 (6.3)
95 (23.8)
116 (29.0)
38 (9.5)
25 (6.3)
22 (5.5)

19 (5.9)
42 (13.1)
20 (6.3)
77 (24.1)
94 (29.4)
31 (9.7)
19 (5.9)
18 (5.6)

6 (7.5)
12 (15.0)
5 (6.3)
18 (22.5)
22 (27.5)
7 (8.8)
6 (7.5)
4 (5.0)

0.062
0.054
0.000
0.037
0.042
0.032
0.062
0.029

Percent
Positive Cores
– n(%)
<50%
>50%
[Missing]

860 (80.1)
214 (19.9)
[746]

800 (81.1)
187 (19.0)
[729]

60 (69.0)
27 (31.0)
[17]

0.282

189 (76.5)
58 (23.5)
[153]

147 (80.3)
36 (19.7)
[137]

42 (65.6)
22 (34.4)
[16]

0.336

Treatment
Centre – n(%)
1
2
3

536 (29.5)
687 (37.8)
597 (32.8)

495 (28.9)
624 (36.4)
597 (34.8)

41 (39.4)
63 (60.6)
0 (0)

0.224
0.500
1.033

124 (31.0)
170 (42.5)
106 (26.5)

91 (28.4)
123 (38.4)
106 (33.1)

33 (41.3)
47 (58.8)
0 (0)

0.271
0.415
1.000

*Age – mean ±
SDev, median,
(min – max)
*Baseline PSA
– mean ± SDev,
median, (min –
max)

0.295

S.D.
0.012

0.013

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; LDR+EBRT = total cohort of low dose rate brachytherapy and external beam
patients; PSA = prostate specific antigen; RT = radiation therapy; S.D. = standardized difference;
SDev = standard deviation
*Variable(s) used in propensity-score computation procedures (if NO asterisk(*)
shown, then not used in propensity-score model).

	
  

87	
  
Table 19: Baseline characteristics for all patients (n=496) and patients matched on
propensity scores (n=254), stratified by treatment type in intermediate-risk LDR-BT vs.
EBRT comparison.
All Patients
N=496
VARIABLE

LDR +
EBRT
n = 496
68.31 ±
6.82
69.00
(45.00 –
83.00)
8.24 ±
3.94
7.46
(0.46 –
19.97)

LDR
n = 231

EBRT
n = 265

S.D.

65.88 ±
7.24
67.00
(46.00 –
83.00)
7.49 ±
3.39
7.00
(0.46 –
18.00)

70.42 ±
5.64
71.00
(45.00 –
82.00)
8.89 ±
4.26
7.83
(1.13 –
19.97)

0.700

*Gleason Total
– n(%)
6
7

146 (29.4)
350 (70.6)

95 (41.1)
136 (58.9)

51 (19.3)
214 (80.8)

0.491

*T Stage – n(%)
Any T1
Low T2
High T2

212 (42.7)
211 (42.5)
73 (14.7)

110 (47.6)
79 (34.2)
42 (18.2)

102 (38.5)
132 (49.8)
31 (11.7)

Percent
Positive Cores
– n(%)
<50%
>50%
[Missing]

240 (59.0)
167 (41.0)
[89]

119 (70.8)
49 (29.2)
[63]

Gleason
Pattern – n(%)
3+3
3+4
4+3
[Missing]

110 (24.8)
251 (56.7)
82 (18.5)
[53]

RT Start Year
- n (%)
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008

1 (0.2)
2 (0.4)
0 (0)
16 (3.2)
23 (4.6)
47 (9.5)
94 (19.0)
80 (16.1)
44 (8.9)
56 (11.3)
72 (14.5)
15 (3.0)
20 (4.0)

*Age – mean ±
SDev, median,
(min – max)
*Baseline PSA
– mean ± SDev,
median, (min –
max)

LDR +
EBRT
n = 254
68.63 ±
6.33
69.00
(45.00 –
83.00)
7.78 ±
3.40
7.12
(1.30 –
18.00)

Matched Patients
N = 254
Caliper: 0.01
Ratio: 1 LDR : 1 EBRT
LDR
EBRT
n = 127
n = 127

S.D.

68.72 ±
6.56
69.00
(46.00 –
83.00)
7.87 ±
2.99
7.41
(1.30 –
18.00)

68.54 ±
6.12
69.00
(45.00 –
82.00)
7.70 ±
3.77
6.80
(1.48 –
17.00)

0.029

57 (22.4)
197 (77.6)

30 (23.6)
97 (76.4)

27 (21.3)
100(78.7)

0.057

0.185
0.320
0.183

109 (42.9)
118 (46.5)
27 (10.6)

56 (44.1)
56 (44.1)
15 (11.8)

53 (41.7)
62 (48.8)
12 (9.5)

0.048
0.095
0.077

121 (50.6)
118 (49.4)
[26]

0.423

140 (62.8)
83 (37.2)
[31]

77 (72.6)
29 (27.4)
[21]

63 (53.9)
54 (46.2)
[10]

0.398

59 (33.2)
100 (56.2)
19 (10.7)
[53]

51 (19.3)
151 {57.0)
63 (23.8)
[0]

0.320
0.016
0.352

47 (20.0)
145 (61.7)
43 (18.3)
[19]

20 (18.5)
73 (67.6)
15 (13.9)
[19]

27 (21.3)
72 (56.7)
28 (22.1)
[0]

0.069
0.226
0.214

1 (0.4)
2 (0.9)
0 (0)
11 (4.8)
6 (2.6)
13 (5.6)
13 (5.6)
16 (6.9)
19 (8.2)
33 (14.3)
56 (24.2)
15 (6.5)
20 (8.7)

0 (0)
0 (0)
0 (0)
5 (1.9)
17 (6.4)
34 (12.8)
81 (30.6)
64 (24.2)
25 (9.4)
23 (8.7)
16 (6.0)
0 (0)
0 (0)

0.093
0.132
0.000
0.161
0.185
0.251
0.685
0.489
0.043
0.177
0.525
0.373
0.435

0 (0)
0 (0)
0 (0)
3 (1.2)
12 (4.7)
23 (9.1)
41 (16.1)
35 (13.8)
24 (9.5)
33 (13.0)
59 (23.2)
5 (2.0)
11 (4.3)

0 (0)
0 (0)
0 (0)
2 (1.6)
2 (1.6)
3 (2.4)
6 (4.7)
5 (3.9)
12 (9.5)
23 (18.1)
50 (39.4)
5 (3.9)
11 (8.7)

0 (0)
0 (0)
0 (0)
1 (0.8)
10 (7.9)
20 (15.8)
35 (27.6)
30 (23.6)
12 (9.5)
10 (7.9)
9 (7.1)
0 (0)
0 (0)

0.000
0.000
0.000
0.073
0.300
0.480
0.653
0.596
0.000
0.308
0.827
0.286
0.436

0.361
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2009
2010
Treatment
Centre – n(%)
1
2
3

15 (3.0)
11 (2.2)

15 (6.5)
11 (4.8)

0 (0)
0 (0)

0.373
0.316

3 (1.2)
5 (2.0)

3 (2.4)
5 (3.9)

0 (0)
0 (0)

0.220
0.286

130 (26.2)
313 (63.1)
53 (10.7)

93 (40.3)
85 (36.8)
53 (22.9)

37 (14.0)
228 (86.0)
0 (0)

0.619
1.173
0.777

83 (32.7)
152 (59.8)
19 (7.5)

65 (51.2)
43 (33.9)
19 (15.0)

18 (14.2)
109 (85.8)
0 (0)

0.859
1.250
0.593

Abbreviations: EBRT = external beam radiation therapy; LDR = low dose rate
brachytherapy; LDR+EBRT = total cohort of low dose rate brachytherapy and external beam
patients; PSA = prostate specific antigen; RT = radiation therapy; S.D. = standardized difference;
SDev = standard deviation
*Variable(s) used in propensity-score computation procedures (if NO asterisk(*)
shown, then not used in propensity-score model).
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Table 20: Baseline characteristics for all patients (n=655) and patients matched on
propensity scores (n=388), stratified by treatment type in intermediate-risk HDRBT+EBRT vs. EBRT comparison.
All Patients
N=655
VARIABLE

Matched Patients
N=388
Caliper: 0.2*1SDevLogit
Ratio: 1 HDR : 1 EBRT
Total
HDR+
EBRT
Sample
EBRT
n = 194
n = 388
n = 194
69.19 ±
69.20 ±
69.17 ±
5.25
5.03
5.48
70.00
70.00
70.00
(55.00 –
(57.00 –
(55.00 –
82.00)
81.00)
82.00)
8.77 ±
8.92 ±
8.62 ±
4.06
4.01
4.13
7.79
8.00
7.60
(1.00 –
(1.00 –
(1.48 –
19.76)
19.76)
19.60)

Total
Sample
n = 655
67.59 ±
6.62
69.00
(45.00 –
82.00)
8.51 ±
4.06
7.41
(0.37 –
19.97)

HDR+
EBRT
n = 390
65.66 ±
6.55
66.00
(47.00 –
81.00)
8.26 ±
3.91
7.23
(0.37 –
19.96)

EBRT
n = 265

S.D.

70.42 ±
5.64
71.00
(45.00 –
82.00)
8.89 ±
4.26
7.83
(1.13 –
19.97)

0.779

*Gleason Total
– n(%)
6
7

93 (14.2)
562 (85.8)

42 (10.8)
348 (89.2)

51 (19.3)
214 (80.8)

0.239

57 (14.7)
331 (85.3)

27 (13.9)
167 (86.1)

30 (15.5)
164 (84.5)

0.044

*T Stage –
n(%)
Any T1
Low T2
High T2

344 (52.5)
263 (40.2)
48 (7.3)

242 (62.1)
131 (33.6)
17 (4.4)

102 (38.5)
132 (49.8)
31 (11.7)

0.485
0.334
0.273

184 (47.4)
179 (46.1)
25 (6.4)

92 (47.4)
90 (46.4)
12 (6.2)

92 (47.4)
89 (45.9)
13 (6.7)

0.000
0.010
0.021

Percent
Positive Cores
– n(%)
<50%
>50%
[Missing]

173 (53.9)
148 (46.1)
[334]

52 (63.4)
30 (36.6)
[308]

121 (50.6)
118 (49.4)
[26]

0.260

121 (54.5)
101 (45.5)
[166]

30 (62.5)
18 (37.5)
[146]

91 (52.3)
83 (47.7)
[20]

0.207

Gleason
Pattern – n(%)
3+3
3+4
4+3
[Missing]

65 (18.5)
202 (57.6)
84 (23.9)
[304]

14 [16.3)
51 (59.3)
21 (24.4)
[304]

51 (19.3)
151 (57.0)
63 (23.8)
[0]

0.078
0.047
0.015

39 (15.9)
145 (59.2)
61 (24.9)
[143]

9 (17.7)
29 (56.9)
13 (25.5)
[143]

30 (15.5)
116 (59.8)
48 (24.7)
[0]

0.059
0.060
0.017

RT Start Year
– n(%)
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010

5 (0.8)
17 (2.6)
44 (6.7)
102 (15.6)
84 (12.8)
54 (8.2)
50 (7.6)
47 (7.2)
55 (8.4)
98 (15.0)
73 (11.2)
26 (4.0)

0 (0)
0 (0)
10 (2.6)
21 (5.4)
20 (5.1)
29 (7.4)
27 (6.9)
31 (8.0)
55 (14.1)
98 (25.1)
73 (18.7)
26 (6.7)

5 (1.9)
17 (6.4)
34 (12.8)
81 (30.6)
64 (24.2)
25 (9.4)
23 (8.7)
16 (6.0)
0 (0)
0 (0)
0 (0)
0 (0)

0.196
0.370
0.392
0.694
0.559
0.072
0.066
0.075
0.573
0.819
0.679
0.378

4 (1.0)
15 (3.9)
31 (8.0)
74 (19.1)
50 (12.9)
36 (9.3)
35 (9.0)
28 (7.2)
25 (6.4)
50 (12.9)
28 (7.2)
12 (3.1)

0 (0)
0 (0)
6 (3.1)
12 (6.2)
12 (6.2)
16 (8.3)
15 (7.7)
18 (9.3)
25 (12.9)
50 (25.8)
28 (14.4)
12 (6.2)

4 (2.1)
15 (7.7)
25 (12.9)
62 (32.0)
38 (19.6)
20 (10.3)
20 (10.3)
10 (5.2)
0 (0)
0 (0)
0 (0)
0 (0)

0.205
0.409
0.367
0.694
0.408
0.071
0.090
0.160
0.544
0.833
0.581
0.363

*Age – mean ±
SDev, median,
(min – max)
*Baseline PSA
– mean ± SDev,
median, (min –
max)

0.155

	
  

S.D.
0.006

0.074
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Treatment
Centre – (n%)
1
2
3
4

37 (5.7)
228 (34.8)
303 (46.3)
87 (13.3)

0 (0)
0 (0)
303 (77.7)
87 (22.3)

37 (14.0)
228 (86.0)
0 (0)
0 (0)

0.570
3.511
2.640
0.758

35 (9.0)
159 (41.0)
142 (36.6)
52 (13.4)

0 (0)
0 (0)
142 (73.2)
52 (26.8)

35 (18.0)
159 (82.0)
0 (0)
0 (0)

0.664
3.014
2.337
0.856

Abbreviations: EBRT = external beam radiation therapy; HDR+EBRT = high dose rate
brachytherapy with external beam radiation therapy; PSA = prostate specific antigen; RT =
radiation therapy; S.D. = standardized difference; SDev = standard deviation
*Variable(s) used in propensity-score computation procedures (if NO asterisk(*)
shown, then not used in propensity-score model).
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6.2

Survival Outcomes

Low-Risk LDR-BT vs. EBRT Match:
Kaplan-Meier curves comparing both OS and bFFS for LDR-BT and EBRT in
low-risk PS matched prostate cancer patients are shown in Figures 6 and 7. No
significant difference was found comparing OS in the low-risk LDR-BT vs. EBRT match
(hazard ratio = 1.41, 95% CI 0.52-3.86, p = 0.50). The 5-year and 10-year actuarial
percentages for OS were 96% and 88% for LDR-BT patients and 95% and 95% for
EBRT patients, respectively. However, LDR-BT was associated with a statistically
significant improvement in bFFS when compared with EBRT (hazard ratio = 0.35, 95%
CI 0.17-0.71, p=0.004). The 5-year and 10-year actuarial percentages for bFFS were
96% and 91% in the LDR-BT group and 89% and 78% in the EBRT group, respectively.
In total, 17 (5.3%) LDR-BT patients and 10 (12.5%) EBRT patients experienced a
biochemical failure, while 21 (6.6%) LDR-BT patients and 4 (5%) EBRT patients died.
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Fig. 6. Overall survival for low-risk patients in LDR-BT vs. EBRT comparison group
following propensity score match.
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Fig. 7. Biochemical failure-free survival for low-risk patients in LDR-BT vs. EBRT
comparison group following propensity score match.
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Intermediate-Risk LDR-BT vs. EBRT Match:
Kaplan-Meier curves comparing both OS and bFFS for LDR-BT and EBRT in
intermediate-risk PS matched prostate cancer patients are shown in Figures 8 and 9. No
significant difference was found comparing OS in the intermediate-risk LDR-BT vs.
EBRT match (hazard ratio = 0.79, 95% CI 0.24-2.53, p = 0.69). The 5-year and 10-year
actuarial percentages for OS were 97% and 83% for LDR-BT patient and 96% and 80%
for EBRT patients, respectively. LDR-BT was associated with a statistically significant
improvement in bFFS when compared with EBRT (hazard ratio = 0.22, 95% CI 0.090.50, p=0.001). The 5-year and 10-year actuarial percentages for bFFS were 93% and
93% in the LDR-BT group and 78% and 28% in the EBRT group, respectively. In total,
5 (3.9%) LDR-BT patients and 41 (32.3%) EBRT patients experienced a biochemical
failure, while 4 (3.1%) LDR-BT patients and 12 (9.4%) EBRT patients died.
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Fig. 8. Overall survival for intermediate-risk patients in LDR-BT vs. EBRT comparison
group following propensity score match.
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Fig. 9. Biochemical failure-free survival for intermediate-risk patients in LDR-BT vs.
EBRT comparison group following propensity score match.
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Intermediate-Risk HDR-BT+EBRT vs. EBRT Match:
Kaplan-Meier curves comparing both OS and bFFS for HDR-BT+EBRT and
EBRT in intermediate-risk PS matched prostate cancer patients are shown in Figures 10
and 11. No significant difference was found comparing OS in the intermediate-risk
HDR-BT+EBRT vs. EBRT match (hazard ratio = 0.64, 95% CI 0.20-2.13, p = 0.47). The
5-year and 10-year actuarial percentages for OS were 99% and 95% for HDR-BT+EBRT
patients and 96% and 75% for EBRT patients, respectively. HDR-BT+EBRT was
associated with a statistically significant improvement in bFFS when compared with
EBRT (hazard ratio = 0.48, 95% CI 0.26-0.89, p=0.007). The 5-year and 10-year
actuarial percentages for bFFS were 89% and 84% in the HDR-BT+EBRT group and
76% and 29% in the EBRT group, respectively. In total, 13 (6.7%) HDR-BT+EBRT
patients and 64 (33.0%) EBRT patients experienced a biochemical failure, while 3 (1.5%)
HDR-BT+EBRT patients and 16 (8.2%) EBRT patients died.
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Fig. 10. Overall survival for intermediate-risk patients in HDR-BT+EBRT vs. EBRT
comparison group following propensity score match.
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Fig. 11. Biochemical failure-free survival for intermediate-risk patients in HDRBT+EBRT vs. EBRT comparison group following propensity score match.
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6.3

Pre-Match Versus Post-Match Comparison

Kaplan-Meier survival curves showing differences in OS and bFFS in prematched cohorts are shown in Figures 12-17. The hazard ratio for pre-matched OS was
0.60 (95% CI 0.31-1.16, p=0.13) for the low-risk cohort, 1.07 (95% CI 0.49-2.32,
p=0.87) for the intermediate-risk LDR-BT vs. EBRT cohort, and 0.36 (95% CI 0.10-1.27,
p=0.10) for the intermediate risk HDR-BT+EBRT vs. EBRT cohort. The hazard ratio for
pre-matched bFFS was 0.31 (95% CI 0.18-0.55, p<0.0001) for the low-risk cohort, 0.19
(95% CI 0.10-0.36, p<0.0001) for the intermediate-risk LDR-BT vs. EBRT cohort, and
0.52 (95% CI 0.34-0.80, p=0.003) for the HDR-BT+EBRT vs. EBRT cohort.
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Fig. 12. Overall survival for low-risk patients in LDR-BT vs. EBRT comparison group
prior to propensity score matching.
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Fig. 13. Biochemical failure-free survival for low-risk patients in LDR-BT vs. EBRT
comparison group prior to propensity score matching.
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Fig. 14. Overall survival for intermediate-risk patients in LDR-BT vs. EBRT comparison
group prior to propensity score matching.

	
  

104	
  

Fig. 15. Biochemical failure-free survival for intermediate-risk patients in LDR-BT vs.
EBRT comparison group prior to propensity score matching.
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Fig. 16. Overall survival for intermediate-risk patients in HDR-BT+EBRT vs. EBRT
comparison group prior to propensity score matching.
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Fig. 17. Biochemical failure-free survival for intermediate-risk patients in HDRBT+EBRT vs. EBRT comparison group prior to propensity score matching.
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7.0

Discussion
7.1

Survival Outcomes Assessment

Propensity score matched analysis demonstrated no difference in OS comparing
BT options to EBRT in any of the comparison groups (LDR-BT vs. EBRT or HDRBT+EBRT vs. EBRT in low-risk or intermediate-risk matches) (Fig. 6, 8 and 10). This
matched analysis successfully adjusted for the baseline prognostic factors of age, PSA,
Gleason total score and T-stage, which are the primary factors used to risk-stratify
patients and tailor their radiation therapy (Keyes 2013, Rubin 2001, Thompson 2007).
Prospective randomized data comparing OS in intermediate- to high-risk patients
receiving combination BT with EBRT vs. EBRT alone have reported 5-year actuarial
percentages of 94% vs. 92%, respectively (Santhya 2005). Our PS matched analysis
reported 5-year OS percentages of 99% HDR-BT+EBRT vs. 96% EBRT (p=0.47) in the
intermediate-risk cohort (Fig. 10). Similarly, observational data reporting on
intermediate-risk LDR-BT vs. EBRT found no statistically significant OS difference with
5-year actuarial percentages of 94% vs. 94% (Klein 2009). Our results comparing LDRBT vs. EBRT in intermediate-risk patients found a similar 5-year OS result of 97% vs.
96% (p=0.69), respectively (Fig. 8). Results from observational studies show that OS for
prostate cancer patients with favorable-risk disease is very high, with 5-year actuarial
percentages reported at 97% (Wong 2009). Results from our study showed no
statistically significant OS difference in the low-risk matched cohort with survival rates
of 96% LDR-BT vs. 95% EBRT (p=0.50) (Fig. 6).
A statistically significant difference in biochemical failure was found in both lowrisk and intermediate-risk matched cohorts comparing LDR-BT vs. EBRT, with BT
providing superior bFFS in both cases (Fig. 7 and 9). Observational studies comparing
ASTRO Phoenix defined bFFS as their primary outcome have reported similar results
when comparing LDR-BT to EBRT. In strictly low-risk comparisons, literature reported
5-year bFFS actuarial percentages of ≥ 94% for LDR-BT were constantly higher than
EBRT compared values, ranging from 84% to 95% (Goldner 2012, Pe 2009, Pickles
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2010, Wong 2009). Results from our matched analysis of LDR-BT vs. EBRT in the lowrisk cohort demonstrated 5-year bFFS percentages of 96% LDR-BT vs. 89% EBRT
(p=0.004) (Fig. 7). Previously reported CER on entirely intermediate-risk patients
comparing LDR-BT vs. EBRT have also reported improved bFFS in direct comparisons
(Klein 2009, Pickles 2010, Vassil 2010, Wong 2009). The results from our matched
study are agreeable with the literature, with a hazard ratio of 0.22 (95% CI 0.09-0.50,
p=0.001) favoring BT in the intermediate-risk LDR-BT vs. EBRT compared cohort (Fig.
9).
In the combination HDR-BT+EBRT vs. EBRT PS matched, intermediate-risk
comparison, statistically significant improvement in bFFS was observed in the HDRBT+EBRT group. The 5-year bFFS percentages were 89% in the HDR-BT+EBRT group
and 76% in the EBRT group, respectively (p=0.007) (Fig. 11). Our results agree with
other CER directly comparing HDR-BT+EBRT vs. EBRT in strictly intermediate-risk
patients, which have reported similar results that favor combination therapy (Khor 2013,
Deutsch 2010). However, the results from one of these studies using Cox regression
modeling for confounding adjustment, reported results on intermediate-risk in subgroup
analysis but did not account for differences in ADT use between groups (Deutsch 2010).
Results from our study on intermediate-risk HDR-BT+EBRT vs. EBRT patients was
obtained from a homogenous intermediate-risk cohort that received no ADT use.
Isolating the effect of radiation therapy alone on survival without hormone assistance was
an advantage of our study over a large proportion of comparative RT outcome studies
available.
Visually, in both intermediate-risk comparisons, no apparent difference in
biochemical failure was observed until ≥3-years, at which point a sharp drop off in bFFS
was noted in the EBRT cohorts (Fig. 9 and 11). This visual trend was similar in the lowrisk comparison, where no observable difference in bFFS was seen until roughly 4-years
post treatment (Fig. 7). The need for PSA to reach nadir prior to any indication of
biochemical failure using the ASTRO-RTOG Phoenix II definition (Roach 2006) is a
likely explanation for this visual trend. The time to reach PSA nadir following RT has
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been demonstrated to take as long as 3-years (Shi 2013), which would agree with our
results, where larger frequencies of biochemical failures were not present until roughly 3years after RT treatment was given. These results demonstrate the importance of having
follow-up times of at least 5-years to adequately assess PSA failure following RT in
patients with prostatic cancer. Another interesting discovery was that although a larger
proportion of EBRT patients experienced biochemical failure, this did not correlate to a
poorer overall survival probability. A possible explanation for this discrepancy between
biochemical failure and survival in the EBRT cohorts may be a result of salvage therapy.
This would agree with current studies on BT salvage following EBRT, which have
demonstrated adequate biochemical control at 5-years (Vargas 2014, Yamada 2013).
Upon literature review, only one other CER study directly comparing BT versus
EBRT treatment survival outcomes was found that used PS matched analysis for
confounding adjustment. In their study, Khor et al matched 344 EBRT with 344 HDRBT+EBRT patients with intermediate- and high-risk disease, reporting a bFFS hazard
ratio of 0.44 (95% CI 0.28-0.70, p<0.001), favoring combination therapy in intermediaterisk subgroup analysis. However, in this study ADT use was only effectively balanced
between treatment groups in their primary match, which included both intermediate-risk
and high-risk patients. Therefore, among other factors included in their PS match model,
ADT use in the intermediate-risk cohort was no longer balanced and may have
confounded their subgroup analysis. Results from our analysis of intermediate-risk
HDR-BT+EBRT vs. EBRT showed a bFFS hazard ratio of 0.48 (95% CI 0.26-0.89,
p=0.007) (Fig. 11) in favor of combination HDR-BT+EBRT. Additionally, our results
are from a matched, strictly intermediate-risk cohort that had balanced baseline
prognostic factors with no ADT use in either group.
When comparing pre-matched, unadjusted survival curves to PS matched curves,
some differences were observed. For example, in the pre-match low-risk cohort, a slight
visual difference in OS with borderline significance favoring LDR-BT was present (Fig.
12). This borderline visual difference in OS was no longer present in the low-risk PS
matched curve (Fig. 6). Visual comparison of additional pre-match to post-match curves
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provided similar results. In the intermediate-risk HDR-BT+EBRT vs. EBRT
comparison, OS is borderline statistically significant pre-match (Fig. 16) but not
following PS matching (Fig. 10). Although reduced sample size in the matched cohorts
compared to the original pre-matched population could explain this change in statistical
significance, under visual inspection, survival between treatment groups appears to
become more similar after PS matching. This visual trend is also noticeable in the prematch and post-match bFFS curves in the intermediate-risk LDR-BT vs. EBRT cohort
(Fig. 9 and 15) with a slight reduction in strength of difference between groups postmatch. These results demonstrate that PS matching can be an effective tool at removing
imbalances in baseline prognostic factors that impact survival and can provide results
with a reduced amount of bias.
To our knowledge, this was the first multi-institutional Canadian study comparing
primary BT vs. EBRT survival outcomes in separate prostate cancer risk groups using PS
matched analysis. Through retrospective data analysis, we were able to obtain results of
biochemical failure and overall survival of patients treated at four major cancer
institutions in Canada, with over 10-years of follow-up data. Another advantage of this
study was that it controlled for the phenomenon of PSA bounce, or the benign spike in
PSA measurement that can occur following BT treatment (Mehta 2013). An attempt to
control for PSA bounce was either not mentioned or attempted in most comparative
studies found in the literature. In an exploratory analysis, we created additional Kaplan
Meier curves that did not factor in PSA bounce in the matched cohorts and compared
them to the original survival curves (see Appendix IV). Under visual inspection of the
bFFS curves, when PSA bounce was not accounted for, EBRT appeared to be initially
protective compared with BT options over the first 1 to 3 years, until BT eventually
became superior. This initial protective effect of EBRT is no longer present when PSA
bounce was factored into the biochemical survival analysis (Fig. 7, 9 and 11). This
demonstrates the potential effect PSA bounce can have on biochemical outcome analysis
in prostate cancer, specifically when assessing PSA failures from BT treatments within
the first few years of follow-up.
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7.2

Study Limitations

1. Data Source: A major limitation to this study was that results were from a secondary
analysis that was not originally planned during the creation of the ProCaRS database. As
a result, our analysis was restricted to the data originally present in the ProCaRS
database. Outcome data was restricted to survival and biochemical failure only. There
was no information on acute or late side effects available in the database, including data
on GI or GU toxicities, impotency, or any measurement on patient reported quality of
life. Information on these additional patient important outcomes would have
strengthened this study by allowing a more in depth assessment of the mortality and
morbidity associated with the various RT treatments.
2. Sample Size: Matching was restricted to patients with complete data for all variables
included in the PS models (logistic regression models) and based on specific sets of
exclusion criteria used to create homogenous comparison groups. This resulted in a
reduction in sample size and power in our matched comparisons.
3. Confounding Variable Selection: Variable eligibility for inclusion in PS models was
restricted to those readily available in the database and of sufficient level of
completeness. For example, information on both percent positive core biopsy and
Gleason 7 sub-pattern (3+4 vs. 4+3) was generally incompletely entered and could not be
controlled for in our analysis. The variation in RT management of prostate cancer across
different treatment centres could potentially impact outcomes (Cooperberg 2010),
however, the method of data collection from the various cancer institutions made it
impossible to include a ‘treatment centre’ variable in the PS models.
4. Comparisons: Again, due to limitations in available data, no RT modality
comparisons were made with high-risk prostate cancer patients. Additionally, there were
no comparisons of the RT treatments to conservative management strategies (watchful
waiting or active surveillance) or radical prostatectomy.
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7.3

Future Work

Given the completion of this CER study on prostate cancer outcomes, and the
effort expended in creating the ProCaRS database containing RT data on roughly 8000
patients, additional uses for this database could be explored. A potential retrospective
study aimed at exploring the relationship between biochemical failure and overall
survival is warranted. Identifying patient characteristics that best predict survival
following biochemical failure would help investigators better understand the relationship
between these two important patient outcomes. Additionally, identifying the importance
of ADT use in LDR-BT patients could be explored to better understand the impact of
hormone therapy in this patient population.
With respect to future work in the field of prostate cancer CER, expansion of the
ProCaRS database to include more patients treated with higher doses of EBRT (>78 Gy)
with more modern techniques, such as image guided IMRT, would allow for higher
quality comparisons of BT versus dose escalated IMRT treatments. Incorporating
outcome data on acute and late toxicities, impotency and patient reported quality of life
into the ProCaRS database would also be beneficial. Exploring patient toxicities as well
as other side effects from compared therapies could strengthen the quality of comparisons
made between treatment groups. Additionally, integrating information on health care
costs into the ProCaRS database would enable economic assessment. This could allow
for a more complete understanding of strengths and weaknesses between therapies and
ultimately aid decision-making by health policy makers. Finally, improving the volume
of high-risk patients in the ProCaRS database could allow for RT outcome comparisons
to be made in this patient population that, as yet, were not achievable.
Potential randomized phase III trials comparing both survival and side effect
outcomes in patients receiving BT or EBRT could be explored. Results from our study
indicate that BT treatments appear to lead to fewer treatment failures in low-risk and
intermediate-risk patients. However, confirmation of the overall benefit of BT compared
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to EBRT from a treatment effectiveness standpoint that includes both survival and sideeffect data is not yet fully understood.
7.4

Conclusions

Propensity score matched analysis showed BT options significantly improved
bFFS in low- and intermediate-risk prostate cancer patients after 10-years of follow-up,
but did not lead to statistically significant improvements in OS. The comparisons made
demonstrated that LDR-BT led to relatively fewer treatment failures than EBRT in both
low-risk and intermediate-risk patients. Combination HDR-BT+EBRT was also found to
have a superior benefit in reducing biochemical failures compared with EBRT in men
with intermediate-risk prostate cancer. The results of this study add to an increasing
amount of evidence favoring BT over EBRT with respect to biochemical control in the
treatment of localized prostate cancer. Assuming this research question is still of interest
to the radiation oncology community, our results also provide preliminary evidence for
implementation of an RCT comparing RT survival outcomes of BT vs. EBRT in lowrisk, intermediate-risk and potentially high-risk prostate cancer patients.
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Appendix I: Summary of CER Articles on Primary RT Outcomes.
Author

Date

Study Type

Confounder
Adjustment

Comparison
(n per treatment)

RT Dose (Tx)

% Prostate Cancer
Risk Groups per
treatment

AbelWahab et
al

2008

Retrospective

Cox PH
Regression

NR

NR

Aoki et al

2009

Retrospective

Cox PH
Regression

BT (10214)
vs.
EBRT (28225)
vs.
BT+EBRT (9078)
LDR-BT (252)
vs.
LDR-BT+EBRT
(44)

LDR-BT:
144 Gy I-125
vs.
LDR-BT+EBRT:
110 Gy I-125 +
44-46 Gy EBRT

Beyer et
al

2000

Retrospective

Cox PH
Regression

LDR-BT (595)
vs.
EBRT (1527)

Burdick
et al

2009

Retrospective

Cox PH
Regression

LDR-BT (127)
vs.
EBRT (268)

Coen et al

2012

Retrospective

Individual
1:1 Case
Match

Proton + EBRT
(141)
vs.
LDR-BT (141)

D'Amico
et al

1998

Retrospective

Cox PH
Regression

LDR-BT (218)
vs.
EBRT (766)

LDR-BT:
120 Gy Pd-103 or
160 Gy I-125
vs.
EBRT:
66 Gy
LDR-BT:
144 Gy I-125
vs.
EBRT:
70 Gy
Proton + EBRT:
20 Gy to 29 Gy
Proton EBRT +
50 Gy Photon
EBRT
vs.
LDR-BT:
145 Gy I-125 or
115 Gy Pd-103
LDR-BT:
115 Gy Pd-103
vs.
EBRT:
66-72 Gy

LDR-BT:
(Low=65%;Int=33
%;High=2%)
vs.
LDR-BT+EBRT:
(Int=75%;High=25
%)
NR

da Silva
Franca et
al

2010

Retrospective

Cox PH
Regression

LDR-BT (72)
vs.
LDR-BT+EBRT
(24)

LDR-BT:
145 Gy I-125
vs.
LDR-BT+EBRT:
110 Gy I-125 +
45 Gy EBRT

Davis et
al

2001

Prospective

None

LDR-BT (142)
vs.
EBRT (222)

LDR-BT:
115 Gy Pd-103
vs.
EBRT:
70 Gy

	
  

NR

Proton EBRT:
(Low=80%;Int=20
%)
vs.
LDR-BT:
(Low=84%;Int=16
%)
LDR-BT:
(low=56%;int=23%
;high=20%)
vs.
EBRT:
(low=29%;int=31%
;high=40%)
LDR-BT:
(Int=64%;High=36
%)
vs.
LDR-BT+EBRT:
(Int=29%;High=71
%)
NR
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Deutsch
et al

2010

Retrospective

Cox PH
Regression

EBRT (470)
vs.
HDR-BT+EBRT
(160)

EBRT:
86 Gy
vs.
HDR-BT+EBRT:
21 Gy Ir-192 + 50
Gy EBRT

EBRT:
(Low=21%;Int=40
%;High=39%)
vs.
HDR-BT+EBRT:
(Low=14%;Int=71
%;High=15%)

Eade et al

2008

Retrospective

Cox PH
Regression

LDR-BT (158)
vs.
EBRT (216)

100% low

Elliot et
al

2007

Retrospective

Cox PH
Regression

BT (799)
vs.
EBRT (645)

LDR-BT:
145-166 Gy I-125
vs.
EBRT:
70-78 Gy
NR

Ferrer et
al

2008

Prospective

GEE

LDR-BT (275)
vs.
EBRT (205)

LDR-BT:
144 Gy I-125
vs.
EBRT:
74 Gy

Gelbium
et al

2000

Retrospective

Cox PH
Regression

LDR-BT (685)
vs.
LDR-BT+EBRT
(140)

Goldner
et al

2012

Retrospective

Cox PH
Regression

LDR-BT (667)
vs.
70 Gy EBRT (82)
vs.
74 Gy EBRT
(170)

Gondi et
al

2007

Retrospective

Cox PH
Regression

LDR-BT or LDRBT+EBRT ±
ADT (72)
vs.
EBRT+ADT (84)
vs.
EBRT only (141)

Huang et
al

2010

Retrospective

Regression

BT (219)
vs.
EBRT (154)

LDR-BT:
144 Gy I-125 or
120 Gy Pd-103
vs.
LDR-BT+EBRT:
100 Gy I-125 or
90 Gy Pd-103 +
41-45 Gy EBRT
LDR-BT:
144 Gy I-125
vs.
EBRT:
70 Gy
vs.
EBRT:
74 Gy
LDR-BT or LDRBT+EBRT ±
ADT:
145 Gy I-125 or
120 Gy Pd-103 or
110 Gy I-125 +
45 Gy EBRT or
90 Gy Pd-103 +
45 Gy EBRT
vs.
EBRT+ADT:
66-70 Gy + ADT
vs.
EBRT:
66-70 Gy
NS

LDR-BT:
(Low=88%;Int=11
%:High=1%)
vs.
EBRT:
(Low=48%;Int=34
%;High=18%)
NR

	
  

NR

100% low-risk
patients

100% Intermediaterisk patients

BT:
(Low=65%;Int=27
%;High=7%)
vs.
EBRT:
(Low=25%;Int=38
%;High=37%)
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Joseph et
al

2008

Prospective

None

EBRT (111)
vs.
HDR-BT+EBRT
(23)

EBRT:
66-70 Gy
vs.
HDR-BT+EBRT:
17 Gy Ir-192 + 40
Gy EBRT

NR - all int/highrisk

Kalakota
et al

2010

Prospective

Cox PH
Regression

LDR-BT (62)
vs.
LDR-BT+EBRT
(48)

NR

Klein et
al

2009

Retrospective

Cox PH
Regression

LDR-BT (204)
vs.
EBRT (321)

LDR-BT:
144 Gy I-125
vs.
LDR-BT+EBRT:
108 Gy I-125 +
45 Gy EBRT
LDR-BT:
144 Gy I-125
vs.
EBRT:
81 Gy

Khor et al

2013

Retrospective

Propensity
Score Match

EBRT (344)
vs.
HDR-BT+EBT
(344)

EBRT:
74 Gy
vs.
HDR-BT+EBRT:
19.5 Gy Ir-192 +
46 Gy EBRT

EBRT:
(Int=59%;High=41
%)
vs.
HDR-BT+EBRT:
(Int=59%;High=41
%)

Krestin et
al

2000

Retrospective

Individual
1:1 Case
Match

EBRT (161)
vs.
HDR+EBRT
(161)

NR

Kupelian
et al

2004

Retrospective

Cox PH
Regression

LDR-BT (950)
vs.
EBRT≥72Gy
(301)
vs.
EBRT<72Gy
(484)
vs.
LDR-BT+EBRT
(222)

Lee et al

2001

Prospective

None

LDR-BT (44)
vs.
EBRT (23)

Lev et al

2009

Prospective

Regression

Nieder et
al

2008

Retrospective

Cox PH
Regression

LDR-BT+EBRT
(61)
vs.
HDR-BT+EBRT
(49)
BT (22889)
vs.
EBRT (93059)
vs.

EBRT:
66 Gy
vs.
HDR-BT+EBRT:
16-21 Gy Ir-192 +
46 Gy EBRT
LDR-BT:
144 Gy I-125 or
136 Gy Pd-103
vs.
EBRT≥72Gy:
72-82 Gy
vs.
EBRT<72Gy
63-70 Gy
vs.
LDR-BT+EBRT:
108 Gy I-125 +
41 Gy EBRT or
102 Gy Pd-103 +
45 Gy EBRT
LDR-BT:
144 Gy I-125
vs.
EBRT:
70-72 Gy
NR

NR

NR

	
  

100% Intermediaterisk patients

NR - T1/T2 disease

LDR-BT:
(100% low/int)
vs.
EBRT:
(low/int/<10%high)
NR
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BT+EBRT
(17956)

Ojha et al

2010

Retrospective

Cox PH
Regression

BT (20259)
vs.
EBRT (41986)
LDR-BT (171)
vs.
EBRT (189)

NR

NR

Pe et al

2009

Retrospective

Cox PH
Regression

LDR-BT:
145 Gy I-125
vs.
EBRT:
74 Gy
LDR-BT:
145 Gy I-125
vs.
EBRT:
52-72 Gy

100% low-risk
patients

Pickles et
al

2010

Retrospective

Individual
1:1 Case
Match

LDR-BT (139)
vs.
EBRT (139)

Pinkawa
et al

2010

Retrospective

Cox PH
Regression

LDR-BT (94)
vs.
EBRT (135)
vs.
HDR-BT+EBRT
(66)

LDR-BT:
145 Gy I-125
vs.
EBRT:
70 Gy
vs.
HDR-BT+EBRT:
18 Gy Ir-192 + 50
Gy

LDR-BT:
(Low=65%;Int=35
%)
vs.
EBRT:
(Low=27%;Int=24
%;High=49%)
vs.
HDR-BT+EBRT
(Low=35%;Int=26
%;High=39%)

Santhya
et al

2005

RCT

Cox PH
Regression

HDR-BT+EBRT
(51)
vs.
EBRT (53)

HDR-BT+EBRT:
35 Gy BT + 40
Gy EBRT
vs.
EBRT:
66 Gy

Prospective

Regression

NR

2003

Prospective

Regression

LDR-BT (58)
vs.
HDR-BT (47)
vs.
EBRT (123)
BT (80)
vs.
EBRT (182)

HDR-BT+EBRT:
(int=41%;high=59
%)
vs.
EBRT:
(int=40%;high=60
%)
NR

Smith et
al

2009

Talcott et
al

Vassil et
al

2010

Retrospective

Cox PH
Regression

LDR-BT (256)
vs.
EBRT (305)

LDR-BT:
144 Gy I-125
vs.
EBRT:
70-80 Gy

	
  

NR

LDR-BT:
(Low=77%;Int=23
%)
vs.
EBRT:
(Low=77%;Int=23
%)

BT:
(Low=35%;Int=32
%;High=33%;unkn
own=4%)
vs.
EBRT:
(Low=55%;Int=22
%;High=23%;Unkn
own=7%)
100% Intermediaterisk patients
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Wong et
al

2009

Retrospective

Cox PH
Regression

LDR-BT (225)
vs.
3D-CRT (270)
vs.
IMRT (314)
vs.
LDR-BT+EBRT
(44)

LDR-BT:
144 Gy I-125 or
120 Pd-103
vs.
3D-CRT:
66-71 Gy
vs.
IMRT:
75-77 Gy
vs.
LDR-BT_EBRT)
110 Gy I-125 or
90 Gy Pd-103 +
45 Gy 3D-CRT

LDR-BT:
(Low=70%;Int=26
%;High=9%)
vs.
3D-CRT:
(Low=44%;Int=41
%;High=15%);
vs.
IMRT:
(Low=35%;Int=48
%;High=17%)
vs.
LDR-BT+EBRT
(Low=32%;Int=52
%;High=16%)

Zelefsky
et al

1999

Retrospective

Cox PH
Regression

LDR-BT (145)
vs.
EBRT (137)

LDR-BT:
144 Gy I-125
vs.
EBRT:
65-81 Gy

100% low-risk
patients

Zelefsky
et al

2008

Retrospective

Cox PH
Regression

LDR-BT (127)
vs.
LDR-BT+EBRT
(216)

LDR-BT:
144 Gy I-125
vs.
LDR-BT+EBRT:
110 Gy I-125 +
50 Gy EBRT

Zelefsky
et al

2011

Retrospective

Cox PH
Regression

LDR-BT (448)
vs.
EBRT (281)

Zhou et al

2009

Retrospective

Cox PH
Regression

BT (644)
vs.
EBRT (876)

LDR-BT:
144 Gy I-125
vs.
EBRT:
81 Gy
NR

LDR-BT:
(Low=28%;Int=64
%;High=8%)
vs.
LDR-BT+EBRT:
(Low=88%;Int=12
%)
100% low-risk
patients

NR

Appendix I: Continued.
Author

ADT
use?

Primary
Outcome

Reported Result of
Primary Outcome

Secondary
Outcomes

AbelWahab et
al

NR

Secondary
Cancer
Incidence
>5 years

Aoki et al

No ADT
patients
excluded

Beyer et
al

Yes Mixed
use in
both
groups

Late Grade
2 GI
toxicity
(rectal
bleeding)
FFS

Actuarial
percentages > 5
years:
4.7% (BT) vs.
10.3% (EBRT) vs.
5.7% (BT+EBRT),
p<0.001
9.1% (LDR-BT) vs.
36% (LDRBT+EBRT),
p <0.01
Actuarial
percentages > 5
years: 71% (LDRBT) vs. 69%
(EBRT), p=0.91

	
  

Country

No

Reported Result
of Secondary
Outcome (s)
N/A

USA

Multicentred
?
Y

No

N/A

Japan

N

No

N/A

USA

N
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Burdick
et al

Yes Mixed
use in
both
groups

bFFS
(Phoenix)

Coen et al

No ADT
patients
excluded

bFFS
(Phoenix)

D'Amico
et al

Yes used in
LDR-BT
group

PSAF

da Silva
Franca et
al

Yes Mixed
use in
both
groups

bFFS
(Phoenix)

Davis et
al

Yes Mixed
use in
both
groups
Yes Mixed in
both
groups

Eade et al

No ADT
patients
excluded

bFFS
(Phoenix)

Elliot et
al

Yes Mixed
use in
both
groups
Yes Mixed
use in
both
groups

Urethral
Stricture
Incidence

Deutsch
et al

Ferrer et
al

Actuarial
percentages @ 5
years: 88% (95%
CI 80-95%) LDRBT vs. 84% (95%
CI 78-91%) EBRT
Actuarial
percentages @ 8
years: 92% (Proton
EBRT) vs. 84%
(LDR-BT),
p=0.44[log-rank]

No

N/A

USA

N

OS

USA

Y

Relative Risk not
reported; showed no
significant
difference in lowrisk (p=0.3), int-risk
(p=0.6), or high-risk
(0.5)
Actuarial
percentages @ 5
years: 96% (LDRBT) vs. 72% (LDRBT+EBRT)

No

Actuarial
percentages @ 8
years: 93%
(Proton EBRT)
vs. 96% (LDRBT),
p=0.45[logrank]
N/A

USA

Y

No

N/A

Brazil

Y

SF-36

Reported a variety
of results from SF36 questionnaire

No

N/A

USA

N

bFFS
(Phoenix)

Actuarial
percentages @ 5
years: 82% (EBRT)
vs. 98% (HDRBT+EBRT),
p<0.001
Actuarial
percentages @ 4
years: 99% (LDRBT) vs. 93%
(EBRT), p=0.09

No

N/A

USA

Y

Late
Grade 2 or
higher
GI/GU
toxicity

USA

N

Actuarial
percentages at 4
years: 1.8% (BT)
vs. 1.7% (EBRT),
p=NS
EBRT led to
significantly worse
bowel (p<0.001),
sexual (p<0.01), and
hormonal (p<0.01)
function than LDRBT

No

Actuarial
percentages @ 4
years: GI: 7.8%
(LDR-BT) vs.
2.4% (EBRT),
p=0.03; GU:
19.2% (LDRBT) vs. 3.5%
(EBRT),
p<0.001
N/A

USA

Y

No

N/A

Spain

Y

EPIC
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Gelbium
et al

Yes Mixed in
both
groups

Late Grade
2 or higher
GI toxicity

Actuarial
percentages @ 4
years: 6.9% (LDRBT) vs. 7.8%,
p=NR

No

N/A

USA

N

Goldner
et al

YesMixed in
all
groups

bFFS
(Phoenix)

No

N/A

Austria

Y

Gondi et
al

Yes Mixed in
LDR-BT
group

bFFS
(ASTRO1)

Actuarial
percentages @ 5
years: 94% (LDRBT) vs. 91% (74 Gy
EBRT) vs. 84% (70
Gy EBRT), p<0.01
Actuarial
percentages @ 5
years: 88% (LDRBT or LDRBT+EBRT ± ADT)
vs. 60%
(EBRT+ADT) vs.
49% (EBRT only),
p<0.001

bFFS
(Phoenix)

USA

N

Huang et
al

NS

SF-36

No

USA

Y

Joseph et
al

NR

FACT-P

No

N/A

Canada

Y

Kalakota
et al

Yes Mixed
use in
both
groups

Late Grade
2 GI
toxicity

Primary Treatment
was significant
predictor of SF-36
scoring of urinary,
bowel and sexual
function (all
p<0.001)
Overall FACT-P
scores @ 1 year: 98
(EBRT) vs. 95
(HDR-BT+EBRT),
p=0.67
Actuarial
percentages @ 4
years: 91% (LDRBT) vs. 82% (LDRBT+EBRT), p=0.30

Actuarial
percentages @ 5
years: 81%
(LDR-BT or
LDRBT+EBRT ±
ADT) vs. 85%
(EBRT+ADT)
vs. 64% (EBRT
only), p=0.014
N/A

No

N/A

USA

Y

Klein et
al

No ADT
patients
excluded

bFFS
(Phoenix)

Actuarial
percentages @ 5
and 8 years: 82%
and 82% (LDR-BT)
vs. 80% and 75%
(EBRT), p=NS

RFS, OS

USA

Y

Khor et al

Yes Equal
use in
both tx
groups

bFFS
(Phoenix)

Hazard Ratio for
HDR-BT+EBRT vs.
EBRT = 0.59 (95%
CI 0.43-0.81,
p<0.01)

No

Actuarial
percentages for
RFS @ 5 and 8
years: 97% and
81% (LDR-BT)
vs. 95% and
90% (EBRT),
p=0.02;
Actuarial
percentages for
OS @ 5 and 8
years: 94% and
94% (LDR-BT)
vs. 93% and
81% (EBRT),
p=0.05
N/A

Australia

N
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Krestin et
al

NR

bFFS
(ASTRO1)

Actuarial
percentages @ 5
years: 44% (EBRT)
vs. 67% (HDRBT+EBRT)
Actuarial
percentages @ 5
and 7 years: 83%
and 76% (LDR-BT)
vs. 81% and 81%
(EBRT) vs. 51%
and 48% (EBRT)
vs. 77% and 77%
(LDR-BT+EBRT);
When EBRT<72 Gy
removed, no
significant
difference between
treatment groups

No

N/A

USA

N

Kupelian
et al

Yes Mixed
use in all
groups

bFFS
(ASTRO1)

No

N/A

USA

Y

Lee et al

Yes Mixed
use in
both
groups
NR

FACT-P

Reported a variety
of results from the
FACT-P
questionnaire

No

N/A

USA

N

HQoL

RT treatment not a
significant predictor
of HQoL

No

N/A

USA

Y

Nieder et
al

NR

Secondary
Cancer

No significant
difference between
treatment groups

No

N/A

USA

Y

Ojha et al

NR

Secondary
Cancer

HR = 1.68 (p=NS)
favors BT

No

N/A

USA

Y

Pe et al

No ADT
patients
excluded

bFFS
(Phoenix)

No

N/A

USA

N

Pickles et
al

Yes Equal
use in
both tx
groups

bFFS(Phoe
nix)

No

N/A

Canada

N

Pinkawa
et al

Yes Mixed
used in
all
groups

bFFS
(Phoenix)

Actuarial
percentages @ 5
years: 96% (LDRBT) vs. 95%
(EBRT), p=0.70
Actuarial
percentages @ 5
and 7 years: 95%
and 95% (LDR-BT)
vs. 85% and 75%
(EBRT), p<0.001
Hazard Ratios:
LDR-BT vs. EBRT:
0.5 (95% CI 0.30.8, p<0.01);
HDRT-BT+EBRT
vs. EBRT: 0.6 (95%
CI 0.4-0.97, p=0.04)

No

N/A

Germany

N

Santhya
et al

Yes,
Mixed
use in
both
groups

OS

HR = 1.36 (p=0.54)
favors EBRT

BCF,
GI/GU
toxicity

BCF: HR=0.42
(p=0.02), favors
HDRBT+EBRT;
GI/GU toxicity:
p=NS

Canada

No

Lev et al
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Smith et
al

Yes Mixed
used in
all
groups
Yes Mixed
use in
both
groups
Yes Mixed
use in
both
groups
Yes Mixed
use in all
groups

HQoL

Reported on a
variety of results
from their HQoL
questionnaire

No

N/A

Australia

Y

SF-36

Reported on a
variety of results
from SF-36
questionnaire

No

N/A

USA

Y

bFFS
(Phoenix)

LDR-BT vs. EBRT
HR = 0.99 (95% CI
0.62-1.58, p=0.97)

No

N/A

USA

Y

bFFS
(Phoenix)

OS

N

Yes Mixed
use in all
groups

bFFS
(ASTRO1)

USA

N

Zelefsky
et al

Yes Mixed in
both
groups

Late Grade
2 GI/GU
toxicity

No

USA

Y

Zelefsky
et al

YesMixed
use in
both
groups
NR

bFFS
(Phoenix)

Hazard Ratios for
LDR-BT vs. LDRBT+EBRT: Grade 2
GI Toxicity: 8.9
(p<0.001); Grade 2
GU Toxicity: 2.3
(p<0.01)
Actuarial
percentages @ 7
years: 95% (LDRBT) vs. 89%
(EBRT), p=0.04
Actuarial
percentages @ 7
years: 82% (BT) vs.
72% (EBRT),
p<0.001

Actuarial
percentages @ 5
years: 97%
(LDR-BT) vs.
97% (EBRT)
vs. 97% (LDRBT+EBRT),
p=NR
Actuarial
percentages @ 5
years: 12%
(LDR-BT) vs.
2% (EBRT),
p<0.01
N/A

USA

Zelefsky
et al

Actuarial
percentages @ 5
years: 94% (LDRBT) vs. 74% (3DCRT) vs. 87%
(IMRT) vs. 94%
(LDR-BT+EBRT),
p<0.001
Actuarial
percentages @ 5
years: 88% (LDRBT) vs. 82%
(EBRT), p=0.09

No

N/A

USA

N

DSS

Actuarial
percentages @ 7
years: 97% (BT)
vs. 94%
(EBRT),
p<0.001

USA

Y

Talcott et
al

Vassil et
al

Wong et
al

Zhou et al

OS

Urethral
stricture
incidence

Appendix I: Continued.
Author

Mean/Median Follow-Up
(months)

Abel-Wahab
et al

40 (BT) vs. 64 (EBRT)
vs. 46 (BT+EBRT)

Aoki et al

NR

Total FollowUp Time
(Years)
16 years

Mean/Median
Age of Patients
(Years)
67 (BT) vs. 71
(EBRT) vs. 68
(BT+EBRT)

Independent, low-, intermediate-,
high-risk assessment?

>3 years

68 (LDR-BT) vs.
71 (LDRBT+EBRT)

No

	
  

No
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Beyer et al

51 (LDR-BT) vs. 41
(EBRT)
54 (LDR-BT) vs. 54
(EBRT)

8 years

74 for both

No

10 years

70 (LDR-BT) vs.
69.5 (EBRT)

No

Coen et al

103 (Proton EBRT) vs. 89
(LDR-BT)

>10 years

67 (Proton EBRT)
vs. 65 (LDR-BT)

No significant difference in bFFS
(Phoenix) in low-risk (p=0.74) or
intermediate-risk (p=0.21)

D'Amico et al

41 (LDR-BT) vs. 38
(EBRT)

5 years

NR

Yes - see primary outcome
results

da Silva
Franca et al

105 (LDR-BT) vs. 60
(LDR-BT+EBRT)

5 Years

66 (LDR-BT) vs.
68 (LDRBT+EBRT)

No

Davis et al

22 (LDR-BT) vs. 30
(EBRT)

NR

67 (LDR-BT) vs.
69 (EBRT)

No

Deutsch et al

53 (EBRT) 47 (HDRBT+EBRT)

> 8 Years

68 (EBRT) vs. 65
(HDRBT+EBRT)

Eade et al

48 (LDR-BT) vs. 43
(EBRT)

4 years

65 (LDR-BT) vs.
68 (EBRT)

Actuarial percentages @ 5 years:
Low-risk: 98% (EBRT) vs. 100%
(HDR-BT+EBRT), p=0.71;
Intermediate-risk: 84% (EBRT)
vs. 100% (HDR-BT+EBRT),
p<0.001; High-risk: 71% (EBRT)
vs. 93% (HDR-BT+EBRT),
p=0.23
No

Elliot et al

32 (BT) vs. 32 (EBRT)

4 years

NR

No

Ferrer et al

24 (LDR-BT) vs. 24
(EBRT)

2 years

67 (LDR-BT) vs.
69 (EBRT)

No

Gelbium et al

48 for all patients

>4 years

NR

No

Goldner et al

44 (LDR-BT) vs. 41 (74
Gy EBRT) vs. 81 (70 Gy
EBRT)

10 years

64 (LDR-BT) vs.
71 (EBRT)

N/A - all low-risk patients

Gondi et al

34 for all patients

5 years

NR

No

Huang et al

NR

4 Years

NR

No

Joseph et al

12 for all patients

1 year

69 (EBRT) vs. 69
(HDRBT+EBRT)

No

Kalakota et al

41 for all patients

4 years

65 (LDR-BT) vs.
63 (LDRBT+EBRT)

No

Klein et al

39 (LDR-BT) vs. 58
(EBRT)
68 (EBRT) vs. 61 (HDRBT+EBRT)

>8 years

NR

10 years

69 (EBRT) vs. 67
(HDRBT+EBRT)

N/A - all intermediate-risk
patients
Hazard Ratios for HDRBT+EBRT vs. EBRT:
Intermediate-risk: 0.44 (95% CI
0.28-0.70, p<0.001); High-risk:
0.82 (95% CI 0.52-1.28, p=0.38)

30 (EBRT) vs. 30 (HDRBT+EBRT)

6 years

74 (EBRT) vs. 69
(HDRBT+EBRT)

Burdick et al

Khor et al

Krestin et al

	
  

No
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Kupelian et al

47 (LDR-BT) vs. 49
(EBRT≥72Gy) vs. 75
(EBRT<72Gy) vs. 46
LDR-BT+EBRT

7 Years

70 (LDR-BT) vs.
68 (EBRT≥72Gy)
vs. 70
(EBRT<72Gy) vs.
69 LDRBT+EBRT
67 (LDR-BT) vs.
69 (EBRT)

No

Lee et al

12 (BT) vs. 12 (EBRT)

1 Year

Lev et al

12 for all patients

1 Year

67 (LDRBT+EBRT) vs. 68
(HDRBT+EBRT)

No

Nieder et al

49 for all patients

>10 years

NR

No

Ojha et al

46 (BT) vs. 67 (EBRT)

>10 years

67 (BT) vs. 71
(EBRT)

No

Pe et al

37 (BT) vs. 51 (EBRT)

7 years

65 (LDR-BT) vs.
70 (EBRT)

N/A - all low-risk patients

Pickles et al

68 (LDR-BT) vs. 67
(EBRT)

7 years

64 (LDR-BT) vs.
71 (EBRT) (*did
not match on age)

Actuarial percentages @ 5 years:
Low-risk: 94% (LDR-BT) vs.
88% (EBRT), p<0.001; Int-risk:
100% (LDR-BT) vs. 78%
(EBRT), p=0.02

Pinkawa et al

76 (BT) vs. 67 (EBRT)

5 years

69 (LDR-BT) vs.
71 (EBRT) vs. 72
(HDRBT+EBRT)

No

Santhya et al

NR

10 years

65 HDRBT+EBRT vs. 66
EBRT

Smith et al

NR

3 years

60 (LDR-BT) vs.
62 (HDR-BT) vs.
64 (EBRT)

BCF favors HDR-BT+EBRT in
both Int-risk and High-risk; Intrisk: HR=0.30 (p=0.03); Highrisk: HR=0.47(p=0.03)
No

Talcott et al

24 (BT) vs. 24 (EBRT)

2 Years

65 (BT) vs. 69
(EBRT)

No

Vassil et al

65 for all patients

5 years

69 (LDR-BT) vs.
68 (EBRT)

N/A - all intermediate-risk
patients

Wong et al

49 (LDR-BT) vs. 62 (3DCRT) vs. 56 (IMRT) vs.
63 (LDR-BT+EBRT)

5 years

NR

Zelefsky et al

24 (LDR-BT) vs. 36
(EBRT)

> 7 Years

68 (LDR-BT) vs.
64 (EBRT)

Actuarial percentages @ 5 years:
Low-risk: 97% (LDR-BT) vs.
92% (3D-CRT) vs. 93% (IMRT)
vs. 100% (LDR-BT+EBRT),
p=0.30; Intermediate-risk: 94%
(LDR-BT) vs. 74% (3D-CRT)
vs. 88% (IMRT) vs. 94% (LDRBT+EBRT), p<0.001; High-risk:
50% (LDR-BT) vs. 55% (3DCRT) vs. 76% (IMRT) vs. 100%
(LDR-BT+EBRT), p=0.18
N/A - all low-risk patients

Zelefsky et al

30 for all patients

NR

NR
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Zelefsky et al

77 (LDR-BT) vs. 76
(EBRT)

8 years

65 (LDR-BT) vs.
66 (EBRT)

N/A - all low-risk patients

Zhou et al

NR

7 years

NR

NR

Abbreviations: 3D-CRT = 3-dimensional conformal radiation therapy;
BCF = biochemical or clinical failure: a PSA failure or clinical failure or death; bFFS(ASTRO1) =
biochemical relapse-free survival, American Society for Therapeutic Radiology and Oncology definition:
three consecutive rising PSA levels after nadir; bFFS(Phoenix) = biochemical failure-free survival,
American Society for Therapeutic Radiology and Oncology Phoenix definition: a PSA level of 2ng/mL or
more than nadir; BT = brachytherapy of unknown type; BT+EBRT = brachytherapy of unknown type with
adjuvant external beam radiation therapy; DSS = disease specific survival: date from therapy to prostate
cancer death; EBRT = external beam radiation therapy; EPIC = Expanded Prostate Cancer Index
Composite Questionnaire: a 50 item instrument created at the University of California to assess prostate
cancer patient reported urinary, bowel, sexual, and hormonal functioning; FACT-P= Functional
Assessment of Cancer Therapy-Prostate: a 12 item questionnaire specifically designed to measure quality
of life in prostate cancer patients; FFS = failure free survival: initiation of secondary therapy, positive
biopsy post-treatment, PSA rise of 10 ng/dL or more even without three consecutive elevations,
development of metastasis; GEE = generalized estimating equation modeling; Grade 2 GI Toxicity =
Radiation Therapy Oncology Group defined grade 2 gastrointestinal side effect which includes any
symptom of moderate nature requiring medical therapy eg. rectal bleeding requiring suppositories; Grade 2
GU Toxicity = Radiation Therapy Oncology Group defined grade 2 genitourinary side effects which
includes any symptom of moderate nature requiring medical therapy eg. urinary urgency or dysuria; HDRBT = high dose rate brachytherapy; HDR-BT+EBRT = high dose rate brachytherapy with adjuvant external
beam radiation therapy; HQoL = health quality of life; IMRT = intensity modulated radiation therapy;
LDR-BT = low dose rate brachytherapy; LDR-BT+EBRT = low dose rate brachytherapy with adjuvant
external beam radiation therapy; N/A = Not Applicable; NR = not reported; NS = none significant; OS =
overall survival: date from therapy to death from any cause; PSAF = prostate specific antigen failure = a
patient must have 3 consecutive rising PSA values each obtained at least 3 months apart; RFS = recurrence
free survival: date from treatment until clinically diagnosed recurrence under radiography or biopsy; SF-36
= Medical Outcomes Study 36-Item Short Form Questionnaire: contains 36 items covering eight
dimensions of health related quality of life including physical function, pain, general health, vitality, social,
emotional, and mental health; Tx = treatment group;
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Appendix II
Literature Search Strategy for CER Articles Comparing Different RT Modalities
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Appendix II: Literature Search Strategy for CER Studies Comparing Primary RT
Modalities
The literature search for CER articles directly comparing primary RT modalities
was conducted using the electronic databases of Pubmed, MEDLINE (OVID), Cochrane
Library, EMBASE, and Google Scholar; also the clinical trials registry at
‘www.clinicaltrials.gov’ was searched to identify any potential RCTs. The search period
was from January 1, 1996 to December 2013 and was limited to English publications.
The following key terms were used in combination to search the databases: prostate,
prostate cancer, cancer, comparative effectiveness, brachytherapy, external beam
radiation therapy, external beam radiotherapy, versus, randomized trial, radiation therapy
or radiotherapy, high-dose rate, low-dose rate, intensity modulated radiation therapy,
survival, biochemical failure, PSA failure, toxicity, impotency, secondary cancer, and
quality of life. Relevant studies were also searched for in review articles or on reference
lists of identified articles. The relevant RT guideline websites such as the RTOG and the
European Organization for Research and Treatment of Cancer were checked for
systematic reviews and randomized trials. All articles included in this review required a
sample size ≥30 patients and must have directly compared at least two RT treatment
modalities with respect to the outcomes of overall survival, biochemical or PSA failure,
late toxicities or side effects, or patient reported outcomes.
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Appendix III
ProCaRS Variable List and Descriptions
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PROCARS: Variable List (Last Updated December 2, 2013)
#
1

Variable
ID

2

ID2

3
4
5
6

ID_PMH
PMH_9907
Centre
Centrex

7

Cohort_7cat

8
9

Age
BasePSA

10

BasePSA_ROUND

11

Tstage

12

Tstage_CRU

13
14
15
16
17
18
19

Tstage_CORR
Tstage_CORR_4cat
Tstage_CORR_4catx
TNMyear
GleasonPattern
GleasonPattern_CORR
GleasonMajor

20

GleasonMajor_CORR

21

GleasonMinor

22

GleasonMinor_CORR

23

GleasonTotal

24

GleasonTotal_CORR

25
26
27
28
29
30
31
32

GleasonTotal_CORR_4cat
Cores_total
Cores_pos
Cores_neg
Cores_rejected
PosCores_Percent
PosCores_ge50pct
Bilateral_biopsy_pos

Description
Patient ID Number: Centre‐XX (e.g. BCCA‐1012)
Patient ID Number: 1, 2, 3,...,7973, 7974 [For Sorting Purposes
Only]
Patients included in PMH cohorts only
Patients included in PMH Trial #9907 cohort only
Centre: 1, 2, 3, 4
Centre: Description
Cohort (7 categories): BCCA, PMH LDR, PMH Dose Escalation,
PMH Trial #9907, Laval LDR, Laval HDR+EBRT, McGill
Age
Baseline PSA (ng/mL)
Baseline PSA (ng/mL) **ROUNDED TO NEAREST WHOLE
NUMBER**
T‐Stage: '4', '8' and '12' corresponding to Tstage '2', '3' and '4' coded
as MISSING **IGNORE**
T‐Stage: '4', '8' and '12' corresponding to Tstage '2', '3' and '4'
RETAINED **IGNORE**
T‐Stage (including Sub‐Type): n = 7839 (frequency missing = 135)
T‐Stage (excluding Sub‐Type): n = 7839 (frequency missing = 135)
T‐Stage (excluding Sub‐Type): n = 7860 (frequency missing = 114)
TNM Year
Gleason Pattern: 1, 2, 3,...24, 25
Gleason Pattern: 1+1, 1+2...5+4, 5+5
Gleason Major: 1st number in pattern **DO NOT USE**
Gleason Major: Re‐derived based on FIRST number in Gleason
Pattern **CORRECTED**
Gleason Minor: 2nd number in pattern **DO NOT USE**
Gleason Minor: Re‐derived based on SECOND number in Gleason
Pattern **CORRECTED**
Total Gleason Score: Add 2 numbers in pattern **DO NOT USE**
Total Gleason Score: Re‐derived based on corrected Gleason Major
and Minor **CORRECTED**
Total Gleason Score (4 categories): (1) 2‐5, (2) 6, (3) 7, (4) 8‐10
Biopsy Cores: Total Number
Biopsy Cores: Number of cores containing any cancer
Biopsy Cores: Number of cores NOT containing any cancer
Biopsy Cores: Number of cores rejected
Biopsy Cores: Percent of Positive Cores
Biopsy Cores: Positive Cores: (1) ≥ 50 % , (0) < 50%
Bilateral Biopsy Status: 0, 1, 8, 9
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PROCARS: Variable List (Last Updated December 2, 2013)
#
33
34
35
36
37

Variable
Bilat_Biopsy_Status_CORR
Hormones
HormStart
HormEnd
AdjHT_months

38

AdjHT_months_OLD

39
40

RTStart
RTStart_Year

41

RTStart_Year_4cat

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

RTEnd
RTdays
EBRT
EBRT_Dose
EBRT_Dose_GT70
EBRT_Dose_GT70x
EBRT_Fractions
EBRT_FractionDose
EBRT_BED_Gy
LDR
LDR_Dose
LDR_Fractions
HDR
HDR_Dose
HDR_Fractions
Brachy
Radiation_Type

59

Radiation_Type_5cat

60
61
62
63
64
65
66
67
68

LocalRelapse
LocalRelapseDate
PostRTHormStart
Dead
Dead_5yr
Status
StatDate
Survival_months
Surmon

Description
Bilateral Biopsy Status: No, Yes, Unknown, N/A
Hormones: (1) Yes, (0) No
Hormones: Start Date
Hormones: End Date
Adjuvant Hormone Therapy (Months): ZEROs coded as MISSING
Adjuvant Hormone Therapy (Months): ZEROs kept as ZEROs (for
modeling)
RT Start Date
RT Start Year
RT Start Year (4 categories): (1) 1994‐1999, (2) 2000‐2002, (3) 2003‐
2005, (4) 2006‐2010
RT End Date
Number of Days of RT
EBRT: (1) Yes, (0) No
EBRT Dose (cGy)
EBRT Dose: (1) > 70 Gy, (0) ≤ 70 Gy
EBRT Dose Label
EBRT: Number of Fractions
EBRT: Dose per Fraction (cGy)
EBRT Biologic Equivalent Dose (Gy)
LDR: Low Dose Rate Brachytherapy

HDR: High Dose Rate Brachytherapy

Brachytherapy: (1) Yes, (0) No
Radiation Type: Brachy + EBRT, Brachy only, EBRT only
Radiation Type (5 categories): Brachy(LDR) only, Brachy(HDR)
only, EBRT only, Brachy(LDR) + EBRT, Brachy(HDR) + EBRT
Clin/Path confirmed Local Relapse
Date of Local Relapse
Salvage Hormone Therapy Start Date
Dead: (1) Dead, (0) Alive
Dead (≤ 5 years): (1) Dead, (0) Alive

Survival in MONTHS
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PROCARS: Variable List (Last Updated December 2, 2013)
#
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91

Variable
AliveDate
DeathDate
DeathCause
CauseofDeath
CauseofDeath_CORR
CauseofDeath_CORRx
Date_data_pulled
Notes
PSADT2
PSAvelocity
PSADT
npsa
BrachyAINorm
rownames
Amico
GUROC
GUROC2
GUROC_OLD
GUROC2_OLD
CAPSURE
EAU
NICE
AUA

92

NCCN

93
94
95
96
97

NCCN_5cat
ESMO
George
GeorgeII
procars_6cat

98

procars_6catx

99

procars_5cat

100

procars_5catx

101
102
103
104

procars_4cat
procars_4catx
Simplified
Time

Description
Date of Death
Cause of Death
Denominator = 7974

AMICO Classification: Low, Intermediate, High
GUROC Classification: Low, Intermediate, High
GUROC2 Classification: 1, 2, 3
**UNCORRECTED VERSION (For Earlier Manuscript(s))**
**UNCORRECTED VERSION (For Earlier Manuscripts(s))**
CAPSURE Classification: Low, Intermediate, High
EAU Classification: Low, Intermediate, High
NICE Classification: Low, Intermediate, High
AUA Classification: Low, Intermediate, High
NCCN Classification: Very Low, Low, Intermediate, High, Very
High
NCCN_5cat: 1, 2, 3, 4, 5
ESMO Classification: Low, Intermediate, High
George Classification: Low, Intermediate, High
GeorgeII Classification: Low, Intermediate, High
PROCARS 6 Classification: A, B, C, D, E, F
PROCARS 6 Classification: Extr Low, Low, Inter Low, Inter High,
High, Extr High
PROCARS 5 Classification: AB, C, D, E, F
PROCARS 5 Classification: Low, Inter Low, Inter High, High, Extr
High
PROCARS 4 Classification: AB, C, DE, F
PROCARS 4 Classification: Low, Inter Low, Inter High, High
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PROCARS: Variable List (Last Updated December 2, 2013)

#

Variable

105

CRS

106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125

CRS_5yr
CRStatus
CRS_months
CRTime
AIBFStat
AIBFTime
AIBFFSStat
AIBFFSTime
AIBFFS2Stat
AIBFFS2Time
AIHSTBFStat
AIHSTBFTime
AIHSTBFFSStat
AIHSTBFFSTime
AIHSTBFFS2Stat
AIHSTBFFS2Time
PhBFStat
PhBFTime
PhBFFSStat
PhBFFSTime

126

BFFS2

127
128
129
130

BFFS2_5yr
PhBFFS2Stat
BFFS2_months
PhBFFS2Time

131

BFFS2_months_5yr

132

BFFS2_to_CRS_months

133

BFFS2_CORR

134

BFFS2_CORR_months

135

PSA_Bounce

Description
Prostate Cancer Death (aka Cancer‐Related/Specific Survival): (1)
Yes, (0) No (Equivalent to "CRStatus")
Prostate Cancer Death (≤ 5 years): (1) Yes, (0) No
Cancer‐Related/Specific Survival in MONTHS

Biochemical Failure (aka Biochemical‐Failure‐Free Survival): (1)
Yes, (0) No (Equivalent to "PhBFFS2Stat" ‐ Phoenix Version #2)
Biochemical Failure (≤ 5 years): (1) Yes, (0) No
Biochemical‐Failure‐Free Survival in MONTHS
Biochemical‐Failure‐Free Survival in MONTHS (corresponds with
"BFFS2_5yr")
Time (months) from Biochemical Failure (BFFS2) to Prostate
Cancer Death (CRS)
Biochemical Failure CORRECTED for PSA bounce (Brachytherapy
patients with NO post‐RT hormone therapy meeting previous
ASTRO II Phoenix definition censored if LAST PSA ≤ 0.5 ng/mL).
Biochemical‐Failure‐Free Survival CORRECTED in MONTHS
PSA Bounce (assessed for brachytherapy patients with NO post‐RT
hormone therapy and ASTRO II BF): (1) LAST PSA ≤ 0.5 ng/mL,
(0) LAST PSA > 0.5 ng/mL [opposite to BFFS2_CORR]
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PROCARS: Variable List (Last Updated December 2, 2013)

#
136
137

Variable
Nadir_PSA
Nadir_Months

Description
Nadir PSA (ng/mL)
Time‐to‐Nadir in MONTHS
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Appendix IV
Kaplan Meier Curves of bFFS with and Without Accounting for PSA Bounce
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Low-risk bFFS Match with or Without Accounting for PSA Bounce:

(Accounting for PSA Bounce)

(Not Accounting for PSA Bounce)
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Intermediate-risk LDR-BT vs. EBRT Match with or Without Accounting for PSA
Bounce:

(Accounting for PSA bounce)

(Not Accounting for PSA Bounce)
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Intermediate-risk HDR-BT+EBRT vs. EBRT Match with or Without Accounting
for PSA Bounce:

(Accounting for PSA Bounce)

(Not Accounting for PSA Bounce)
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Appendix V
SAS Code for Intermediate-Risk Cohort Selection
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SAS Code for Selection Process (Intermediate-Risk):
libname thesis 'P:\Graham\Thesis';
data Procars_Interm_Risky;
set thesis.procars_final_03dec2013;
where GUROC = 'Interm';
/*Adjust for T-Stage year, Remove Gleason total 2to5*/
if TNMyear = '0' and Tstage_CORR = '2b' then delete;
if GleasonTotal_CORR_4Cat = '1_2to5' then delete;
if Tstage_CORR = '2b' and TNMyear = '1997' then Tstage_3cat = '3';
if Tstage_CORR = '2b' and TNMyear = '2002' then Tstage_3cat = '2';
if Tstage_CORR = '2b' and TNMyear = '1992' then Tstage_3cat = '2';
if Tstage_CORR = '2a' then Tstage_3cat = '2';
if Tstage_CORR = '2c' then Tstage_3cat = '3';
if Tstage_CORR = '1a' or Tstage_CORR = '1b' or Tstage_CORR = '1c' then Tstage_3cat = '1';
run;
proc freq data=procars_interm_risky;
tables Radiation_Type_5cat /list;
run;
Create T-Stage and Gleason Pattern Variables for Standardized Difference Testing:
data thesis.procars_interm_risk;
set procars_interm_risky;
if Tstage_3cat = 1 then Tstage_T1 = 1;
if Tstage_3cat = 2 or Tstage_3cat = 3 then Tstage_T1 = 0;
if Tstage_3cat = 2 then Tstage_LowT2 = 1;
if Tstage_3cat = 1 or Tstage_3cat = 3 then Tstage_LowT2 = 0;
if Tstage_3cat = 3 then Tstage_HighT2 = 1;
if Tstage_3cat = 1 or Tstage_3cat = 2 then Tstage_HighT2 = 0;
if GleasonTotal_CORR_4cat = "2_6" then GleasonTotal_7 = 0;
if GleasonTotal_CORR_4cat = "3_7" then GleasonTotal_7 = 1;
if GleasonPattern_CORR = "3+4" then GleasonPattern_CORRx3plus4 = 1;
if GleasonPattern_CORR = "4+3" or GleasonPattern_CORR = "3+3" or GleasonPattern_CORR = "." then
GleasonPattern_CORRx3plus4 = 0;
if GleasonPattern_CORR = "4+3" then GleasonPattern_CORRx4plus3 = 1;
if GleasonPattern_CORR = "3+4" or GleasonPattern_CORR = "3+3" or GleasonPattern_CORR = "." then
GleasonPattern_CORRx4plus3 = 0;
if GleasonPattern_CORR = "3+3" then GleasonPattern_CORRx3plus3 = 1;
if GleasonPattern_CORR = "3+4" or GleasonPattern_CORR = "4+3" or GleasonPattern_CORR = "." then
GleasonPattern_CORRx3plus3 = 0;
run;
proc freq data=thesis.procars_interm_risk;
table GleasonTotal_7*GleasonTotal_CORR_4cat Tstage_T1*Tstage_3cat Tstage_LowT2*Tstage_3cat
Tstage_HighT2*Tstage_3cat/list;
run;
Initial Selection of intermediate-risk cohort, including ensuring patients have info on outcomes,
important baseline factors, adequate RT dose and NO hormones:
libname thesis 'P:\Graham\Thesis';
data thesis.Interm_Risk_PS;
set thesis.Procars_Interm_Risk;
if Tstage = '.' then delete;
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if Age = '.' then delete;
if BasePSA = '.' then delete;
if GleasonTotal_CORR = '.' then delete;
if Dead = '.' then delete;
if Survival_months = '.' then delete;
if BFFS2_months = '.' then delete;
if BFFS2 = '.' then delete;
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose = '.' then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = '.' then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and HDR_Dose = '.' then delete;
if Radiation_Type_5cat = 'Brachy(LDR)_only' and LDR_Dose = '.' then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_only' or Radiation_Type_5cat = 'Brachy(LDR)_and_EBRT' then
delete;
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose < 7400 then delete;
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose = 7524 then delete;
if Radiation_Type_5cat = 'Brachy(LDR)_only' and LDR_Dose < 14400 then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4400 and HDR_Dose = 1000
then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4400 and HDR_Dose = 1800
then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4400 and HDR_Dose = 1900
then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4200 and HDR_Dose = 2000
then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4500 and HDR_Dose = 2000
then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4600 and HDR_Dose = 2000
then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' and EBRT_Dose = 4700 and HDR_Dose = 2000
then delete;
where hormones = 0;
run;
proc freq data=thesis.Interm_Risk_PS;
tables Radiation_Type_5cat Radiation_Type_5cat*Centre Radiation_Type_5cat*RTStart_year/list;

	
  

157	
  

Appendix VI
SAS Code for Low-Risk Cohort Selection
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SAS Code for Selection Process (Low-Risk):
libname thesis 'P:\Graham\Thesis';
data Procars_Low_Risky;
set thesis.procars_final_03dec2013;
if GUROC = 'Low';
/*Adjust for T-Stage Year, Restrict RT-Start Year*/
if TNMyear = '0' and Tstage_CORR = '2b' then delete;
if RTStart_Year < 1999 then delete;
if RTStart_Year > 2006 then delete;
if Tstage_CORR = '2b' and TNMyear = '1997' then Tstage_3cat = '3';
if Tstage_CORR = '2b' and TNMyear = '2002' then Tstage_3cat = '2';
if Tstage_CORR = '2b' and TNMyear = '1992' then Tstage_3cat = '2';
if Tstage_CORR = '2a' then Tstage_3cat = '2';
if Tstage_CORR = '2c' then Tstage_3cat = '3';
if Tstage_CORR = '1a' or Tstage_CORR = '1b' or Tstage_CORR = '1c' then Tstage_3cat = '1';
run;
proc freq data=Procars_Low_Risky;
tables Tstage_CORR*TNMyear*Tstage_3cat/list;
run;
Create T-Stage, Gleason Total, RT-Start Year and Treatment Centre Variables for Standardized
Difference Testing:
data thesis.Procars_Low_Risk;
set Procars_Low_Risky;
if Tstage_3cat = 1 then Tstage_T1 = 1;
if Tstage_3cat = 2 or Tstage_3cat = 3 then Tstage_T1 = 0;
if Tstage_3cat = 2 then Tstage_LowT2 = 1;
if Tstage_3cat = 1 or Tstage_3cat = 3 then Tstage_LowT2 = 0;
if Tstage_3cat = 3 then Tstage_HighT2 = 1;
if Tstage_3cat = 1 or Tstage_3cat = 2 then Tstage_HighT2 = 0;
if GleasonTotal_CORR_4cat = "1_2to5" then GleasonTotal_6 = 0;
if GleasonTotal_CORR_4cat = "2_6" then GleasonTotal_6 = 1;
if RTStart_Year = 1999 then RTStart_Year_1999 = 1;
if RTStart_Year > 1999 then RTStart_Year_1999 = 0;
if RTStart_Year = 2000 then RTStart_Year_2000 = 1;
if RTStart_Year > 2000 then RTStart_Year_2000 = 0;
if RTStart_Year < 2000 then RTStart_Year_2000 = 0;
if RTStart_Year = 2001 then RTStart_Year_2001 = 1;
if RTStart_Year > 2001 then RTStart_Year_2001 = 0;
if RTStart_Year < 2001 then RTStart_Year_2001 = 0;
if RTStart_Year = 2002 then RTStart_Year_2002 = 1;
if RTStart_Year > 2002 then RTStart_Year_2002 = 0;
if RTStart_Year < 2002 then RTStart_Year_2002 = 0;
if RTStart_Year = 2003 then RTStart_Year_2003 = 1;
if RTStart_Year > 2003 then RTStart_Year_2003 = 0;
if RTStart_Year < 2003 then RTStart_Year_2003 = 0;
if RTStart_Year = 2004 then RTStart_Year_2004 = 1;
if RTStart_Year > 2004 then RTStart_Year_2004 = 0;
if RTStart_Year < 2004 then RTStart_Year_2004 = 0;
if RTStart_Year = 2005 then RTStart_Year_2005 = 1;
if RTStart_Year > 2005 then RTStart_Year_2005 = 0;
if RTStart_Year < 2005 then RTStart_Year_2005 = 0;
if RTStart_Year = 2006 then RTStart_Year_2006 = 1;
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if RTStart_Year > 2006 then RTStart_Year_2006 = 0;
if RTStart_Year < 2006 then RTStart_Year_2006 = 0;
if centre = 1 then centre1 = 1;
if centre = 2 or centre = 3 then centre1 = 0;
if centre = 2 then centre2 = 1;
if centre = 1 or centre = 3 then centre2 = 0;
if centre = 3 then centre3 = 1;
if centre = 2 or centre = 1 then centre3 = 0;
run;
proc freq data=thesis.Procars_Low_Risk;
table GleasonTotal_6*GleasonTotal_CORR_4cat Tstage_T1*Tstage_3cat Tstage_LowT2*Tstage_3cat
Tstage_HighT2*Tstage_3cat/list;
run;
Initial Selection of low-risk cohort, including ensuring patients have info
on outcomes, important baseline factors, adequate RT dose and NO hormones:
Title 'Low Risk Propensity Score';
libname thesis 'P:\Graham\Thesis';
data thesis.Low_Risk_PS;
set thesis.Procars_Low_Risk;
if Tstage = '.' then delete;
if Age = '.' then delete;
if BasePSA = '.' then delete;
if GleasonTotal_CORR = '.' then delete;
if Dead = '.' then delete;
if Survival_months = '.' then delete;
if BFFS2_months = '.' then delete;
if BFFS2 = '.' then delete;
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose = '.' then delete;
if Radiation_Type_5cat = 'Brachy(LDR)_only' and LDR_Dose = '.' then delete;
if Radiation_Type_5cat = 'Brachy(HDR)_only' or Radiation_Type_5cat = 'Brachy(LDR)_and_EBRT' or
Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' then delete;
if Radiation_Type_5cat = 'EBRT_only' and EBRT_Dose < 7000 then delete;
if Radiation_Type_5cat = 'Brachy(LDR)_only' and LDR_Dose < 14400 then delete;
where Hormones = 0;
run;
proc freq data=thesis.Low_Risk_PS;
tables Radiation_Type_5cat*Hormones EBRT_Dose*Radiation_Type_5cat LDR_Dose
Radiation_Type_5cat/list;
run;
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Appendix VII
SAS Code for PS Model and Matching Intermediate-risk LDR-BT vs. EBRT

	
  

161	
  

Code for LDR-BT vs. EBRT Intermediate-risk PS match:
Title 'Intermediate Risk EBRT vs. LDR';
libname thesis 'P:\Graham\Thesis';
Data Thesis.IR_PS_EBRTvsLDR;
set thesis.Interm_Risk_PS;
if Radiation_Type_5cat = 'Brachy(HDR)_and_EBRT' then delete;
if Radiation_Type_5cat = 'EBRT_only' then Tx = 0;
if Radiation_type_5cat = 'Brachy(LDR)_only' then Tx = 1;
/*Create RT Start Year and Treatment Centre Variables for Standardized Difference Testing*/
if RTStart_Year = 1996 then RTStart_Year_1996 = 1;
if RTStart_Year > 1996 then RTStart_Year_1996 = 0;
if RTStart_Year = 1997 then RTStart_Year_1997 = 1;
if RTStart_Year > 1997 then RTStart_Year_1997 = 0;
if RTStart_Year < 1997 then RTStart_Year_1997 = 0;
if RTStart_Year = 1998 then RTStart_Year_1998 = 1;
if RTStart_Year > 1998 then RTStart_Year_1998 = 0;
if RTStart_Year < 1998 then RTStart_Year_1998 = 0;
if RTStart_Year = 1999 then RTStart_Year_1999 = 1;
if RTStart_Year > 1999 then RTStart_Year_1999 = 0;
if RTStart_Year < 1999 then RTStart_Year_1999 = 0;
if RTStart_Year = 2000 then RTStart_Year_2000 = 1;
if RTStart_Year > 2000 then RTStart_Year_2000 = 0;
if RTStart_Year < 2000 then RTStart_Year_2000 = 0;
if RTStart_Year = 2000 then RTStart_Year_2000 = 1;
if RTStart_Year > 2000 then RTStart_Year_2000 = 0;
if RTStart_Year < 2000 then RTStart_Year_2000 = 0;
if RTStart_Year = 2001 then RTStart_Year_2001 = 1;
if RTStart_Year > 2001 then RTStart_Year_2001 = 0;
if RTStart_Year < 2001 then RTStart_Year_2001 = 0;
if RTStart_Year = 2002 then RTStart_Year_2002 = 1;
if RTStart_Year > 2002 then RTStart_Year_2002 = 0;
if RTStart_Year < 2002 then RTStart_Year_2002 = 0;
if RTStart_Year = 2003 then RTStart_Year_2003 = 1;
if RTStart_Year > 2003 then RTStart_Year_2003 = 0;
if RTStart_Year < 2003 then RTStart_Year_2003 = 0;
if RTStart_Year = 2004 then RTStart_Year_2004 = 1;
if RTStart_Year > 2004 then RTStart_Year_2004 = 0;
if RTStart_Year < 2004 then RTStart_Year_2004 = 0;
if RTStart_Year = 2005 then RTStart_Year_2005 = 1;
if RTStart_Year > 2005 then RTStart_Year_2005 = 0;
if RTStart_Year < 2005 then RTStart_Year_2005 = 0;
if RTStart_Year = 2006 then RTStart_Year_2006 = 1;
if RTStart_Year > 2006 then RTStart_Year_2006 = 0;
if RTStart_Year < 2006 then RTStart_Year_2006 = 0;
if RTStart_Year = 2007 then RTStart_Year_2007 = 1;
if RTStart_Year > 2007 then RTStart_Year_2007 = 0;
if RTStart_Year < 2007 then RTStart_Year_2007 = 0;
if RTStart_Year = 2008 then RTStart_Year_2008 = 1;
if RTStart_Year > 2008 then RTStart_Year_2008 = 0;
if RTStart_Year < 2008 then RTStart_Year_2008 = 0;
if RTStart_Year = 2009 then RTStart_Year_2009 = 1;
if RTStart_Year > 2009 then RTStart_Year_2009 = 0;
if RTStart_Year < 2009 then RTStart_Year_2009 = 0;
if RTStart_Year = 2010 then RTStart_Year_2010 = 1;
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if RTStart_Year > 2010 then RTStart_Year_2010 = 0;
if RTStart_Year < 2010 then RTStart_Year_2010 = 0;
if centre = 1 then centre1 = 1;
if centre = 2 or centre = 3 then centre1 = 0;
if centre = 2 then centre2 = 1;
if centre = 1 or centre = 3 then centre2 = 0;
if centre = 3 then centre3 = 1;
if centre = 2 or centre = 1 then centre3 = 0;
run;
proc freq data=Thesis.IR_PS_EBRTvsLDR;
tables Tstage_CORR*tx GleasonTotal*tx Radiation_Type_5cat*tx GleasonTotal_CORR_4cat*tx
Tstage_3cat*tx /list;
run;
Create PS model for LDR vs. EBRT Intermediate-risk match:
proc logistic descending data=Thesis.IR_PS_EBRTvsLDR;
class GleasonTotal_CORR_4cat (param=ref ref="2_6");
class Tstage_3cat (param=ref ref="1");
model Tx = Age BasePSA GleasonTotal_CORR_4cat Tstage_3cat/lackfit rsquare;
output out=Propensity_Scores predprobs=Individual;
run;
Create 1:1 and 2:1 PS matches for LDR vs. EBRT intermediate-risk match – Caliper 0.01:
data thesis.Pscores_IR_EBRTvsLDR;
set Propensity_Scores;
Pscore=IP_1;
drop _from_ _into_ IP_0 IP_1;
run;
proc sort data=Thesis.Pscores_IR_EBRTvsLDR;
by ID2;
run;
data Brachy_LDR_pscores_C1;
set Thesis.Pscores_IR_EBRTvsLDR;
where Tx=1;
Brachy_LDR_ID=ID2;
Brachy_LDR_Pscore=Pscore;
keep Brachy_LDR_ID Brachy_LDR_Pscore;
run;
data EBRT_pscores_C1;
set Thesis.Pscores_IR_EBRTvsLDR;
where Tx=0;
EBRT_ID=ID2;
EBRT_Pscore=Pscore;
keep EBRT_ID EBRT_Pscore;
run;
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/*==========================================================*/
/*==== Caliper Matching (Without Replacement): Wave 1 =================*/
/*================== Caliper = 0.01 ============================*/
/*==========================================================*/
data Matched_C025_W1(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w1);
length ebrt_pscore 8;
length EBRT_ID 8;
if _N_= 1 then do;
declare hash h(dataset: "EBRT_pscores_C1", ordered: 'no');
declare hiter iter('h');
h.defineKey('EBRT_ID');
h.defineData('EBRT_Pscore', 'EBRT_ID');
h.defineDone();
call missing(EBRT_ID, EBRT_Pscore);
end;
set Brachy_LDR_pscores_C1;
retain BestDistance 99;
rc= iter.first();
if (rc=0) then BestDistance= 99;
do while (rc= 0);
if (Brachy_LDR_Pscore - 0.01) <= EBRT_Pscore <= (Brachy_LDR_Pscore + 0.01) then do;
ScoreDistance= abs(Brachy_LDR_Pscore - EBRT_Pscore);
if ScoreDistance < BestDistance then do;
BestDistance= ScoreDistance;
EBRT_ID_matched= EBRT_ID;
Brachy_LDR_ID_matched= Brachy_LDR_ID;
C025_w1=1;
end;
end;
rc= iter.next();
if (rc~= 0) and BestDistance~= 99 then do;
output;
rc1= h.remove(key: EBRT_ID_matched);
end;
end;
run;
/*==========================================================*/
/*======== Remove EBRT Patients Selected in Wave 1 ==================*/
/*==========================================================*/
data C025_W1_EBRT_ID;
set Matched_C025_W1;
EBRT_ID=EBRT_ID_matched;
keep EBRT_ID C025_w1;
run;
proc sort data=C025_W1_EBRT_ID;
by EBRT_ID;
run;
data C025_W2_EBRT_pscores;
merge EBRT_pscores_C1 (in=EBRT_pscores_C1)
C025_W1_EBRT_ID (in=C025_W1_EBRT_ID);
by EBRT_ID;
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if EBRT_pscores_C1;
run;
data C025_W2_EBRT_pscoresB;
set C025_W2_EBRT_pscores;
if C025_w1=1 then delete;
run;
/*==========================================================*/
/*==== Caliper Matching (Without Replacement): Wave 2 =================*/
/*================== Caliper = 0.01 ============================*/
/*==========================================================*/
data Matched_C025_W2(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w2);
length EBRT_ID 8;
length EBRT_pscore 8;
if _N_= 1 then do;
declare hash h(dataset: "C025_W2_EBRT_pscoresB", ordered: 'no');
declare hiter iter('h');
h.defineKey('EBRT_ID');
h.defineData('EBRT_pscore', 'EBRT_ID');
h.defineDone();
call missing(EBRT_ID, EBRT_pscore);
end;
set Brachy_LDR_pscores_C1;
retain BestDistance 99;
rc= iter.first();
if (rc=0) then BestDistance= 99;
do while (rc= 0);
if (Brachy_LDR_pscore - 0.01) <= EBRT_pscore <= (Brachy_LDR_pscore + 0.01) then do;
ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore);
if ScoreDistance < BestDistance then do;
BestDistance= ScoreDistance;
EBRT_ID_matched= EBRT_ID;
Brachy_LDR_ID_matched= Brachy_LDR_ID;
C025_w2=1;
end;
end;
rc= iter.next();
if (rc~= 0) and BestDistance~= 99 then do;
output;
rc1= h.remove(key: EBRT_ID_matched);
end;
end;
run;
/*==========================================================*/
/*====== Remove EBRT Patients Selected in Wave 1 or 2 =================*/
/*==========================================================*/
data C025_W2_EBRT_ID;
set Matched_C025_W2;
EBRT_ID=EBRT_ID_matched;
keep EBRT_ID C025_w2;
run;
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proc sort data=C025_W2_EBRT_ID;
by EBRT_ID;
run;
data C025_W3_EBRT_pscores;
merge EBRT_pscores_C1 (in=EBRT_pscores_C1)
C025_W2_EBRT_ID (in=C025_W2_EBRT_ID)
C025_W1_EBRT_ID (in=C025_W1_EBRT_ID);
by EBRT_ID;
if EBRT_pscores_C1;
run;
/*==========================================================*/
/*============ Re-Import Matched ID Datasets ======================*/
/*==========================================================*/
data Matched_C025_W1_F;
set Matched_C025_W1;
Brachy_LDR_ID=Brachy_LDR_ID_matched;
EBRT_ID1=EBRT_ID_matched;
drop Brachy_LDR_ID_matched EBRT_ID_matched;
run;
data Matched_C025_W2_F;
set Matched_C025_W2;
Brachy_LDR_ID=Brachy_LDR_ID_matched;
EBRT_ID2=EBRT_ID_matched;
drop Brachy_LDR_ID_matched EBRT_ID_matched;
run;
/*==========================================================*/
/*======== Merge Datasets and Fix Variable Order =====================*/
/*==========================================================*/
data Matched_C025;
merge Matched_C025_W1_F (in=Matched_C025_W1_F)
Matched_C025_W2_F (in=Matched_C025_W2_F)
;
by Brachy_LDR_ID;
if Matched_C025_W1_F;
run;
data Matched_C025B;
retain Brachy_LDR_ID
EBRT_ID1 C025_W1
EBRT_ID2 C025_w2
set Matched_C025;
run;
/*==========================================================*/
/*========== Re-Import Updated ID Matched Flags ====================*/
/*==========================================================*/
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data matched_C025B_F;
set matched_C025B;
run;
*Caliper=0.025, 1:1;
data C025_1to1;
set matched_C025B_F;
if C025_w1=1; C025_1to1=1;
pair = _N_;
run;
data C025_1to1_Brachy_LDR;
set C025_1to1;
ID2=Brachy_LDR_ID;
keep ID2 C025_1to1 pair;
run;
data C025_1to1_EBRT1;
set C025_1to1;
ID2=EBRT_ID1;
keep ID2 C025_1to1 pair;
run;
data C025_1to1x;
set C025_1to1_Brachy_LDR
C025_1to1_EBRT1;
run;
proc sort data=C025_1to1x;
by ID2;
run;
data IR_PS_EBRTvsLDR;
set Thesis.IR_PS_EBRTvsLDR;
run;
data C025_EBRT_LDR_IR;
merge C025_1to1x (in=C025_1to1x)
IR_PS_EBRTvsLDR (in=IR_PS_EBRTvsLDR);
by ID2;
if C025_1to1x;
run;
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Appendix VIII
SAS code for PS Model and Matching Intermediate-risk HDR-BT+EBRT vs. EBRT

	
  

168	
  
Code for HDR-BT+EBRT vs. EBRT Intermediate-risk PS match:
Title 'Intermediate Risk: EBRT vs. HDR+EBRT';
libname thesis 'P:\Graham\Thesis';
Data Thesis.IR_PS_EBRTvsHDRandEBRT;
set thesis.Interm_Risk_PS;
if Radiation_Type_5cat = 'Brachy(LDR)_only' then delete;
if Radiation_Type_5cat = 'EBRT_only' then Tx = 0;
if Radiation_type_5cat = 'Brachy(HDR)_and_EBRT' then Tx = 1;
/*Create RT Start Year and Treatment Centre Variables for Standardized Difference Analysis*/
if RTStart_Year = 1996 then RTStart_Year_1996 = 1;
if RTStart_Year > 1996 then RTStart_Year_1996 = 0;
if RTStart_Year = 1997 then RTStart_Year_1997 = 1;
if RTStart_Year > 1997 then RTStart_Year_1997 = 0;
if RTStart_Year < 1997 then RTStart_Year_1997 = 0;
if RTStart_Year = 1998 then RTStart_Year_1998 = 1;
if RTStart_Year > 1998 then RTStart_Year_1998 = 0;
if RTStart_Year < 1998 then RTStart_Year_1998 = 0;
if RTStart_Year = 1999 then RTStart_Year_1999 = 1;
if RTStart_Year > 1999 then RTStart_Year_1999 = 0;
if RTStart_Year < 1999 then RTStart_Year_1999 = 0;
if RTStart_Year = 2000 then RTStart_Year_2000 = 1;
if RTStart_Year > 2000 then RTStart_Year_2000 = 0;
if RTStart_Year < 2000 then RTStart_Year_2000 = 0;
if RTStart_Year = 2000 then RTStart_Year_2000 = 1;
if RTStart_Year > 2000 then RTStart_Year_2000 = 0;
if RTStart_Year < 2000 then RTStart_Year_2000 = 0;
if RTStart_Year = 2001 then RTStart_Year_2001 = 1;
if RTStart_Year > 2001 then RTStart_Year_2001 = 0;
if RTStart_Year < 2001 then RTStart_Year_2001 = 0;
if RTStart_Year = 2002 then RTStart_Year_2002 = 1;
if RTStart_Year > 2002 then RTStart_Year_2002 = 0;
if RTStart_Year < 2002 then RTStart_Year_2002 = 0;
if RTStart_Year = 2003 then RTStart_Year_2003 = 1;
if RTStart_Year > 2003 then RTStart_Year_2003 = 0;
if RTStart_Year < 2003 then RTStart_Year_2003 = 0;
if RTStart_Year = 2004 then RTStart_Year_2004 = 1;
if RTStart_Year > 2004 then RTStart_Year_2004 = 0;
if RTStart_Year < 2004 then RTStart_Year_2004 = 0;
if RTStart_Year = 2005 then RTStart_Year_2005 = 1;
if RTStart_Year > 2005 then RTStart_Year_2005 = 0;
if RTStart_Year < 2005 then RTStart_Year_2005 = 0;
if RTStart_Year = 2006 then RTStart_Year_2006 = 1;
if RTStart_Year > 2006 then RTStart_Year_2006 = 0;
if RTStart_Year < 2006 then RTStart_Year_2006 = 0;
if RTStart_Year = 2007 then RTStart_Year_2007 = 1;
if RTStart_Year > 2007 then RTStart_Year_2007 = 0;
if RTStart_Year < 2007 then RTStart_Year_2007 = 0;
if RTStart_Year = 2008 then RTStart_Year_2008 = 1;
if RTStart_Year > 2008 then RTStart_Year_2008 = 0;
if RTStart_Year < 2008 then RTStart_Year_2008 = 0;
if RTStart_Year = 2009 then RTStart_Year_2009 = 1;
if RTStart_Year > 2009 then RTStart_Year_2009 = 0;
if RTStart_Year < 2009 then RTStart_Year_2009 = 0;
if RTStart_Year = 2010 then RTStart_Year_2010 = 1;
if RTStart_Year > 2010 then RTStart_Year_2010 = 0;
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if RTStart_Year < 2010 then RTStart_Year_2010 = 0;
if centre = 1 then centre1 = 1;
if centre = 2 or centre = 3 or centre = 4 then centre1 = 0;
if centre = 2 then centre2 = 1;
if centre = 1 or centre = 3 or centre = 4 then centre2 = 0;
if centre = 3 then centre3 = 1;
if centre = 2 or centre = 1 or centre = 4 then centre3 = 0;
if centre = 4 then centre4 = 1;
if centre = 3 or centre = 2 or centre = 1 then centre4 = 0;
run;
proc freq data=Thesis.IR_PS_EBRTvsHDRandEBRT;
tables Tstage_CORR*tx GleasonTotal*tx Radiation_Type_5cat*tx GleasonTotal_CORR_4cat*tx
Tstage_3cat*tx /list;
run;
Create PS model for HDR+EBRT vs EBRT Intermediate-risk match:
proc logistic descending data=Thesis.IR_PS_EBRTvsHDRandEBRT;
class GleasonTotal_CORR_4cat (param=ref ref="2_6");
class Tstage_3cat (param=ref ref="1");
model Tx = Age BasePSA GleasonTotal_CORR_4cat Tstage_3cat/lackfit rsquare;
output out=Propensity_Scores predprobs=Individual xbeta=logitps;
run;
proc means data=Propensity_Scores std;
run;
Create 1:1 and 2:1 PS matches for HDR+EBRT vs EBRT intermediate-risk match – Caliper 1STD[logit]*(0.2):
data thesis.Pscores_IR_EBRTvsHDR;
set Propensity_Scores;
Pscore=logitps;
drop _from_ _into_ IP_0 IP_1;
run;
proc sort data=Thesis.Pscores_IR_EBRTvsHDR;
by ID2;
run;
data Brachy_LDR_pscores_C1;
set Thesis.Pscores_IR_EBRTvsHDR;
where Tx=0;
Brachy_LDR_ID=ID2;
Brachy_LDR_Pscore=Pscore;
keep Brachy_LDR_ID Brachy_LDR_Pscore;
run;
data EBRT_pscores_C1;
set Thesis.Pscores_IR_EBRTvsHDR;
where Tx=1;
EBRT_ID=ID2;
EBRT_Pscore=Pscore;
keep EBRT_ID EBRT_Pscore;
run;
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/*=============================================================*/
/*==== Caliper Matching (Without Replacement): Wave 1 ===================*/
/*================== Caliper =1STD[logit]*(0.2)=======================*/
/*=============================================================*/
data Matched_C025_W1(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w1);
length ebrt_pscore 8;
length EBRT_ID 8;
if _N_= 1 then do;
declare hash h(dataset: "EBRT_pscores_C1", ordered: 'no');
declare hiter iter('h');
h.defineKey('EBRT_ID');
h.defineData('EBRT_Pscore', 'EBRT_ID');
h.defineDone();
call missing(EBRT_ID, EBRT_Pscore);
end;
set Brachy_LDR_pscores_C1;
retain BestDistance 99;
rc= iter.first();
if (rc=0) then BestDistance= 99;
do while (rc= 0);
if (Brachy_LDR_Pscore - (1.0143704*0.2)) <= EBRT_Pscore <= (Brachy_LDR_Pscore +
(1.0143704*0.2)) then do;
ScoreDistance= abs(Brachy_LDR_Pscore - EBRT_Pscore);
if ScoreDistance < BestDistance then do;
BestDistance= ScoreDistance;
EBRT_ID_matched= EBRT_ID;
Brachy_LDR_ID_matched= Brachy_LDR_ID;
C025_w1=1;
end;
end;
rc= iter.next();
if (rc~= 0) and BestDistance~= 99 then do;
output;
rc1= h.remove(key: EBRT_ID_matched);
end;
end;
run;
/*==========================================================*/
/*======== Remove EBRT Patients Selected in Wave 1 ================*/
/*==========================================================*/
data C025_W1_EBRT_ID;
set Matched_C025_W1;
EBRT_ID=EBRT_ID_matched;
keep EBRT_ID C025_w1;
run;
proc sort data=C025_W1_EBRT_ID;
by EBRT_ID;
run;
data C025_W2_EBRT_pscores;
merge EBRT_pscores_C1 (in=EBRT_pscores_C1)
C025_W1_EBRT_ID (in=C025_W1_EBRT_ID);
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by EBRT_ID;
if EBRT_pscores_C1;
run;
data C025_W2_EBRT_pscoresB;
set C025_W2_EBRT_pscores;
if C025_w1=1 then delete;
run;

/*===========================================================*/
/*==== Caliper Matching (Without Replacement): Wave 2 ==================*/
/*============= Caliper 1STD[logit]*(0.2)===========================*/
/*==========================================================*/
data Matched_C025_W2(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w2);
length EBRT_ID 8;
length EBRT_pscore 8;
if _N_= 1 then do;
declare hash h(dataset: "C025_W2_EBRT_pscoresB", ordered: 'no');
declare hiter iter('h');
h.defineKey('EBRT_ID');
h.defineData('EBRT_pscore', 'EBRT_ID');
h.defineDone();
call missing(EBRT_ID, EBRT_pscore);
end;
set Brachy_LDR_pscores_C1;
retain BestDistance 99;
rc= iter.first();
if (rc=0) then BestDistance= 99;
do while (rc= 0);
if (Brachy_LDR_pscore – (1.0143704*0.2) <= EBRT_pscore <= (Brachy_LDR_pscore +
(1.0143704*0.2) then do;
ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore);
if ScoreDistance < BestDistance then do;
BestDistance= ScoreDistance;
EBRT_ID_matched= EBRT_ID;
Brachy_LDR_ID_matched= Brachy_LDR_ID;
C025_w2=1;
end;
end;
rc= iter.next();
if (rc~= 0) and BestDistance~= 99 then do;
output;
rc1= h.remove(key: EBRT_ID_matched);
end;
end;
run;
/*==========================================================*/
/*====== Remove EBRT Patients Selected in Wave 1 or 2 ==============*/
/*==========================================================*/
data C025_W2_EBRT_ID;
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set Matched_C025_W2;
EBRT_ID=EBRT_ID_matched;
keep EBRT_ID C025_w2;
run;
proc sort data=C025_W2_EBRT_ID;
by EBRT_ID;
run;
data C025_W3_EBRT_pscores;
merge EBRT_pscores_C1 (in=EBRT_pscores_C1)
C025_W2_EBRT_ID (in=C025_W2_EBRT_ID)
C025_W1_EBRT_ID (in=C025_W1_EBRT_ID);
by EBRT_ID;
if EBRT_pscores_C1;
run;
/*==========================================================*/
/*============ Re-Import Matched ID Datasets =====================*/
/*==========================================================*/
data Matched_C025_W1_F;
set Matched_C025_W1;
Brachy_LDR_ID=Brachy_LDR_ID_matched;
EBRT_ID1=EBRT_ID_matched;
drop Brachy_LDR_ID_matched EBRT_ID_matched;
run;
data Matched_C025_W2_F;
set Matched_C025_W2;
Brachy_LDR_ID=Brachy_LDR_ID_matched;
EBRT_ID2=EBRT_ID_matched;
drop Brachy_LDR_ID_matched EBRT_ID_matched;
run;
/*==========================================================*/
/*======== Merge Datasets and Fix Variable Order ===================*/
/*==========================================================*/
data Matched_C025;
merge Matched_C025_W1_F (in=Matched_C025_W1_F)
Matched_C025_W2_F (in=Matched_C025_W2_F)
;
by Brachy_LDR_ID;
if Matched_C025_W1_F;
run;
data Matched_C025B;
retain Brachy_LDR_ID
EBRT_ID1 C025_W1
EBRT_ID2 C025_w2
set Matched_C025;
run;
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/*==========================================================*/
/*========== Re-Import Updated ID Matched Flags ===================*/
/*==========================================================*/
data matched_C025B_F;
set matched_C025B;
run;
Caliper=1STDlogit*0.2, 1:1;
data C025_1to1;
set matched_C025B_F;
if C025_w1=1; C025_1to1=1;
pair = _N_;
run;
data C025_1to1_Brachy_LDR;
set C025_1to1;
ID2=Brachy_LDR_ID;
keep ID2 C025_1to1 pair;
run;
data C025_1to1_EBRT1;
set C025_1to1;
ID2=EBRT_ID1;
keep ID2 C025_1to1 pair;
run;
data C025_1to1x;
set C025_1to1_Brachy_LDR
C025_1to1_EBRT1;
run;
proc sort data=C025_1to1x;
by ID2;
run;
data IR_PS_EBRTvsHDR;
set Thesis.IR_PS_EBRTvsHDRandEBRT;
run;
data C025_EBRT_HDR_IR;
merge C025_1to1x (in=C025_1to1x)
IR_PS_EBRTvsHDR (in=IR_PS_EBRTvsHDR);
by ID2;
if C025_1to1x;
run;
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Appendix IX
SAS Code for PS Model and Matching Low-risk LDR-BT vs. EBRT
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Code for LDR vs. EBRT Low-risk PS match:
libname thesis 'P:\Graham\Thesis';
Data Thesis.LR_PS_EBRTvsLDR;
set thesis.Low_Risk_PS;
if Radiation_Type_5cat = 'EBRT_only' then Tx = 0;
if Radiation_type_5cat = 'Brachy(LDR)_only' then Tx = 1;
run;
proc freq data=Thesis.LR_PS_EBRTvsLDR;
tables Tstage_CORR*tx GleasonTotal*tx Radiation_Type_5cat*tx GleasonTotal_CORR_4cat*tx
Tstage_3cat*tx /list;
Title 'Low Risk Propensity Score Match EBRT vs LDR';
run;
Create PS model for LDR vs EBRT Low-risk match:
proc logistic descending data=Thesis.LR_PS_EBRTvsLDR;
class GleasonTotal_CORR_4cat (param=ref ref="2_6");
class Tstage_3cat (param=ref ref="1");
class RTStart_Year (param=ref ref="1999");
model Tx = Age BasePSA GleasonTotal_CORR_4cat Tstage_3cat RTStart_Year/lackfit rsquare;
output out=Propensity_Scores predprobs=Individual xbeta=logitps;
run;
Create 1:1, 2:1, 3:1 and 4:1 (LDR:EBRT) PS matches for LDR vs EBRT Low-risk match – Caliper 1STD[logit]*(0.2):
data Thesis.LR_PS_EBRTvsLDR;
set Propensity_Scores;
Pscore=logitps;
drop _from_ _into_ IP_0 IP_1;
run;
proc sort data=Thesis.LR_PS_EBRTvsLDR;
by ID2;
run;
data Brachy_LDR_pscores_C1;
set Thesis.LR_PS_EBRTvsLDR;
where Tx=0;
Brachy_LDR_ID=ID2;
Brachy_LDR_Pscore=Pscore;
keep Brachy_LDR_ID Brachy_LDR_Pscore;
run;
data EBRT_pscores_C1;
set Thesis.LR_PS_EBRTvsLDR;
where Tx=1;
EBRT_ID=ID2;
EBRT_Pscore=Pscore;
keep EBRT_ID EBRT_Pscore;
run;
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/*===========================================================*/
/*==== Caliper Matching (Without Replacement): Wave 1 ==================*/
/*============= Caliper = 1STD[logit]*(0.2)==========================*/
/*===========================================================*/
data Matched_C025_W1(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w1);
length ebrt_pscore 8;
length EBRT_ID 8;
if _N_= 1 then do;
declare hash h(dataset: "EBRT_pscores_C1", ordered: 'no');
declare hiter iter('h');
h.defineKey('EBRT_ID');
h.defineData('EBRT_Pscore', 'EBRT_ID');
h.defineDone();
call missing(EBRT_ID, EBRT_Pscore);
end;
set Brachy_LDR_pscores_C1;
retain BestDistance 99;
rc= iter.first();
if (rc=0) then BestDistance= 99;
do while (rc= 0);
if (Brachy_LDR_Pscore - (1.1565042*0.2)) <= EBRT_Pscore <= (Brachy_LDR_Pscore +
(1.1565042*0.2)) then do;
ScoreDistance= abs(Brachy_LDR_Pscore - EBRT_Pscore);
if ScoreDistance < BestDistance then do;
BestDistance= ScoreDistance;
EBRT_ID_matched= EBRT_ID;
Brachy_LDR_ID_matched= Brachy_LDR_ID;
C025_w1=1;
end;
end;
rc= iter.next();
if (rc~= 0) and BestDistance~= 99 then do;
output;
rc1= h.remove(key: EBRT_ID_matched);
end;
end;
run;
/*==========================================================*/
/*======== Remove EBRT Patients Selected in Wave 1 ==================*/
/*==========================================================*/
data C025_W1_EBRT_ID;
set Matched_C025_W1;
EBRT_ID=EBRT_ID_matched;
keep EBRT_ID C025_w1;
run;
proc sort data=C025_W1_EBRT_ID;
by EBRT_ID;
run;
data C025_W2_EBRT_pscores;
merge EBRT_pscores_C1 (in=EBRT_pscores_C1)
C025_W1_EBRT_ID (in=C025_W1_EBRT_ID);
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by EBRT_ID;
if EBRT_pscores_C1;
run;
data C025_W2_EBRT_pscoresB;
set C025_W2_EBRT_pscores;
if C025_w1=1 then delete;
run;
/*==========================================================*/
/*==== Caliper Matching (Without Replacement): Wave 2 =================*/
/=========== Caliper = 1STD[logit]*(0.2) ===========================*/
/*==========================================================*/
data Matched_C025_W2(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w2);
length EBRT_ID 8;
length EBRT_pscore 8;
if _N_= 1 then do;
declare hash h(dataset: "C025_W2_EBRT_pscoresB", ordered: 'no');
declare hiter iter('h');
h.defineKey('EBRT_ID');
h.defineData('EBRT_pscore', 'EBRT_ID');
h.defineDone();
call missing(EBRT_ID, EBRT_pscore);
end;
set Brachy_LDR_pscores_C1;
retain BestDistance 99;
rc= iter.first();
if (rc=0) then BestDistance= 99;
do while (rc= 0);
if (Brachy_LDR_pscore - (1.1565042*0.2)) <= EBRT_pscore <= (Brachy_LDR_pscore +
(1.1565042*0.2)) then do;
ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore);
if ScoreDistance < BestDistance then do;
BestDistance= ScoreDistance;
EBRT_ID_matched= EBRT_ID;
Brachy_LDR_ID_matched= Brachy_LDR_ID;
C025_w2=1;
end;
end;
rc= iter.next();
if (rc~= 0) and BestDistance~= 99 then do;
output;
rc1= h.remove(key: EBRT_ID_matched);
end;
end;
run;
/*==========================================================*/
/*====== Remove EBRT Patients Selected in Wave 1 or 2 ==============*/
/*==========================================================*/
data C025_W2_EBRT_ID;
set Matched_C025_W2;
EBRT_ID=EBRT_ID_matched;
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keep EBRT_ID C025_w2;
run;
proc sort data=C025_W2_EBRT_ID;
by EBRT_ID;
run;
data C025_W3_EBRT_pscores;
merge EBRT_pscores_C1 (in=EBRT_pscores_C1)
C025_W2_EBRT_ID (in=C025_W2_EBRT_ID)
C025_W1_EBRT_ID (in=C025_W1_EBRT_ID);
by EBRT_ID;
if EBRT_pscores_C1;
run;
data C025_W3_EBRT_pscoresB;
set C025_W3_EBRT_pscores;
if C025_w1=1 or C025_w2=1 then delete;
run;
/*==========================================================*/
/*==== Caliper Matching (Without Replacement): Wave 3 =================*/
/*========== Caliper = 1STD[logit]*(0.2) ===========================*/
/*==========================================================*/
data Matched_C025_W3(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w3);
length EBRT_ID 8;
length EBRT_pscore 8;
if _N_= 1 then do;
declare hash h(dataset: "C025_W3_EBRT_pscoresB", ordered: 'no');
declare hiter iter('h');
h.defineKey('EBRT_ID');
h.defineData('EBRT_pscore', 'EBRT_ID');
h.defineDone();
call missing(EBRT_ID, EBRT_pscore);
end;
set Brachy_LDR_pscores_C1;
retain BestDistance 99;
rc= iter.first();
if (rc=0) then BestDistance= 99;
do while (rc= 0);
if (Brachy_LDR_pscore - (1.1565042*0.2)) <= EBRT_pscore <= (Brachy_LDR_pscore +
(1.1565042*0.2)) then do;
ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore);
if ScoreDistance < BestDistance then do;
BestDistance= ScoreDistance;
EBRT_ID_matched= EBRT_ID;
Brachy_LDR_ID_matched= Brachy_LDR_ID;
C025_w3=1;
end;
end;
rc= iter.next();
if (rc~= 0) and BestDistance~= 99 then do;
output;
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rc1= h.remove(key: EBRT_ID_matched);
end;
end;
run;
/*==========================================================*/
/*====== Remove EBRT Patients Selected in Wave 1 or 2 or 3 ===========*/
/*==========================================================*/
data C025_W3_EBRT_ID;
set Matched_C025_W3;
EBRT_ID=EBRT_ID_matched;
keep EBRT_ID C025_w3;
run;
proc sort data=C025_W3_EBRT_ID;
by EBRT_ID;
run;
data C025_W4_EBRT_pscores;
merge EBRT_pscores_C1 (in=EBRT_pscores_C1)
C025_W2_EBRT_ID (in=C025_W2_EBRT_ID)
C025_W1_EBRT_ID (in=C025_W1_EBRT_ID)
C025_W3_EBRT_ID (in=C025_W3_EBRT_ID);
by EBRT_ID;
if EBRT_pscores_C1;
run;
data C025_W4_EBRT_pscoresB;
set C025_W4_EBRT_pscores;
if C025_w1=1 or C025_w2=1 or C025_w3 then delete;
run;
/*==========================================================*/
/*==== Caliper Matching (Without Replacement): Wave 4 =================*/
/*========== Caliper = 1STD[logit]*(0.2) ===========================*/
/*==========================================================*/
data Matched_C025_W4(keep= EBRT_ID_matched Brachy_LDR_ID_matched C025_w4);
length EBRT_ID 8;
length EBRT_pscore 8;
if _N_= 1 then do;
declare hash h(dataset: "C025_W4_EBRT_pscoresB", ordered: 'no');
declare hiter iter('h');
h.defineKey('EBRT_ID');
h.defineData('EBRT_pscore', 'EBRT_ID');
h.defineDone();
call missing(EBRT_ID, EBRT_pscore);
end;
set Brachy_LDR_pscores_C1;
retain BestDistance 99;
rc= iter.first();
if (rc=0) then BestDistance= 99;
do while (rc= 0);
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if (Brachy_LDR_pscore - (1.1565042*0.2)) <= EBRT_pscore <= (Brachy_LDR_pscore +
(1.1565042*0.2)) then do;
ScoreDistance= abs(Brachy_LDR_pscore - EBRT_pscore);
if ScoreDistance < BestDistance then do;
BestDistance= ScoreDistance;
EBRT_ID_matched= EBRT_ID;
Brachy_LDR_ID_matched= Brachy_LDR_ID;
C025_w4=1;
end;
end;
rc= iter.next();
if (rc~= 0) and BestDistance~= 99 then do;
output;
rc1= h.remove(key: EBRT_ID_matched);
end;
end;
run;
/*==========================================================*/
/*============ Re-Import Matched ID Datasets =====================*/
/*==========================================================*/
data Matched_C025_W1_F;
set Matched_C025_W1;
Brachy_LDR_ID=Brachy_LDR_ID_matched;
EBRT_ID1=EBRT_ID_matched;
drop Brachy_LDR_ID_matched EBRT_ID_matched;
run;
data Matched_C025_W2_F;
set Matched_C025_W2;
Brachy_LDR_ID=Brachy_LDR_ID_matched;
EBRT_ID2=EBRT_ID_matched;
drop Brachy_LDR_ID_matched EBRT_ID_matched;
run;
data Matched_C025_W3_F;
set Matched_C025_W3;
Brachy_LDR_ID=Brachy_LDR_ID_matched;
EBRT_ID3=EBRT_ID_matched;
drop Brachy_LDR_ID_matched EBRT_ID_matched;
run;
data Matched_C025_W4_F;
set Matched_C025_W4;
Brachy_LDR_ID=Brachy_LDR_ID_matched;
EBRT_ID4=EBRT_ID_matched;
drop Brachy_LDR_ID_matched EBRT_ID_matched;
run;
/*==========================================================*/
/*======== Merge Datasets and Fix Variable Order =====================*/
/*==========================================================*/
data Matched_C025;
merge Matched_C025_W1_F (in=Matched_C025_W1_F)
Matched_C025_W2_F (in=Matched_C025_W2_F)
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Matched_C025_W3_F (in=Matched_C025_W3_F)
Matched_C025_W4_F (in=Matched_C025_W4_F);
by Brachy_LDR_ID;
if Matched_C025_W1_F;
run;
data Matched_C025B;
retain Brachy_LDR_ID
EBRT_ID1 C025_W1
EBRT_ID2 C025_w2
EBRT_ID3 C025_w3
EBRT_ID4 C025_w4;
set Matched_C025;
run;
/*==========================================================*/
/*========== Re-Import Updated ID Matched Flags ====================*/
/*==========================================================*/
data matched_C025B_F;
set matched_C025B;
run;
*Caliper=0.02logit, 1:1;
data C025_1to1;
set matched_C025B_F;
if C025_w1=1; C025_1to1=1;
pair = _N_;
run;
data C025_1to1_Brachy_LDR;
set C025_1to1;
ID2=Brachy_LDR_ID;
keep ID2 C025_1to1 pair;
run;
data C025_1to1_EBRT1;
set C025_1to1;
ID2=EBRT_ID1;
keep ID2 C025_1to1 pair;
run;
data C025_1to1x;
set C025_1to1_Brachy_LDR
C025_1to1_EBRT1;
run;
proc sort data=C025_1to1x;
by ID2;
run;
*Caliper=0.2logit, 1:2;
data C025_1to2;
set matched_C025B;
if C025_w1=1 and C025_w2=1;
C025_1to2=1;
pair = _N_;
run;
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data C025_1to2_Brachy_LDR;
set C025_1to2;
ID2=Brachy_LDR_ID;
keep ID2 C025_1to2 pair;
run;
data C025_1to2_EBRT1;
set C025_1to2;
ID2=EBRT_ID1;
keep ID2 C025_1to2 pair;
run;
data C025_1to2_EBRT2;
set C025_1to2;
ID2=EBRT_ID2;
keep ID2 C025_1to2 pair;
run;
data C025_1to2x;
set C025_1to2_Brachy_LDR
C025_1to2_EBRT1
C025_1to2_EBRT2;
run;
proc sort data=C025_1to2x;
by ID2;
run;
*Caliper=0.2logit, 1:3;
data C025_1to3;
set matched_C025B;
if C025_w1=1 and C025_w2=1 and C025_w3=1;
C025_1to3=1;
pair = _N_;
run;
data C025_1to3_Brachy_LDR;
set C025_1to3;
ID2=Brachy_LDR_ID;
keep ID2 C025_1to3 pair;
run;
data C025_1to3_EBRT1;
set C025_1to3;
ID2=EBRT_ID1;
keep ID2 C025_1to3 pair;
run;
data C025_1to3_EBRT2;
set C025_1to3;
ID2=EBRT_ID2;
keep ID2 C025_1to3 pair;
run;
data C025_1to3_EBRT3;
set C025_1to3;
ID2=EBRT_ID3;
keep ID2 C025_1to3 pair;
run;
data C025_1to3x;
set C025_1to3_Brachy_LDR
C025_1to3_EBRT1
C025_1to3_EBRT2
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C025_1to3_EBRT3;
run;
proc sort data=C025_1to3x;
by ID2;
run;
*Caliper=0.2logit, 1:4;
data C025_1to4;
set matched_C025B;
if C025_w1=1 and C025_w2=1 and C025_w3=1 and C025_w4=1;
C025_1to4=1;
pair = _N_;
run;
data C025_1to4_Brachy_LDR;
set C025_1to4;
ID2=Brachy_LDR_ID;
keep ID2 C025_1to4 pair;
run;
data C025_1to4_EBRT1;
set C025_1to4;
ID2=EBRT_ID1;
keep ID2 C025_1to4 pair;
run;
data C025_1to4_EBRT2;
set C025_1to4;
ID2=EBRT_ID2;
keep ID2 C025_1to4 pair;
run;
data C025_1to4_EBRT3;
set C025_1to4;
ID2=EBRT_ID3;
keep ID2 C025_1to4 pair;
run;
data C025_1to4_EBRT4;
set C025_1to4;
ID2=EBRT_ID4;
keep ID2 C025_1to4 pair;
run;
data C025_1to4x;
set C025_1to4_Brachy_LDR
C025_1to4_EBRT1
C025_1to4_EBRT2
C025_1to4_EBRT3
C025_1to4_EBRT4;
run;
proc sort data=C025_1to4x;
by ID2;
run;
data LR_PS_EBRTvsLDR;
set Thesis.LR_PS_EBRTvsLDR;
run;
data C025_EBRT_LDR_LR;
merge C025_1to4x (in=C025_1to4x)
LR_PS_EBRTvsLDR (in=LR_PS_EBRTvsLDR);
by ID2;
if C025_1to4x;
run;
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Appendix X
SAS Code for Standardized Difference Testing
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Standardized Difference Testing:
Intermediate-risk LDR vs EBRT Match:
proc sort data=C025_EBRT_LDR_IR;
by Tx;
run;
/*== Macro for computing standardized difference for continuous variables ===*/
%macro cont(var=,label=);
proc means mean stddev data=C025_EBRT_LDR_IR noprint;
var &var;
by Tx;
output out=outmean (keep = Tx mean stddev) mean = mean stddev=stddev;
run;
data EBRT;
set outmean;
if Tx = 0;
mean_0 = mean;
s_0 = stddev;
keep mean_0 S_0;
run;
data Brachy;
set outmean;
if Tx = 1;
mean_1 = mean;
s_1 = stddev;
keep mean_1 s_1;
run;
data newdata;
length label $ 25;
merge EBRT Brachy;
d = (mean_1 - mean_0)/sqrt((s_1*S_1 + S_0*s_0)/2);
d = round(abs(d),0.00001);
label = &label;
keep d label;
run;
proc append data=newdata base=standiff force;
run;
%mend cont;
/*== Macro for computing standardized difference for categorical variables ===*/
%macro binary(var=,label=);
proc means mean data=C025_EBRT_LDR_IR noprint;
var &var;
by Tx;
output out=outmean (keep = Tx mean) mean = mean;
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run;
data EBRT;
set outmean;
if Tx = 0;
mean_0 = mean;
keep mean_0;
run;
data Brachy;
set outmean;
if Tx = 1;
mean_1 = mean;
keep mean_1;
run;
data newdata;
length label $ 25;
merge EBRT Brachy;
d = (mean_1 - mean_0)/sqrt((mean_1*(1-mean_1) + mean_0*(1-mean_0))/2);
d = round(abs(d),0.0001);
label = &label;
keep d label;
run;
proc append data=newdata base=standiff force;
run;
%mend binary;
%cont(var=age,label="Age");
%cont(var=BasePSA,label="Baseline PSA ng/mL");
%binary(var=Tstage_T1,label="Any T1");
%binary(var=Tstage_LowT2,label="Low T2");
%binary(var=Tstage_HighT2,label="High T2");
%binary(var=GleasonTotal_7,label="Gleason Total 7 vs 6");
%binary(var=PosCores_ge50pct,label="Percent Positive Cores > 50");
%binary(var=GleasonPattern_CORRx3plus3,label="Gleason Pattern 3+3");
%binary(var=GleasonPattern_CORRx3plus4,label="Gleason Pattern 3+4");
%binary(var=GleasonPattern_CORRx4plus3,label="Gleason Pattern 4+3");
%binary(var=RTStart_Year_1996;,label="RT Start YR 1996");
%binary(var=RTStart_Year_1997;,label="RT Start YR 1997");
%binary(var=RTStart_Year_1998;,label="RT Start YR 1998");
%binary(var=RTStart_Year_1999;,label="RT Start YR 1999");
%binary(var=RTStart_Year_2000;,label="RT Start YR 2000");
%binary(var=RTStart_Year_2001;,label="RT Start YR 2001");
%binary(var=RTStart_Year_2002;,label="RT Start YR 2002");
%binary(var=RTStart_Year_2003;,label="RT Start YR 2003");
%binary(var=RTStart_Year_2004;,label="RT Start YR 2004");
%binary(var=RTStart_Year_2005;,label="RT Start YR 2005");
%binary(var=RTStart_Year_2006;,label="RT Start YR 2006");
%binary(var=RTStart_Year_2007;,label="RT Start YR 2007");
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%binary(var=RTStart_Year_2008;,label="RT Start YR 2008");
%binary(var=RTStart_Year_2009;,label="RT Start YR 2009");
%binary(var=RTStart_Year_2010;,label="RT Start YR 2010");
%binary(var=centre1;,label="Centre 1");
%binary(var=centre2;,label="Centre 2");
%binary(var=centre3;,label="Centre 3");
proc print data=standiff;
title "Standard Difference in Matched Sample";
run;
proc freq data=C025_EBRT_LDR_IR;
table RTStart_Year*tx centre*tx PosCores_ge50pct*tx GleasonPattern_CORR*tx Tstage_3cat*tx
GleasonTotal_7*Tx Tstage_T1*Tx Tstage_LowT2*Tx Tstage_HighT2*tx/list chisq;
run;
proc freq data=C025_EBRT_LDR_IR;
table PosCores_ge50pct*tx GleasonPattern_CORR*Tx GleasonTotal_CORR /missprint;
run;
data BrachyC025_Age_PSA;
set C025_EBRT_LDR_IR;
where Tx = 1;
run;
proc means data=brachyC025_Age_PSA N mean median std max min;
var age basePSA;
Title 'Mean AGE and BASELINE PSA in Brachytherapy Group';
run;
data EBRTC025_Age_PSA;
set C025_EBRT_LDR_IR;
where tx = 0;
run;
proc means data=EBRTC025_Age_PSA N mean median std max min;
var age basePSA;
Title 'Mean AGE and BASELINE PSA in EBRT Group';
run;
proc ttest data=C025_EBRT_LDR_IR;
class tx;
var age basePSA;
run;
Proc means data=C025_EBRT_LDR_IR N mean median std max min;
var age basePSA;
run;
data Thesis.Final_LDRvsEBRT_Int_PS;
set C025_EBRT_LDR_IR;
Survival_Years = Survival_Months/12;
BFFS2_Years = BFFS2_months/12;
CRS_Years = CRS_months/12;
run;
Intermediate-risk HDR+EBRT vs EBRT Match:
proc sort data=C025_EBRT_HDR_IR;
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by Tx;
run;
/*== Macro for computing standardized difference for continuous variables ===*/
%macro cont(var=,label=);
proc means mean stddev data=C025_EBRT_HDR_IR noprint;
var &var;
by Tx;
output out=outmean (keep = Tx mean stddev) mean = mean stddev=stddev;
run;
data EBRT;
set outmean;
if Tx = 0;
mean_0 = mean;
s_0 = stddev;
keep mean_0 S_0;
run;
data Brachy;
set outmean;
if Tx = 1;
mean_1 = mean;
s_1 = stddev;
keep mean_1 s_1;
run;
data newdata;
length label $ 25;
merge EBRT Brachy;
d = (mean_1 - mean_0)/sqrt((s_1*S_1 + S_0*s_0)/2);
d = round(abs(d),0.00001);
label = &label;
keep d label;
run;
proc append data=newdata base=standiff force;
run;
%mend cont;
/*== Macro for computing standardized difference for categorical variables ===*/
%macro binary(var=,label=);
proc means mean data=C025_EBRT_HDR_IR noprint;
var &var;
by Tx;
output out=outmean (keep = Tx mean) mean = mean;
run;
data EBRT;
set outmean;
if Tx = 0;
mean_0 = mean;
keep mean_0;
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run;
data Brachy;
set outmean;
if Tx = 1;
mean_1 = mean;
keep mean_1;
run;
data newdata;
length label $ 25;
merge EBRT Brachy;
d = (mean_1 - mean_0)/sqrt((mean_1*(1-mean_1) + mean_0*(1-mean_0))/2);
d = round(abs(d),0.0001);
label = &label;
keep d label;
run;
proc append data=newdata base=standiff force;
run;
%mend binary;
%cont(var=age,label="Age");
%cont(var=BasePSA,label="Baseline PSA ng/mL");
%binary(var=Tstage_T1,label="Any T1");
%binary(var=Tstage_LowT2,label="Low T2");
%binary(var=Tstage_HighT2,label="High T2");
%binary(var=GleasonTotal_7,label="Gleason Total 7 vs 6");
%binary(var=PosCores_ge50pct,label="Percent Positive Cores > 50");
%binary(var=GleasonPattern_CORRx3plus3,label="Gleason Pattern 3+3");
%binary(var=GleasonPattern_CORRx3plus4,label="Gleason Pattern 3+4");
%binary(var=GleasonPattern_CORRx4plus3,label="Gleason Pattern 4+3");
%binary(var=RTStart_Year_1996;,label="RT Start YR 1996");
%binary(var=RTStart_Year_1997;,label="RT Start YR 1997");
%binary(var=RTStart_Year_1998;,label="RT Start YR 1998");
%binary(var=RTStart_Year_1999;,label="RT Start YR 1999");
%binary(var=RTStart_Year_2000;,label="RT Start YR 2000");
%binary(var=RTStart_Year_2001;,label="RT Start YR 2001");
%binary(var=RTStart_Year_2002;,label="RT Start YR 2002");
%binary(var=RTStart_Year_2003;,label="RT Start YR 2003");
%binary(var=RTStart_Year_2004;,label="RT Start YR 2004");
%binary(var=RTStart_Year_2005;,label="RT Start YR 2005");
%binary(var=RTStart_Year_2006;,label="RT Start YR 2006");
%binary(var=RTStart_Year_2007;,label="RT Start YR 2007");
%binary(var=RTStart_Year_2008;,label="RT Start YR 2008");
%binary(var=RTStart_Year_2009;,label="RT Start YR 2009");
%binary(var=RTStart_Year_2010;,label="RT Start YR 2010");
%binary(var=centre1;,label="Centre 1");
%binary(var=centre2;,label="Centre 2");
%binary(var=centre3;,label="Centre 3");
%binary(var=centre4;,label="Centre 4");
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proc print data=standiff;
title "Standard Difference in Matched Sample";
run;
proc freq data=C025_EBRT_HDR_IR;
table GleasonPattern_CORR*Tx PosCores_ge50pct*tx /missprint;
run;
proc freq data=C025_EBRT_HDR_IR;
table RTStart_Year*tx centre*tx PosCores_ge50pct*tx GleasonPattern_CORR*tx
PosCores_ge50pct*centre GleasonPattern_CORR*centre Tstage_3cat*tx GleasonTotal_7*Tx
Tstage_T1*Tx Tstage_LowT2*Tx Tstage_HighT2*tx/list chisq missprint;
run;
data BrachyC025_Age_PSA;
set C025_EBRT_HDR_IR;
where Tx = 1;
run;
proc means data=brachyC025_Age_PSA N mean median std max min;
var age basePSA;
Title 'Mean AGE and BASELINE PSA in Brachytherapy Group';
run;
data EBRTC025_Age_PSA;
set C025_EBRT_HDR_IR;
where tx = 0;
run;
proc means data=EBRTC025_Age_PSA N mean median std max min;
var age basePSA;
Title 'Mean AGE and BASELINE PSA in EBRT Group';
run;
Proc means data=C025_EBRT_HDR_IR N mean median std max min;
var age basePSA;
run;
proc ttest data=C025_EBRT_HDR_IR;
class tx;
var age basePSA;
run;
data Thesis.Final_HDRplusEBRTvsEBRT_Int_PS;
set C025_EBRT_HDR_IR;
Survival_Years = Survival_Months/12;
BFFS2_Years = BFFS2_months/12;
CRS_Years = CRS_months/12;
run;
Low-risk LDR vs EBRT Match:
proc sort data=C025_EBRT_LDR_LR;
by Tx;
run;
/*== Macro for computing standardized difference for continuous variables ===*/
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%macro cont(var=,label=);
proc means mean stddev data=C025_EBRT_LDR_LR noprint;
var &var;
by Tx;
output out=outmean (keep = Tx mean stddev) mean = mean stddev=stddev;
run;
data EBRT;
set outmean;
if Tx = 0;
mean_0 = mean;
s_0 = stddev;
keep mean_0 S_0;
run;
data Brachy;
set outmean;
if Tx = 1;
mean_1 = mean;
s_1 = stddev;
keep mean_1 s_1;
run;
data newdata;
length label $ 25;
merge EBRT Brachy;
d = (mean_1 - mean_0)/sqrt((s_1*S_1 + S_0*s_0)/2);
d = round(abs(d),0.00001);
label = &label;
keep d label;
run;
proc append data=newdata base=standiff force;
run;
%mend cont;
/*== Macro for computing standardized difference for categorical variables ===*/
%macro binary(var=,label=);
proc means mean data=C025_EBRT_LDR_LR noprint;
var &var;
by Tx;
output out=outmean (keep = Tx mean) mean = mean;
run;
data EBRT;
set outmean;
if Tx = 0;
mean_0 = mean;
keep mean_0;
run;
data Brachy;
set outmean;
if Tx = 1;
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mean_1 = mean;
keep mean_1;
run;
data newdata;
length label $ 25;
merge EBRT Brachy;
d = (mean_1 - mean_0)/sqrt((mean_1*(1-mean_1) + mean_0*(1-mean_0))/2);
d = round(abs(d),0.0001);
label = &label;
keep d label;
run;
proc append data=newdata base=standiff force;
run;
%mend binary;
%cont(var=age,label="Age");
%cont(var=BasePSA,label="Baseline PSA ng/mL");
%binary(var=Tstage_T1,label="Any T1");
%binary(var=Tstage_LowT2,label="Low T2");
%binary(var=GleasonTotal_6,label="Gleason Total 6 vs 2to5");
%binary(var=RTStart_Year_1999,label="RT Start Year 1999");
%binary(var=RTStart_Year_2000,label="RT Start Year 2000");
%binary(var=RTStart_Year_2001,label="RT Start Year 2001");
%binary(var=RTStart_Year_2002,label="RT Start Year 2002");
%binary(var=RTStart_Year_2003,label="RT Start Year 2003");
%binary(var=RTStart_Year_2004,label="RT Start Year 2004");
%binary(var=RTStart_Year_2005,label="RT Start Year 2005");
%binary(var=RTStart_Year_2006,label="RT Start Year 2006");
%binary(var=PosCores_ge50pct,label="Percent Positive Cores > 50");
%binary(var=centre1,label="Treatment Centre 1");
%binary(var=centre2,label="Treatment Centre 2");
%binary(var=centre3,label="Treatment Centre 3");
proc print data=standiff;
title "Standard Difference in Matched Sample";
run;
proc freq data=C025_EBRT_LDR_LR;
table centre*tx PosCores_ge50pct*tx RTStart_Year*tx Tstage_3cat*tx GleasonTotal_6*Tx Tstage_T1*Tx
Tstage_LowT2*Tx Tstage_HighT2*tx/list chisq;
run;
proc freq data=C025_EBRT_LDR_LR;
table PosCores_ge50pct*tx /missprint;
run;
data BrachyC025_Age_PSA;
set C025_EBRT_LDR_LR;
where Tx = 1;
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run;
proc means data=brachyC025_Age_PSA N mean median std max min;
var age basePSA;
Title 'Mean AGE and BASELINE PSA in Brachytherapy Group';
run;
data EBRTC025_Age_PSA;
set C025_EBRT_LDR_LR;
where tx = 0;
run;
proc means data=EBRTC025_Age_PSA N mean median std max min;
var age basePSA;
Title 'Mean AGE and BASELINE PSA in EBRT Group';
run;
proc ttest data=C025_EBRT_LDR_LR;
class tx;
var age basePSA;
run;
proc datasets lib=work nolist;
delete C025_1to1 C025_1to1x C025_1to1_Brachy_LDR C025_1to1_EBRT1 C025_1to2 C025_1to2x
C025_1to2_Brachy_LDR C025_1to2_EBRT1 C025_1to2_EBRT2 C025_1to3 C025_1to3x
C025_1to3_EBRT1 C025_1to3_EBRT2;
run;
proc means data=C025_EBRT_LDR_LR N mean median std max min;
var age basePSA;
run;
data Thesis.Final_LDRvsEBRT_LOW_PS;
set C025_EBRT_LDR_LR;
Survival_Years = Survival_Months/12;
BFFS2_Years = BFFS2_months/12;
CRS_Years = CRS_months/12;
run;
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Appendix XI
SAS Code for Kaplan Meier Curves, Cox Adjusted and Extended Models (Time
Dependent Covariate Models), and Model Assumption Tests (Visual and Global Tests)
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OS Comparison Intermediate-risk LDR vs EBRT PS Matched Cohort:
ods graphics on;
libname thesis 'P:\Graham\Thesis';
Title "Intermediate Risk: LDR vs EBRT (Propensity Score Match)";
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS outsurv=S_INT_LDRvsEBRT_PS maxtime=120
notable
plots=(survival(atrisk=0 to 120 by 24));
time Survival_Months*Dead(0);
label Survival_Months = 'Time (Months)';
strata Radiation_Type_5cat / group=pair;
run;
/*Creating Kaplan Meier Curves*/
goptions cback=white;
symbol1 line=1 color=black width=2 i=stepj;
symbol2 line=4 color=black width=2 i=stepj;
axis1 label=(angle=90 'Survival (%)'
font="Swiss/bold")
order=(0 to 1 by 0.2)
major=(height=3) minor=none color=black;
axis2 label=('Time (Months)'
font="Swiss/bold")
order=(0 to 120 by 24)
major=(height=3) minor=none color=black;
legend1 label=none mode=protect position=(bottom left inside)
offset=(-8 -4) across=1
value=(tick=1 justify=L "LDR" font="Swiss/bold"
tick=2 justify=L "EBRT" font="Swiss/bold");
ods pdf startpage=now;
proc gplot data=thesis.survival_INT_LDR;
plot SURVIVAL*Survival_Months = Radiation_Type_5cat /
vaxis=axis1 haxis=axis2 legend=legend1;
format survival percent12.;
run;
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum
Test*/
proc phreg data=Thesis.Final_LDRvsEBRT_INT_PS covs(aggregate);
class Radiation_Type_5cat (param=ref ref="EBRT_only");
model Survival_Months*Dead(0) = Radiation_Type_5cat /rl;
id pair;
assess proportionalhazards / resample seed=1004;
output out=outRT ressch=Radiation_Type_5cat;
run;
/*Log of Negative Log of Estimated Survival Visual Test*/
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS notable maxtime=120
plots=(lls);
time Survival_Months*Dead(0);
strata Radiation_Type_5cat;
label Survival_Months = 'Time (Months)';
survival out=out1;
run;
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/*Schoenfeld Residual Plot*/
proc sgplot data=outRT;
loess x=Survival_Months y=Radiation_Type_5cat2;
title 'Schoenfeld residuals plot for Radiation_5cat';
run;
/*Schoenfeld Global Test*/
proc corr data=outRT;
var Radiation_Type_5cat2;
with Survival_Months;
run;
/*Test for Radiation Type as Time Dependent Covariate for OS Using Extended Cox PH Model*/
data TDC_LDRvsEBRT_INT2;
set Thesis.Final_LDRvsEBRT_INT_PS;
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1;
If Radiation_Type_5cat = "Brachy(LDR)_only" then Radiation_Type_Num = 2;
run;
proc phreg data=TDC_LDRvsEBRT_INT2;
class Radiation_Type_Num (param=ref ref="1");
model Survival_months*Dead(0) = Radiation_Type_Num RT5cat_Log_Surv/rl;
RT5cat_Log_Surv=Radiation_Type_Num*LOG(Survival_months);
run;
BFFS Comparison Intermediate-risk LDR vs EBRT PS Matched:
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS notable outsurv=BFFS_INT_LDRvsEBRT_PS
maxtime=120
plots=(survival(atrisk=0 to 120 by 24));
time BFFS2_CORR_months*BFFS2_CORR(0);
strata Radiation_Type_5cat / test=logrank;
label BFFS2_CORR_months = 'Time (Months)';
run;
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS notable outsurv=BFFS_INT_LDRvsEBRT_PS
maxtime=120
plots=(survival(atrisk=0 to 120 by 24));
time BFFS2_CORR_months*BFFS2_CORR(0);
strata Radiation_Type_5cat / group=pair;
label BFFS2_CORR_months = 'Time (Months)';
run;
/*Creating Kaplan Meier Curves*/
goptions cback=white;
symbol1 line=1 color=black width=2 i=stepj;
symbol2 line=4 color=black width=2 i=stepj;
axis1 label=(angle=90 'Survival (%)'
font="Swiss/bold")
order=(0 to 1 by 0.2)
major=(height=3) minor=none color=black;
axis2 label=('Time (Months)'
font="Swiss/bold")
order=(0 to 120 by 24)
major=(height=3) minor=none color=black;
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legend1 label=none mode=protect position=(bottom left inside)
offset=(-8 -4) across=1
value=(tick=1 justify=L "LDR" font="Swiss/bold"
tick=2 justify=L "EBRT" font="Swiss/bold");
ods pdf startpage=now;
proc gplot data=thesis.bff_INT_LDR;
plot SURVIVAL*bffs2_CORR_Months = Radiation_Type_5cat /
vaxis=axis1 haxis=axis2 legend=legend1;
format survival percent12.;
run;
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum
Test*/
proc phreg data=Thesis.Final_LDRvsEBRT_INT_PS covs(aggregate);
class Radiation_Type_5cat (param=ref ref="EBRT_only");
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_5cat /rl;
id pair;
assess proportionalhazards / resample seed=1004;
output out=outRT2 ressch=Radiation_Type_5cat;
run;
/*Log of Negative Log of Estimated Survival Visual Test*/
proc lifetest data=Thesis.Final_LDRvsEBRT_INT_PS notable maxtime=120
plots=(lls);
time BFFS2_CORR_months*BFFS2_CORR(0);
strata Radiation_Type_5cat;
label BFFS2_CORR_months = 'Time (Months)';
survival out=out2;
run;
/*Schoenfeld Residual Plot*/
proc sgplot data=outRT2;
loess x=BFFS2_CORR_Months y=Radiation_Type_5cat2;
title 'Schoenfeld residuals plot for Radiation_5cat';
run;
/*Schoenfeld Global Test*/
proc corr data=outRT2;
var Radiation_Type_5cat2;
with BFFS2_CORR_Months;
run;
/*Test for Radiation Type as Time Dependent Covariate for BFFS Using Extended Cox PH Model */
data TDC_LDRvsEBRT_INT1;
set Thesis.Final_LDRvsEBRT_INT_PS;
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1;
If Radiation_Type_5cat = "Brachy(LDR)_only" then Radiation_Type_Num = 2;
run;
proc phreg data=TDC_LDRvsEBRT_INT1;
class Radiation_Type_Num (param=ref ref="1");
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_Num RT5cat_Log_BFFS2/rl;
RT5cat_Log_BFFS2=Radiation_Type_Num*LOG(BFFS2_CORR_months);
run;
ods graphics off;
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OS Comparison Intermediate-risk HDR+EBRT vs EBRT PS Matched Cohort:
ods graphics on;
libname thesis 'P:\Graham\Thesis';
Title "Intermediate Risk: HDR+EBRT vs EBRT (Propensity Score Match)";
proc lifetest data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS outsurv=S_INT_HDRvsEBRT_PS
maxtime=120 notable
plots=(survival(atrisk=0 to 120 by 24));
time Survival_Months*Dead(0);
label Survival_Months = 'Time (Months)';
strata Radiation_Type_5cat / group=pair;
run;
/*Creating Kaplan Meier Curves*/
goptions cback=white;
symbol1 line=1 color=black width=2 i=stepj;
symbol2 line=4 color=black width=2 i=stepj;
axis1 label=(angle=90 'Survival (%)'
font="Swiss/bold")
order=(0 to 1 by 0.2)
major=(height=3) minor=none color=black;
axis2 label=('Time (Months)'
font="Swiss/bold")
order=(0 to 120 by 24)
major=(height=3) minor=none color=black;
legend1 label=none mode=protect position=(bottom left inside)
offset=(-8 -4) across=1
value=(tick=1 justify=L "HDR+EBRT" font="Swiss/bold"
tick=2 justify=L "EBRT" font="Swiss/bold");
ods pdf startpage=now;
proc gplot data=thesis.survival_INT_HDR;
plot SURVIVAL*Survival_Months = Radiation_Type_5cat /
vaxis=axis1 haxis=axis2 legend=legend1;
format survival percent12.;
run;
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum
Test*/
proc phreg data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS covs(aggregate);
class Radiation_Type_5cat (param=ref ref="EBRT_only");
model Survival_Months*Dead(0) = Radiation_Type_5cat / rl;
id pair;
assess proportionalhazards / resample seed=1004;
output out=outRT ressch=Radiation_Type_5cat;
run;
/*Log of Negative Log of Estimated Survival Visual Test*/
proc lifetest data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS notable maxtime=120
plots=(lls);
time Survival_Months*Dead(0);
label Survival_Months = 'Time (Months)';
strata Radiation_Type_5cat;
survival out=out1;
run;
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/*Schoenfeld Residual Plot*/
proc sgplot data=outRT;
loess x=Survival_Months y=Radiation_Type_5cat2;
title 'Schoenfeld residuals plot for Radiation_5cat';
run;
/*Schoenfeld Global Test*/
proc corr data=outRT;
var Radiation_Type_5cat2;
with Survival_Months;
run;
/*Test for Radiation Type as Time Dependent Covariate for OS Using Extended Cox PH Model*/
data TDC_HDRvsEBRT_INT;
set Thesis.Final_HDRplusEBRTvsEBRT_INT_PS;
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1;
If Radiation_Type_5cat = "Brachy(HDR)_and_EBRT" then Radiation_Type_Num = 2;
run;
proc phreg data=TDC_HDRvsEBRT_INT;
class Radiation_Type_Num (param=ref ref="1");
model Survival_months*Dead(0) = Radiation_Type_Num RT5cat_Log_Surv/rl;
RT5cat_Log_Surv=Radiation_Type_Num*LOG(Survival_months);
run;
BFFS Comparison Intermediate-risk HDR+EBRT vs EBRT PS Matched Cohort:
proc lifetest data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS notable
outsurv=BFFS_INT_HDRvsEBRT_PS maxtime=120
plots=(survival(atrisk=0 to 120 by 24));
time BFFS2_CORR_months*BFFS2_CORR(0);
strata Radiation_Type_5cat / group=pair;
label BFFS2_CORR_months = 'Time (Months)';
run;
/*Creating Kaplan Meier Curves*/
goptions cback=white;
symbol1 line=1 color=black width=2 i=stepj;
symbol2 line=4 color=black width=2 i=stepj;
axis1 label=(angle=90 'Survival (%)'
font="Swiss/bold")
order=(0 to 1 by 0.2)
major=(height=3) minor=none color=black;
axis2 label=('Time (Months)'
font="Swiss/bold")
order=(0 to 120 by 24)
major=(height=3) minor=none color=black;
legend1 label=none mode=protect position=(bottom left inside)
offset=(-8 -4) across=1
value=(tick=1 justify=L "HDR+EBRT" font="Swiss/bold"
tick=2 justify=L "EBRT" font="Swiss/bold");
ods pdf startpage=now;
proc gplot data=thesis.bff_INT_HDR;
plot SURVIVAL*bffs2_CORR_Months = Radiation_Type_5cat /

	
  

200	
  
vaxis=axis1 haxis=axis2 legend=legend1;
format survival percent12.;
run;
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum
Test*/
proc phreg data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS covs(aggregate);
class Radiation_Type_5cat (param=ref ref="EBRT_only");
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_5cat /rl;
id pair;
assess proportionalhazards / resample seed=1004;
output out=outRT2 ressch=Radiation_Type_5cat;
run;
/*Log of Negative Log of Estimated Survival Visual Test*/
proc lifetest data=Thesis.Final_HDRplusEBRTvsEBRT_INT_PS notable maxtime=120
plots=(lls);
time BFFS2_CORR_months*BFFS2_CORR(0);
strata Radiation_Type_5cat;
label BFFS2_CORR_months = 'Time (Months)';
survival out=out2;
run;
/*Schoenfeld Residual Plot*/
proc sgplot data=outRT2;
loess x=BFFS2_CORR_Months y=Radiation_Type_5cat2;
title 'Schoenfeld residuals plot for Radiation_5cat';
run;
/*Schoenfeld Global Test*/
proc corr data=outRT2;
var Radiation_Type_5cat2;
with BFFS2_CORR_Months;
run;
/*Test for Radiation Type as Time Dependent Covariate for BFFS Using Extended Cox PH Model*/
data TDC_HDRvsEBRT_INT;
set Thesis.Final_HDRplusEBRTvsEBRT_INT_PS;
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1;
If Radiation_Type_5cat = "Brachy(HDR)_and_EBRT" then Radiation_Type_Num = 2;
run;
proc phreg data=TDC_HDRvsEBRT_INT;
class Radiation_Type_Num (param=ref ref="1");
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_Num RT5cat_Log_BFFS2/rl;
RT5cat_Log_BFFS2=Radiation_Type_Num*LOG(BFFS2_CORR_months);
run;
ods graphics off;
OS Comparison Low-risk LDR vs EBRT PS Matched Cohort:
ods graphics on;
libname thesis 'P:\Graham\Thesis';
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Title "Low Risk: LDR vs EBRT (Propensity Score Match)";
proc lifetest data=Thesis.Final_LDRvsEBRT_LOW_PS outsurv=S_LOW_LDRvsEBRT_PS maxtime=120
notable
plots=(survival(atrisk=0 to 120 by 24));
time Survival_Months*Dead(0);
label Survival_Months = 'Time (Months)';
strata Radiation_Type_5cat / group=pair;
run;
/*Creating Kaplan Meier Curves*/
goptions cback=white;
symbol1 line=1 color=black width=2 i=stepj;
symbol2 line=4 color=black width=2 i=stepj;
axis1 label=(angle=90 'Survival (%)'
font="Swiss/bold")
order=(0 to 1 by 0.2)
major=(height=3) minor=none color=black;
axis2 label=('Time (Months)'
font="Swiss/bold")
order=(0 to 120 by 24)
major=(height=3) minor=none color=black;
legend1 label=none mode=protect position=(bottom left inside)
offset=(-8 -4) across=1
value=(tick=1 justify=L "LDR" font="Swiss/bold"
tick=2 justify=L "EBRT" font="Swiss/bold");
ods pdf startpage=now;
proc gplot data=thesis.survival_lr;
plot SURVIVAL*Survival_Months = Radiation_Type_5cat /
vaxis=axis1 haxis=axis2 legend=legend1;
format survival percent12.;
run;
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum
Test*/
proc phreg data=Thesis.Final_LDRvsEBRT_LOW_PS covs(aggregate);
class Radiation_Type_5cat (param=ref ref="EBRT_only");
model Survival_Months*Dead(0) = Radiation_Type_5cat /rl;
id pair;
assess proportionalhazards / resample seed=1004;
output out=outRT ressch=Radiation_Type_5cat;
run;
/*Log of Negative Log of Estimated Survival Visual Test*/
proc lifetest data=Thesis.Final_LDRvsEBRT_LOW_PS notable maxtime=120
plots=(lls);
time Survival_Months*Dead(0);
strata Radiation_Type_5cat;
label Survival_Months = 'Time (Months)';
survival out=out;
run;
/*Schoenfeld Residual Plot*/
proc sgplot data=outRT;
loess x=Survival_Months y=Radiation_Type_5cat2;
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title 'Schoenfeld residuals plot for Radiation_5cat';
run;
/*Schoenfeld Global Test*/
proc corr data=outRT;
var Radiation_Type_5cat2;
with Survival_Months;
run;
/*Test for Radiation Type as Time Dependent Covariate for OS Using Extended Cox PH Model*/
data TDC_LDRvsEBRT_low;
set Thesis.Final_LDRvsEBRT_LOW_PS;
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1;
If Radiation_Type_5cat = "Brachy(LDR)_only" then Radiation_Type_Num = 2;
run;
proc phreg data=TDC_LDRvsEBRT_low;
class Radiation_Type_Num (param=ref ref="1");
model Survival_months*Dead(0) = Radiation_Type_Num RT5cat_Log_Surv/rl;
RT5cat_Log_Surv=Radiation_Type_Num*LOG(Survival_months);
run;
data thesis.S_LOW_LDRvsEBRT_PS;
set S_LOW_LDRvsEBRT_PS;
run;
BFFS Comparison Low-risk LDR vs EBRT PS Matched Cohort:
proc lifetest data=Thesis.Final_LDRvsEBRT_LOW_PS notable outsurv=BFFS_LOW_LDRvsEBRT_PS
maxtime=120
plots=(survival(atrisk=0 to 120 by 24));
time BFFS2_CORR_months*BFFS2_CORR(0);
strata Radiation_Type_5cat / group=pair;
label BFFS2_CORR_months = 'Time (Months)';
run;
/*Creating Kaplan Meier Curves*/
goptions cback=white;
symbol1 line=1 color=black width=2 i=stepj;
symbol2 line=4 color=black width=2 i=stepj;
axis1 label=(angle=90 'Survival (%)'
font="Swiss/bold")
order=(0 to 1 by 0.2)
major=(height=3) minor=none color=black;
axis2 label=('Time (Months)'
font="Swiss/bold")
order=(0 to 120 by 24)
major=(height=3) minor=none color=black;
legend1 label=none mode=protect position=(bottom left inside)
offset=(-8 -4) across=1
value=(tick=1 justify=L "LDR" font="Swiss/bold"
tick=2 justify=L "EBRT" font="Swiss/bold");
ods pdf startpage=now;
proc gplot data=thesis.bff_lr;
plot SURVIVAL*bffs2_CORR_Months = Radiation_Type_5cat /
vaxis=axis1 haxis=axis2 legend=legend1;
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format survival percent12.;
run;
/*Cox PH Regression of Treatment Type Stratified by Matched Pair with Kolmogorov-Supremum
Test*/
proc phreg data=Thesis.Final_LDRvsEBRT_LOW_PS covs(aggregate);
class Radiation_Type_5cat (param=ref ref="EBRT_only");
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_5cat /rl;
id pair;
assess proportionalhazards / resample seed=1004;
output out=outRT2 ressch=Radiation_Type_5cat;
run;
/*Log of Negative Log of Estimated Survival Visual Test*/
proc lifetest data=Thesis.Final_LDRvsEBRT_LOW_PS notable maxtime=120
plots=(lls);
time BFFS2_CORR_months*BFFS2_CORR(0);
strata Radiation_Type_5cat;
label BFFS2_CORR_months = 'Time (Months)';
survival out=out2;
run;
/*Schoenfeld Residual Plot*/
proc sgplot data=outRT2;
loess x=BFFS2_CORR_Months y=Radiation_Type_5cat2;
title 'Schoenfeld residuals plot for Radiation_5cat';
run;
/*Schoenfeld Global Test*/
proc corr data=outRT2;
var Radiation_Type_5cat2;
with BFFS2_CORR_Months;
run;
/*Test for Radiation Type as Time Dependent Covariate for bFFS Using Extended Cox PH Model */
data TDC_LDRvsEBRT_low;
set Thesis.Final_LDRvsEBRT_LOW_PS;
If Radiation_Type_5cat = "EBRT_only" then Radiation_Type_Num = 1;
If Radiation_Type_5cat = "Brachy(LDR)_only" then Radiation_Type_Num = 2;
run;
proc phreg data=TDC_LDRvsEBRT_low;
class Radiation_Type_Num (param=ref ref="1");
model BFFS2_CORR_months*BFFS2_CORR(0) = Radiation_Type_Num RT5cat_Log_BFFS2/rl;
RT5cat_Log_BFFS2=Radiation_Type_Num*LOG(BFFS2_CORR_months);
run;
data thesis.BFFS_LOW_LDRvsEBRT_PS;
set BFFS_LOW_LDRvsEBRT_PS;
run;
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Appendix XII
Results of Global and Visual Tests for Proportional Hazards Assumption and Testing of
Extended Cox Models Using Time Dependent Covariates
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Results of PH Assumption Tests and Test for Treatment as Time Dependent
Covariate Using Log(Survival Time in Months) in Intermediate-Risk LDR vs EBRT
Comparison:
Overall Survival:
Visual Tests:
Schoenfeld Plot:

Log(-Log) Survival Plot:

Global Tests:
Proportional Hazard Assumption Global Test Used

p-value

Schoenfeld Test

0.8958

Suprmum-Kolmogorov Test

0.8030

Test Using Extended Cox PH Regression Including Treatment as

0.9075

TDC using Scale of Log(Survival Months)
Reported p-value (from Adjusted Cox PH, with no TDC)

	
  

0.6867
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Biochemical Failure Free Survival:
Visual Tests:
Schoenfeld Plot:

Log(-Log) Survival Plot:

Global Tests:
Proportional Hazard Assumption Test Used

p-value

Schoenfeld Test

0.5993

Suprmum-Kolmogorov Test

0.7160

Test Using Extended Cox PH Regression Including Treatment as

0.6944

TDC using Scale of Log(Survival Months)
Reported p-value (from Adjusted Cox PH, with no TDC)

	
  

0.0012
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Results of PH Assumption Tests and Test for Treatment as Time Dependent
Covariate Using Log(Survival Time in Months) in Intermediate-Risk HDR+EBRT
vs EBRT Comparison:
Overall Survival:
Visual Tests:
Schoenfeld Plot:

Log(-Log) Survival Plot:

Global Tests:
Proportional Hazard Assumption Test Used

p-value

Schoenfeld Test

0.5176

Suprmum-Kolmogorov Test

0.2020

Test Using Extended Cox PH Regression Including Treatment as

0.2714

TDC using Scale of Log(Survival Months)
Reported p-value (from Adjusted Cox PH, with no TDC)

	
  

0.4696
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Biochemical Failure Free Survival:
Visual Tests:
Schoenfeld Plot:

Log(-Log) Survival Plot:

Global Tests:
Proportional Hazard Assumption Test Used

p-value

Schoenfeld Test

0.1184

Suprmum-Kolmogorov Test

0.0840

Test Using Extended Cox PH Regression Including Treatment as

0.0654

TDC using Scale of Log(Survival Months)
*Reported p-value (from Extended Cox PH, with TDC, using

0.0066

Likelihood Ratio Tests with 2 degrees of freedom)
Reported p-value (from Adjusted Cox PH, with no TDC, from
Sensitivity Analysis)
*p-value reported in study for this comparison

	
  

0.0185
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Results of PH Assumption Tests and Test for Treatment as Time Dependent
Covariate Using Log(Survival Time in Months) in Low-Risk LDR vs EBRT
Comparison:
Overall Survival:
Visual Tests:
Schoenfeld Plot:

Log(-Log) Survival Plot:

Global Tests:
Proportional Hazard Assumption Test Used

p-value

Schoenfeld Test

0.1471

Suprmum-Kolmogorov Test

0.1350

Test Using Extended Cox PH Regression Including Treatment as

0.2004

TDC using Scale of Log(Survival Months)
Reported p-value (from Adjusted Cox PH, with no TDC)

	
  

0.4999
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Biochemical Failure Free Survival:
Visual Tests:
Schoenfeld Plot:

Log(-Log) Survival Plot:

Global Tests:
Proportional Hazard Assumption Test Used

p-value

Schoenfeld Test

0.5897

Suprmum-Kolmogorov Test

0.6380

Test Using Extended Cox PH Regression Including Treatment as

0.3594

TDC using Scale of Log(Survival Months)
Reported p-value (from Adjusted Cox PH, with no TDC)

	
  

0.0041
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Appendix XIII
SAS Code Used for Power Calculations
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Intermediate-risk LDR vs EBRT Power Calculation:
proc power;
twosamplesurvival test=logrank
curve("control") = (1 2) : (0.86 0.81)
refsurvival = "control"
hazardratio = 0.1 to 0.95 by 0.05
accrualtime = 1
followuptime = 1
ntotal = 254
power = .;
run;
proc power;
twosamplesurvival test=logrank
curve("control") = (1 2) : (0.86 0.75)
refsurvival = "control"
hazardratio = 0.1 to 0.95 by 0.05
accrualtime = 1
followuptime = 1
ntotal = 254
power = .;
run;
Intermediate-risk HDR+EBRT vs EBRT Power Calculation:
proc power;
twosamplesurvival test=logrank
curve("control") = (1 2) : (0.86 0.81)
refsurvival = "control"
hazardratio = 0.1 to 0.95 by 0.05
accrualtime = 1
followuptime = 1
ntotal = 388
power = .;
run;
proc power;
twosamplesurvival test=logrank
curve("control") = (1 2) : (0.86 0.75)
refsurvival = "control"
hazardratio = 0.1 to 0.95 by 0.05
accrualtime = 1
followuptime = 1
ntotal = 388
power = .;
run;
Low-risk LDR vs EBRT Power Calculation:
proc power;
twosamplesurvival test=logrank
curve("control") = (1 2) : (0.95 0.89)
refsurvival = "control"
hazardratio = 0.2 to 0.95 by 0.05
accrualtime = 1
followuptime = 1
groupweights = (1 4)

	
  

213	
  
ntotal = 400
power = .;
run;
proc power;
twosamplesurvival test=logrank
curve("control") = (1 2) : (0.95 0.75)
refsurvival = "control"
hazardratio = 0.2 to 0.95 by 0.05
accrualtime = 1
followuptime = 1
groupweights = (1 4)
ntotal = 400
power = .;
run;
proc power;
twosamplesurvival test=logrank
curve("control") = (1 2) : (0.84 0.75)
refsurvival = "control"
hazardratio = 0.2 to 0.95 by 0.05
accrualtime = 1
followuptime = 1
groupweights = (1 4)
ntotal = 400
power = .;
run;
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